Characterization of protective antigens from the human pathogen Streptococcus pyogenes and their contribution to virulence by Fritzer, Andrea
 
 
 
 
 
 
 
DISSERTATION 
 
 
 
 
Titel der Dissertation 
 
 
Characterization of Protective Antigens 
from Streptococcus pyogenes and their 
Contribution to Virulence 
 
 
angestrebter akademischer Grad 
 
 
Doktorin der Naturwissenschaften (Dr. rer.nat.) 
 
 
 
 
 
 
Verfasserin: Mag. Andrea Fritzer 
Matrikel-Nummer: 0103694 
Dissertationsgebiet: Genetik-Mikrobiologie 
Betreuer: Univ.-Prof. Dr. Alexander von Gabain 
 
 
 
 
Wien, im Dezember 2009 
 
 
 
 
 
  
ACKNOWLEDGEMENTS 
 
First of all I would like to thank Prof. Dr. Alexander von Gabain, not only for giving me 
the opportunity to conduct my Ph.D. research and write my thesis at Intercell AG, but 
also for his continuous support and helpful advices during my years of research. Many 
thanks also for giving me the opportunity to attend national and also international 
conferences. 
 
I would like to express my sincere thanks to Dr. Andreas Meinke. He greatly contributed 
to this work with his outstanding scientific and motivating support throughout all the 
years of my thesis. I cannot thank him enough for the discussions and his comments on 
my thesis and for his continuous support after leaving the group. I greatly appreciate the 
time and effort he put into analyzing my thesis critically and his helpful, invaluable 
suggestions how to improve the readability and argumentation of my thesis further.  
 
I also would like to thank Dr. Ulrike Samen for her supervision after Andreas left, for 
her scientific discussions and advices as well as for proofreading my thesis.  
Many thanks to Dr. Martin B. Oleksiewicz and Dr. Sharmila Bakshi who kindly took 
over my supervision when Ulrike went on maternity leave. 
 
Many thanks also to Dr. Eszter Nagy for her helpful advices and interesting discussions 
especially during the Student Seminar. 
 
My special thanks to Carmen Giefing for sharing her technical expertise she gained 
herself during her Ph.D. thesis with me and for never getting tired of discussing specific 
research details and problems that came along the way.  
 
I further would like to thank Prof. Dr. Thomas Decker, Prof. Dr. Pavel Kovarik and Dr. 
Emmanuelle Charpentier for their valuable comments, advice and discussions during 
my Ph.D. committee and various scientific meetings. 
  
Many thanks on this note to all three nominated thesis referees, Prof. Dr. Thomas 
Decker, Prof. Dr. Pavel Kovarik and Prof. Dr. Bernd Kreikemeyer for their prompt 
willingness to examine my Ph.D. thesis. 
 
Thanks also to Dr. Bernd Kreikemeyer at the Medical University of Rostock, Germany, 
who gave me the opportunity to perform Microarray analyses in his lab. In this regard I 
also would like to thank Jana Normann for technical advice and analysis of the 
Microarray data. Additionally, I would like to thank Kerstin Standar, as well as the 
whole team in Rostock, especially Tomas Fiedler and Nikolai Siemens, for their warm 
welcome. 
 
I further would like to thank Dr. Andreas Kungl at the University of Graz for his 
contributing work on Spy0416. 
 
At the Max Perutz Laboratories, Vienna, I would like to thank Josef Gotzmann for his 
technical help in confocal microscopy, and at the Technical University of Vienna I would 
like to thank Karin Whitmore for electron microscopy. 
 
I am greatly thankful to my colleagues: Birgit Noiges, who not only supported me with 
her technical knowledge, but also motivated me throughout the more frustrating times 
at the lab; Dieter Gelbmann and Markus Hanner for their valuable advices and help; 
Wolfgang Schüler for bioinformatic support; Michael Schunn and Ingmar Stoll for their 
help in performing mouse experiments. Additionally, many thanks to the students at 
Intercell, especially Albina Poljak, Zehra Visram and Margarita Smidt for many 
interesting scientific discussions, but also for the less scientific discussions. 
Not to forget all my other colleagues Axel Niebisch, Petra Schlick, Rene Hude, Astrid 
Teubenbacher, Julia Flor, Michaela Weissgram, Verena Salletmayer, Christina Satke, 
Oliver Stein, Kira Jelencsics, Manfred Berger, Jan Sinzinger and Barbara Maierhofer for 
being the nicest people to work with, making the everyday lab life enjoyable.  
I would also like to thank all Intercellers for providing me such a friendly environment. 
 
  
Thanks to all my friends who took me out and ensured that my social life did not suffer 
too much during these three years of my Ph.D. thesis. In this regard special thanks to 
Silvia Spiess, who helped me a lot when I started to study Biology in Vienna. Silvia was 
the one who suggested to me to apply for my diploma thesis at Intercell when she was 
writing her own there. I would also like to thank Ulrike Thumfart, who is my best friend 
since kindergarten, for her moral support and friendship. Also many thanks to Julia 
Etzler for her support. 
 
My very special thanks go to my family for their endless support in all aspects of life. I 
am so grateful for their encouragement and help throughout all this time. Thanks to my 
mother, Gerda, and my father, Rudolf, who always listened to my ‘boring’ biology-
jargon and always had an ear for me during both frustrating and good times. Many 
thanks to my sister Karin. Although she moved to Finland where she finishes her Ph.D 
this year, she is always there for me – not only during my morning coffee via internet, 
but also otherwise. Without my family’s acceptance, support and encouragement it 
would have been much more difficult to pursue my doctoral studies. Thank you for 
always being there for me. 
 
  Table of Contents 
 
TABLE OF CONTENTS 
1 SUMMARY ................................................................................................................ 1 
2 ZUSAMMENFASSUNG ......................................................................................... 3 
3 INTRODUCTION..................................................................................................... 5 
3.1 Streptococcal Pathogenesis and Disease ....................................................................... 5 
3.1.1 Diseases Caused by S. pyogenes and Changes in Epidemiology .................................5 
3.1.2 S. pyogenes - A Global Burden..........................................................................................9 
3.2 S. pyogenes Interactions with the Human Host.......................................................... 11 
3.2.1 Adhesion of S. pyogenes to Human Extracellular Matrix ...........................................11 
3.2.2 Invasion by S. pyogenes of Host Cells............................................................................13 
3.2.3 Streptococcal Immune Evasion Mechanisms ..............................................................15 
3.3 Treatment and Prevention.............................................................................................. 20 
3.4 Vaccine Approaches to Protect Against GAS Pharyngitis ....................................... 21 
3.4.1 M protein Based Vaccine Approaches..........................................................................22 
3.4.2 Protective S. pyogenes Antigens Other than M protein...............................................23 
3.5 Antigenome Technology Applied to GAS.................................................................. 25 
4 STUDY OBJECTIVES ............................................................................................ 29 
5 MATERIALS AND METHODS........................................................................... 30 
5.1 Materials ............................................................................................................................ 30 
5.1.1 Laboratory Equipment....................................................................................................30 
5.1.2 Additional Equipment ....................................................................................................31 
5.1.3 Chemicals and Reagents.................................................................................................33 
5.1.4 Buffers ...............................................................................................................................35 
5.1.5 Antibodies ........................................................................................................................36 
  Table of Contents 
 
5.1.6 Cytokines ..........................................................................................................................36 
5.2 General Methods of Molecular Biology ...................................................................... 37 
5.2.1 Agarose Gel Electrophoresis ..........................................................................................37 
5.2.2 SDS Polyacrylamid Gel Electrophoresis.......................................................................37 
5.2.3 Western Blot .....................................................................................................................37 
5.2.4 Southern Blot....................................................................................................................38 
5.2.5 Northern Blot ...................................................................................................................39 
5.3 Bacterial Strains and Plasmids ...................................................................................... 39 
5.4 Cloning of Genes and Expression of Proteins............................................................ 41 
5.4.1 Preparation of Insert DNA by PCR...............................................................................41 
5.4.2 Ligation of DNA Fragments into Plasmids .................................................................41 
5.4.3 TOPO Cloning..................................................................................................................42 
5.4.4 Transformation of Electrocompetent and Chemically Competent E. coli Cells ......42 
5.4.5 Analysis of Protein Expression......................................................................................43 
5.4.6 Expression of Recombinant S. pyogenes Proteins ........................................................43 
5.4.7 Purification of Recombinant S. pyogenes Proteins .......................................................44 
5.5 Cultivation of S. pyogenes Strains................................................................................. 45 
5.6 Generation of Competent S. pyogenes Cells ............................................................... 45 
5.7 Preparation of S. pyogenes Subcellular Fractions for SDS-PAGE and Western 
Blot Analysis............................................................................................................................... 46 
5.7.1 TCA Precipitation of Culture Supernatants.................................................................46 
5.8 Preparation of S. pyogenes Genomic DNA.................................................................. 47 
5.9 Isolation of S. pyogenes RNA......................................................................................... 47 
5.10 Generation of Polyclonal Antibodies .......................................................................... 48 
5.11 Intraperitoneal Murine Challenge Model................................................................... 48 
5.12 CXC Chemokine Degradation Assay ........................................................................... 49 
  Table of Contents 
 
5.13 Protein Interaction Studies by Surface Plasmon Resonance (SPR)........................ 49 
5.14 Isothermal Fluorescence Titration (IFT)...................................................................... 50 
5.15 Preparation of Human Neutrophils and Intracellular [Ca2+]-Measurement......... 50 
5.16 Generation of Gene Deletion Mutants in Strain M49591 using pGhost5............. 51 
5.17 Electron Microscopy of S. pyogenes Cells.................................................................... 52 
5.18 Adhesion Assay for Human Detroit 562 and Chang cells........................................ 52 
5.19 Protein Binding Assays................................................................................................... 53 
5.20 Immunofluorescence Analysis using Confocal Microscopy ................................... 54 
5.21 Microarray Analysis ........................................................................................................ 54 
5.21.1 Generation and Purification of Cy3- and Cy5-Labelled cDNA ................................55 
5.21.2 Preparation of Microarray Chips and Data Analysis .................................................56 
5.22 Real Time RT-PCR........................................................................................................... 56 
6 RESULTS .................................................................................................................. 58 
6.1 Selection of Nine Protective Antigens from Streptococcus pyogenes Identified 
via Intercell’s ANTIGENome Technology............................................................................ 58 
6.2 Focus on Three of the Nine Candidates Spy0416, Spy0895 and Spy1536 ............. 59 
6.3 Characterization of Spy0416 .......................................................................................... 60 
6.3.1 Recombinant Spy0416 Possesses IL-8 Cleavage Activity...........................................61 
6.3.2 Binding of IL-8 by Spy0416 is Mainly Mediated by the N-terminal Domain .........63 
6.3.3 The Interaction of Spy0416A and Spy0416B Competes with Binding of Spy0416A 
to IL-8 ............................................................................................................................................64 
6.3.4 Influence of IL-8 Degradation by Spy0416A/B on Ca2+-Release of Neutrophils.....65 
6.3.5 Mutation of Single Residues of IL-8 Reduces Degradation by Spy0416..................66 
6.3.6 Deletion of spy0416 Delayed Virulence in an Intraperitoneal Murine Challenge 
Model ............................................................................................................................................67 
  Table of Contents 
 
6.3.7 Generation of Spy0416 Subconstructs ..........................................................................68 
6.3.8 The Entire Spy0416 C-terminal Region is Required for IL-8 Degradation ..............70 
6.3.9 IP-10, MCP-1 and i-TAC are Not Degraded by Spy0416 In Vitro .............................71 
6.4 Generation of spy0895 and spy1536 Gene Deletion Mutants.................................. 72 
6.4.1 Design of Gene Deletion Constructs.............................................................................72 
6.4.2 Generation of Gene Deletion Mutants ΔSpy0895 and ΔSpy1536 in Three Steps ...74 
6.5 Confirmation of spy0895 and spy1536 Gene Deletion.............................................. 79 
6.5.1 Confirmation of spy0895 and spy1536 Gene Deletion by Southern Blot Analysis..80 
6.5.2 Confirmation of spy0895 and spy1536 Gene Deletion by Northern Blot Analysis..82 
6.6 Characterization of spy0895 and spy1536 Gene Deletion Mutants ........................ 83 
6.6.1 ΔSpy0895 and ΔSpy1536 Cells Have No Major Growth Defects under In Vitro 
Growth Conditions.........................................................................................................................84 
6.6.2 Deletion of spy0895 and spy1536 Did Not Decrease Virulence in Mice ...................85 
6.6.3 Electron Microscopy Did Not Reveal a Conspicuous Change of Bacterial Shape in 
the Gene Deletion Mutants............................................................................................................86 
6.6.4 ΔSpy1536 Showed Significantly Reduced Binding to Human Plasma and 
Extracellular Matrix Proteins ........................................................................................................87 
6.6.5 In Absence of spy1536 Surface Expression of M protein and Spy0269 is Reduced 
on S. pyogenes Cells .........................................................................................................................89 
6.6.6 Deletion of spy1536 Does Not Affect emm-Gene Transcription ................................91 
6.6.7 ΔSpy1536 Cells Secrete Mainly Inactive Pyrogenic Exotoxin B in their Culture 
Supernatant......................................................................................................................................93 
6.6.8 Deletion of spy1536 Causes Transcriptional Upregulation of hasA and 
Downregulation of Adhesin Encoding Genes ............................................................................94 
7 DISCUSSION ........................................................................................................ 100 
7.1 Role of Spy0416 in Group A Streptococcal Pathogenesis ...................................... 101 
7.1.1 Contribution of PA, Fn1 and Fn2 Domains to Spy0416 Catalytic Activity ...........102 
7.1.2 Essential Function of Ancillary C-terminal Spy0416 Domains ...............................103 
7.1.3 Specificity of Spy0416 towards IL-8............................................................................104 
7.1.4 Spy0416 Contribution to GAS Virulence In Vivo.......................................................105 
  Table of Contents 
 
7.1.5 Other Contributions of Spy0416 to GAS Pathogenesis ............................................106 
7.2 Targeting of spy0895 and spy1536 for Gene Deletion............................................. 108 
7.2.1 Efficiency of spy0895 and spy1536 Gene Deletion in Strain M49591.......................109 
7.3 Role of Spy0895 in Group A Streptococcal Pathogenesis ...................................... 110 
7.3.1 Attempts to Overcome Lack of spy0895 In Vitro Expression ...................................111 
7.4 Role of Spy1536 in Group A Streptococcal Pathogenesis ...................................... 112 
7.4.1 In Vitro Expression of Spy1536 ....................................................................................112 
7.4.2 In Vitro Growth, Bacterial Shape and In Vivo Virulence were Not Affected in 
ΔSpy1536........................................................................................................................................112 
7.4.3 Spy1536 is Crucial for the Binding of Streptococci to Human Plasma and 
Extracellular Matrix Proteins ......................................................................................................114 
7.4.4 Spy1536 Influences the Surface Expression of Streptococcal Proteins...................115 
7.4.5 Spy1536 is Involved in Regulation of Surface Protein Localization Independent of 
Transcription .................................................................................................................................117 
7.4.6 Spy1536 Affects SpeB Activation in Culture Supernatant .......................................118 
7.4.7 Regulation of Transcription: Is Spy1536 Involved in a Regulatory Network of S. 
pyogenes?.........................................................................................................................................123 
7.5 Conclusion....................................................................................................................... 125 
8 REFERENCES ........................................................................................................ 127 
9 ABBREVIATIONS................................................................................................ 154 
10 APPENDIX ............................................................................................................. 156 
10.1 Appendix I - Primers ..................................................................................................... 156 
10.2 Appendix II -Vectors ..................................................................................................... 158 
10.3 Appendix III - Sequences ............................................................................................. 160 
11 CURRICULUM VITAE........................................................................................ 171 
  Table of Contents 
 
12 THESIS-RELATED PUBLICATIONS............................................................... 173 
12.1 Publications..................................................................................................................... 173 
12.2 Poster and Oral Presentations at Scientific Conferences ....................................... 173 
 
  Summary 
Andrea Fritzer  1 
1 SUMMARY 
Streptococcus pyogenes, belonging to Group A Streptococci, is a gram-positive, 
extracellular bacterial pathogen and can cause a wide variety of human infections that 
range from asymptomatic colonization to life threatening invasive diseases. Although 
antibiotic treatment is very effective, when left untreated S. pyogenes infections can lead 
to post-streptococcal sequelae and severe diseases causing significant morbidity and 
mortality worldwide. Infectious diseases are the second leading cause of death 
worldwide, and the acquisition of antibiotic resistance by many pathogenic bacteria has 
incited interest in generating vaccines to cure or prevent disease. Therefore, Intercell` s 
Antigen Identification Program (AIP) has identified novel S. pyogenes protein antigens 
relying on human sera and bacterial surface display for a prophylactic vaccine based on 
recombinant proteins. Out of the 9 most promising protein candidates, selected by a 
multistep validation program and protection studies in mice, three vaccine candidates, 
Spy0416, Spy0895 and Spy1536, were chosen to evaluate their contribution to GAS 
disease. Spy0416, annotated as ScpC, was further characterized for its biochemical 
function. This demonstrated that the recombinant form of Spy0416 is capable of IL-8 
degradation in vitro in a time and concentration dependent manner. Surprisingly, the 
isolated predicted proteinase domain did not exhibit IL-8 degrading activity, but was 
dependent on the presence of its ancillary C-terminal domains. The evaluation of 
possible contributions of the predicted C-terminal domains to IL-8 degradation showed 
that none of them in combination with the N-terminal proteinase domain degraded IL-8. 
This indicated the Spy0416 protein is in its entirety essential for the enzymatic activity in 
vitro.  
For the two candidates Spy0895 and Spy1536 gene deletion mutants have been 
generated. While the ΔSpy0895 strain did not show a distinct phenotype, deletion of the 
spy1536 gene revealed an important role for Spy1536 to mediate binding to human 
proteins such as fibrinogen, fibronectin, collagen I, plasminogen and laminin in vitro. 
Analysis of the expression of the two surface proteins, the M protein and Spy0269, 
indicated that the reduced binding of ΔSpy1536 streptococcal cells to human plasma- 
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and extracellular matrix-proteins is due to the abrogated localization of these and 
possibly other GAS proteins on the surface of ΔSpy1536. Interestingly, M protein was 
still detectable in the cytoplasm, but not in the bacterial cell wall fraction. This is in 
agreement with microarray analyses which revealed that transcription of the M protein 
and Spy0269 encoding genes was not affected. Furthermore, Microarray and Real Time 
RT-PCR also confirmed the observed phenotype of the spy1536 gene deletion mutant. It 
revealed a ~10-100 fold reduced transcription of fcrA, encoding an M-related protein 
precursor, of sclA and sclB, encoding collagen-like surface proteins ScIA and ScIB, as 
well as reduced transcription of the sfbX49 gene, encoding the fibronectin-binding 
protein SfbX49. Furthermore, hasA encoding hyaluronate synthase for the production of 
hyaluronidase capsule was found to be ~2 fold upregulated.  
The work has therefore provided important evidence that Spy0416 and Spy1536 
contribute to GAS pathogenesis which strongly supports their selection as vaccine 
candidates. 
 
  Zusammenfassung 
Andrea Fritzer  3 
2 ZUSAMMENFASSUNG 
Streptococcus pyogenes zählt zu Gruppe A Streptokokken und ist ein gram-positives 
extrazelluläres bakterielles Pathogen. Es ist fähig eine Vielzahl humaner Infektionen zu 
verursachen, die von asymptomatischer Kolonisierung bis hin zu lebensbedrohlichen 
invasiven Krankheiten reichen. Obwohl die Behandlung mit Antibiotika sehr effektiv ist, 
kann es im Falle einer unbehandelten S. pyogenes Infektion, zu schwerwiegenden 
Folgekrankheiten kommen, die zu signifikanter Morbidität und Mortalität führen 
können. Infektionskrankheiten sind die zweithäufigste Todesursache weltweit. 
Aufgrund zunehmender Antibiotikumresistenz vieler Pathogene, stellen Impfstoffe eine 
wichtige Alternative dar, um bestimmte Krankheiten zu heilen oder diesen sogar 
vorzubeugen. Darum hat Intercell’s Antigen Identifizierungprogramm (AIP) neue 
Proteinantigene identifiziert, basierend auf humanen Seren und `bacterial surface 
display`, für die Entwicklung eines prophylaktischen, antibakteriellen Vakzins, 
beruhend auf rekombinanten Proteinen. Aus den 9 vielversprechendsten Kandidaten, 
die mittels umfassender Validierungsprozeduren und Protektionsstudien in Mäusen 
selektiert werden konnten, wurden drei Impfstoffkandidaten, Spy0416, Spy0895 und 
Spy1536, näher charakterisiert, um deren Rolle in der Krankheitenentwicklung durch 
Gruppe A Streptokokken zu evaluieren. Spy0416, annotiert als ScpC, wurde weiters in 
seiner biochemischen Funktion näher analysiert. Diese Analyse ergab, dass die 
rekombinante Form von Spy0416 Interleukin 8, abhängig von Inkubationszeit und 
Enzymkonzentration, in vitro abbauen kann. Überraschenderweise zeigte die 
Proteinasedomäne alleine keine IL-8 abbauende Aktivität, da diese von der 
Anwesenheit der C-terminalen Hilfsdomänen abhängig war. Die Evaluierung einer 
möglichen Beteiligung der C-terminalen Domänen am IL-8 Abbau zeigte, dass keine 
dieser Domänen in Kombination mit der N-terminalen Proteinasedomäne IL-8 abbaut. 
Das deutet darauf hin, dass Spy0416 in seiner Gesamtheit essenziell für die 
enzymatische Aktivität in vitro ist. 
Mit weiteren zwei Kandidaten, Spy0895 und Spy1536, wurden Gendeletionsmutanten 
generiert. Während der Stamm ΔSpy0895 keinen deutlichen Phänotyp aufwies, ergab 
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die Deletion des spy1536 Gens, dass Spy1536 eine wichtige Funktion in der Bindung an 
humane Proteine wie Fibrinogen, Fibronektin, Collagen I, Plasminogen und Laminin in 
vitro vermittelt. Die Analysen von Expression der beiden Oberflächenproteine, M 
Protein und Spy0269, deuteten darauf hin, dass die reduzierte Bindung von ΔSpy1536 
Zellen an die humanen Plasma- und extrazellulären Matrix Proteine aufgrund einer 
außer Kraft gesetzten Lokalisierung dieser und möglicherweise anderer GAS Proteine 
auf der Oberfläche von ΔSpy1536 herrührt. Interessanterweise war das M Protein nach 
wie vor im Zytoplasma detektierbar, aber nicht in der bakteriellen Zellwand. Dies 
stimmt mit den Microarrayanalysen überein. In diesen war die Transkription von M 
Protein und Spy0269 kodierenden Genen nicht betroffen. 
Weiters bestätigten Microarray und Real Time RT-PCR den beobachteten Phänotyp der 
spy1536 Gendeletionsmutante. Es konnte eine 10-100 fach reduzierte Transkription von 
fcrA, das einen `M-related protein precursor` kodiert, von sclA und sclB gezeigt werden, 
welche die entsprechenden Collagen-ähnlichen Oberflächenproteine SclA und SclB 
kodieren, sowie eine reduzierte Transkription von sfbX49, welches das Fibronektin-
bindende Protein SfbX49 kodiert. Zusätzlich wurde eine 2 fach erhöhte Transkription 
des hasA Gens gezeigt, das eine Hyaluronat Synthase zur Produktion der 
Hyaluronidase-Kapsel kodiert.  
Diese Arbeit hat den Hinweis erbracht, dass Spy0416 und Spy1536 an der 
Krankheitsentwicklung durch Gruppe A Streptokokken beteiligt sind, was deren 
Selektion als Impfstoffkandidaten stark unterstützt.  
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3 INTRODUCTION 
3.1 Streptococcal Pathogenesis and Disease 
Streptococcus pyogenes is a gram-positive, extracellular, non-motile, β-hemolytic bacterial 
pathogen which belongs to Group A streptococci. It is capable of causing a wide variety 
of diseases globally with humans being their only known natural biological host. There 
is no environmental reservoir known for Group A streptococci and transmission of the 
bacteria occurs almost always from person to person [1]. The primary sites for 
colonization involve the nasal and oropharyngeal mucosal epithelium of the upper 
respiratory tract as well as the superficial layers of the epidermis where GAS can 
undergo successful reproductive growth and transmission to the next host. Two reasons 
why this bacterium presents such a challenge for the human body are the existence of 
more than 200 distinct serotypes and the enormous repertoire of different virulence 
factors. The ingenious way the bacterium counteracts host defenses largely contributes 
to the success of GAS in establishing infections in its human host. 
3.1.1 Diseases Caused by S. pyogenes and Changes in Epidemiology 
GAS can thrive in almost any body tissue of the upper respiratory tract and skin lesions 
serve as the primary sites of infection and principle reservoirs of transmission [2-4]. 
Bacteria are transmitted from human to human through respiratory droplets or through 
contact with infected wounds or sores on the skin [2-4].  
Asymptomatic carriage can occur in humans, without triggering a vigorous host 
immune response to many GAS antigens [5]. This is the case for 5-15% of normal 
individuals who harbour the bacterium in their respiratory tract without developing any 
signs of disease. Clinically inapparent infections can also arise whereby the host lacks 
obvious clinical symptoms of illness although there is a significant immune response.  
Once the bacterium has successfully colonized the upper respiratory tract or the 
epidermis, primary disease manifestations often include pharyngitis, impetigo and soft 
tissue infections. GAS is believed to be responsible for 15-30% of acute pharyngitis cases 
in children and also for 10% of cases in adults [6, 7]. Disease in people suffering from 
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skin infections or pharyngitis and tonsillitis is commonly referred to as “strep throat” 
and is most likely a source for spread of the infection. Asymptomatic carriers are less 
contagious. These non-severe infections are superficial self-limiting and usually cause 
only a mild illness. The treatment of an infected person with penicillin for 24 hours 
generally eliminates their ability to spread the bacteria and cures diseases within 10 
days. In 1-3% of untreated infections rheumatic fever and glomerulonephritis may 
follow streptococcal disease. But these conditions and their pathology are not 
attributable to spreading of bacteria, but to aberrant immunological reactions to GAS 
antigens [8]. Intracellular invasion of epithelial cells on the other hand contributes to 
persistence of GAS in the human host because the bacteria get past the defenses of the 
person who is infected. The consequence may be invasive and toxin-mediated diseases 
[9]. Two of the most severe, but least common forms of invasive GAS disease are 
necrotizing fasciitis and streptococcal toxic shock syndrome (STSS). Necrotizing fasciitis 
is caused because bacteria gain access to deep tissue that is normally sterile leading to a 
widespread fascial necrosis with relative sparing of skin and underlying muscle [10]. 
STSS causes blood pressure to drop rapidly and organs (e.g., kidney, liver, lungs) to fail. 
About 20% of patients with necrotizing fasciitis, more than half with STSS and between 
10-15% of patients with other forms of invasive group A streptococcal disease die.  
Clearly the infectivity of a disease agent is complicated and relies on both, the virulence 
of the pathogen and the susceptibility of the host [1]. For example there are discrete 
populations of streptococci found to be commonly associated with either severe 
pharyngitis or impetigo [11]. Based on the nucleotide sequence differences in the region 
of the emm gene encoding the peptidoglycan-spanning domain, Bessen and colleagues 
found that streptococcal isolates from pharyngeal sites showed mainly the emm 
chromosomal pattern A (M1, M3, M6, M12, etc.), B (M5, M8, M14, M29) and C (M6, M18, 
M23, M38). In contrast, impetigo isolates were restricted to emm chromosomal pattern of 
groups D (M27, M28, M30, M32, etc.) and E (M2, M4, M9, M49, etc). Many pattern E 
isolates, such as M type 49 strains, are likely to colonize both tissue sites. Some serotypes 
have been clearly associated with epidemics of rheumatic fever such as M5 [12]. Also 
M3, 6, 14, 18, 19, 24 and a few others are well represented. An outbreak of acute 
rheumatic fever in Salt Lake City, Utah in the year 1987 for example was found to be 
mainly associated with M type 18 and M type 3 group A streptococcal strains [13]. 
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Interestingly, prevalent pharyngeal types as M2, 4 and 12 were reported not to be 
associated with rheumatic fever [12]. Life-threatening infections like toxic shock 
syndrome were associated with GAS strains that frequently belonged to serotypes M1 
and M3 most of which entered through the skin and soft tissue and only occasionally the 
pharynx. 
Development of disease does not only depend on the streptococcal M type alone. It also 
depends on the host susceptibility. Differences in susceptibility may be attributable to 
genetic factors, frequency of underlying illness or living arrangements [14]. Some 
countries in Europe for example have reported higher incidence of GAS diseases 
particularly in ethnic groups. A study from north London found higher rates of 
pharyngeal carriage of GAS in orthodox Jewish children and adults attending primary 
care services than in other attendees, regardless of sore throat symptoms [15]. 
Furthermore, a study from southern Israel found a significantly higher risk of GAS 
disease in its Bedouin population compared to Jewish people among the population [16].  
In case of acute rheumatic fever and rheumatic heart disease disproportionately high 
levels of appearance were found in the Pacific region and in some indigenous groups in 
developed countries. In Aboriginal communities in the Northern Terretory in Australia 
the prevalence of rheumatic heart disease was 11.8 per 1000 and the incidence of acute 
rheumatic fever in children was 254 per 100,000. In contrast the non-Aboriginal 
prevalence in the same region was 0.4 per 1000 and incidence was 1.3 per 100,000 [17-
19]. Interestingly, in the Aboriginal groups in the Australian Northern Territory known 
to have high rates of rheumatic fever, serotypes of GAS traditionally associated with 
rheumatic fever, were not commonly found [19]. Therefore, it is possible that high 
prevalence rates of rheumatic heart disease in developing countries may be due to 
environmental factors including overcrowding, nutrition and access to medical services 
[19]. A study during the 1950s in the United States Air Force Base barracks provided a 
biological basis for a relationship between overcrowding and the incidence of acute 
rheumatic fever. It was found that rates of acquisition of streptococcal infections 
increased when beds were moved closer together [20]. It was also suggested that poor 
nutrition in early childhood plays a primary role in susceptibility to acute rheumatic 
fever. In regard to this, a case control study in Serbia described that a bodyweight 10% 
below average was found to increase the risk of acute rheumatic fever by 42% [21]. 
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Access to medical services may be an explanation for the difference of rheumatic heart 
disease prevalence between developed and developing countries. In Costa Rica, the 
incidence of acute rheumatic fever fell in the 1970s concomitant with a national health 
strategy of penicillin prophylaxis [22]. Immunologic factors such as pre-existing M type-
specific antibodies and other host characteristics may also be important in the clinical 
expression of illness. 
Since there are many factors defined by the bacteria and the host described above that 
influence establishment of Group A streptococcal disease, changes in the epidemiology 
of GAS could depend on similar factors like the molecular basis of Streptococcus pyogenes, 
environment of the host and the host itself. The distinction between pharyngeal and 
impetigo strains briefly discussed before provides focus for addressing the molecular 
basis of the tissue tropism of S. pyogenes as one of the factors that might influence 
streptococcal epidemiology. If emm gene products define at least in part the tissue-
specificity of infection the horizontal transfer of emm genes occurring between different 
group A streptococcal strains may be an important mechanism for the emergence of new 
clones. These new clones might have unique pathogenic qualities which may lead to a 
change in the principle reservoir for transmission [11]. Interestingly, it could be shown 
that changes in epidemiology of group A streptococcal disease in the USA was 
accompanied by a corresponding change in serotype distribution [23]. While 
proportions of invasive M types 1, 3 and 18 increased significantly between 1972 and 
1988, less invasive strains of serotypes M4 and 12 decreased. Several reports in the 
literature have documented changes in the epidemiology of diseases caused by GAS, 
particularly in Northern Europe and North America [2, 24, 25]. For example significant 
changes occurred in the spectrum of invasive group A streptococcal infections in 
Arizona, between 1985 and 1990 [26]. Native Americans were at increased risk of 
acquiring these infections. Patients with the streptococcal toxic shock-like syndrome had 
epidemiologic features that distinguished them from patients with other invasive 
infections, including younger age and less underlying illness. In spite of that, the 
proportion of infections with hypotension, rash, desquamation, renal impairment and 
gastrointestinal involvement increased significantly.  
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In summary, group A streptococci cause various diseases (see Table 1) that range from 
non-severe to severe invasive diseases. Disease outcome is not only dependent on 
genetic factors but also strongly depends on the host and its environment. 
 
Table 1: Diseases caused by Streptococcus pyogenes. 
Category of Disease Examples of Infections 
Superficial 
 
Pharyngitis, skin and soft tissue infections,  
impetigo, erysipelas, vaginitis, 
post-partum infections 
Deep Infections 
 
Bacteraemia, necrotizing fasciitis, deep tissue 
infections, cellulitis, myositis, puerperal sepsis,  
pericarditis, meningitis, pneumonia, septic arthritis 
Toxin-mediated 
 
Scarlet fever, toxic shock-like syndrome 
Immunologically mediated 
 
Rheumatic fever, post-streptococcal glomerulonephritis, 
Reactive arthritis 
3.1.2 S. pyogenes - A Global Burden 
Before the introduction of antimicrobials, serious infections caused by S. pyogenes were 
common [2]. This organism was responsible for as many as half of post-partum deaths 
before World War II and it was the major cause of death in burns patients. Due to the 
use of penicillin, Group A streptococcus was believed to be virtually eliminated as a 
pathogen, as over the last four decades, the industrialized world has witnessed a decline 
in the incidence of these diseases. In the 1970s, there was optimism that serious GAS 
disease had been almost completely eradicated in developed countries and it was noted 
that specific diseases, for example scarlet fever, were abolished in many European 
countries. In the mid to late 1980s, however, concerns about GAS disease were 
heightened since outbreaks of rheumatic fever occurred in different areas, not only in 
developing countries but also populations that had ready access to medical care within 
industrialized countries were affected [2, 27, 28]. For example, Salt Lake City, Utah 
registered an eightfold increase of rheumatic fever over the average annual incidences 
[13]. Regarding invasive diseases in the 1990s, Scotland marked year-on-year rises of 
GAS bacteraemia from the mid 1990s onwards [14]. Between 1993-1996 surveillance data 
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from Sweden showed a rise in invasive GAS infections, before they dropped back to a 
more stable annual rate. More pronounced changes are apparent in Iceland where rates 
of invasive GAS have swung from 1-2 per 100,000 to peaks above 6 per 100,000 which 
were the highest rates observed in any European country between 1992-1994 [14]. 
Regardless of the patterns of invasive GAS disease, there is a general suggestion of 
increasing invasive GAS across Europe over the past two decades.  
According to WHO estimates in 2005 18.1 million people suffer from serious GAS 
disease and another 1.78 million cases occur each year [29]. These diseases are 
responsible for over 500,000 deaths each year. Added to this are over 111 million 
prevalent cases of streptococcal pyoderma and 616 million new cases of pharyngitis each 
year. 
The Centers for Disease Control and Prevention (CDC, USA) estimates that invasive 
GAS disease accounts for ~ 10,000 cases per year in the USA. Among those are ~1350 
deaths. Mortality that results from GAS invasive diseases varies depending on the 
disease manifestation and ranges from 20% for necrotizing fasciitis to ~45% for 
streptococcal toxic shock syndrome [7, 30]. The re-emergence of streptococcal toxic 
shock syndrome and necrotizing fasciitis has also been reported in several countries 
such as the United States, Canada, Northern Europe and New Zealand as well as 
Australia. The fatality rate of invasive disease ranges from 15 to 30%, but can exceed 
50% in cases of STSS [31, 32]. In contrast, rheumatic fever and rheumatic heart diseases 
are rare in developed countries, while indigenous communities and developing 
countries are more affected due to overcrowding and poor access to health care [7, 19]. 
The global burden was estimated to 15.6 million existing cases of rheumatic heart 
disease (RHD), with 460,000 new cases being diagnosed each year and 349,000 RHD-
related deaths each year [7].  
The diversity of serotypes and the described changes in epidemiology of GAS indicates 
that GAS infections still remain a significant health problem in the twenty-first century. 
The  regulated surveillance of GAS disease and of the associated distribution of emm 
types over time would be essential for a better protection against S. pyogenes by 
vaccination for example [32]. 
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3.2 S. pyogenes Interactions with the Human Host 
Human immune defense mechanisms are a complex and effective system to defend the 
body from unwanted intruders such as bacteria. Nevertheless from time to time bacteria 
manage to overcome defenses and to settle down in their new environment. This 
includes the adherence to, internalization into as well as persistence in host cells and 
tissue leading to long-term survival of the bacteria. But also the regulation of the 
processes involved in successful colonization and persistence and of the involved 
bacterial virulence factors are essential to guarantee its continued existence in the 
human host. In case of S. pyogenes the success in establishing disease can be attributed to 
its ability to colonize, rapidly multiply and spread in its host. This is facilitated by 
multiple adhesins that mediate attachment to host extracellular matrix components as 
well as by powerful invasins which contribute to the process of invasion (see Figure 1, 
page 18). The interaction with the human host gets even more complicated since many 
expressed virulence factors have multifunctional properties contributing to complex 
immune evasion mechanisms that outsmart the usually effective host immune system 
resulting in disease. The obstacles S.pyogenes has to face during the course of 
establishing infection in the host and the mechanisms it has to use in order to adapt to its 
new environment to ensure survival and consequently cause disease are briefly 
discussed below. 
3.2.1 Adhesion of S. pyogenes to Human Extracellular Matrix 
Streptococcal infections have as the common first step adherence of GAS to and 
colonization by GAS of epithelial cells of the pharynx or the skin. In order to successfully 
colonize the skin, GAS has to overcome several defense mechanisms/ barriers. For 
instance, fatty acids are secreted by the skin to inhibit bacterial growth. Additionally, 
non-specific host defense mechanisms prevent the bacteria from penetrating through the 
superficial epithelium of the upper respiratory tract [33]. To successfully colonize their 
host streptococci must replicate. The ability to replicate is affected by a variety of human 
factors such as the immunglobulins in the human saliva, specificity of those and normal 
flora of mucosal surfaces.  
Despite the fact that S. pyogenes faces a variety of biological, mechanical and chemical 
forces, it is successful in circumventing these obstacles by the production of many 
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surface components which mediate interaction with host cell receptors. As soon as 
streptococci overcome unspecific interaction, a temporally limited, weak attachment of 
the bacteria mediated by lipoteichoic acid (LTA), firm adherence occurs in a second step. 
Firm adherence relies on the presence and expression of specific adhesins on the 
bacterial surface [34] which primarily target host extracellular matrix (ECM) proteins. 
These proteins [35, 36] include among others collagens, which represent the major 
structural components of the eukaryotic ECM forming different types of interstitial or 
basement membrane networks [37] as well as laminin, exposed to pathogenic bacteria 
most frequently seen in damaged or inflamed tissue. and fibronectin, which is not only a 
substrate for adhesion but serves also as the prototype of adhesion proteins that bind 
specifically to microorganisms [38, 39]. Prebound fibronectin on the streptococcal 
surface for instance supports binding to collagen [40]. Also human plasma glycoproteins 
such as fibrinogen and plasminogen are targeted by S. pyogenes to maintain themselves 
in the host environment.  
Among the streptococcal adhesins is the M protein which is the most prominent protein 
on the streptococcal surface and also the major virulence factor of GAS. It is the basis for 
more than 100 distinct serotypes defined. The M protein of group A streptococci is an α-
helical coiled coil bacterial surface protein often seen as a mosaic of various functional 
domains: a conserved C-terminal, a variable amino-terminal domain and sequence 
repeats making up the central helical rod. The sequence repeats bind a variety of host 
factors [41]. The M protein mediates mainly binding to collagen and fibronectin but it 
also interacts with the plasma proteins fibrinogen and plasminogen [42, 43].  
Since adherence plays a major role for the colonization of S. pyogenes, several other 
surface proteins are expressed which guarantee successful interaction with host 
extracellular matrix components. Collagen binding proteins that have been described to 
mediate adherence of streptococcal cells to collagen rich tissues are Cpa, directly binding 
to collagen type I [44, 45]. This protein is also an example for conceivable tissue site 
preferences since it displays high affinity binding to human collagen type I [44], a form 
that is abundant in the dermis of human skin. Also SclA and SclB, both containing 
collagen-like domains, bind collagen [46-49]. One of the best studied molecules involved 
in adherence is SfbI protein or its allelic variant protein F1 both binding fibronectin [50-
53]. The involvement of protein F1/SfbI in adhesion was shown by the introduction of 
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the Protein F encoding gene prtF into an enterococcal strain which proved solely protein 
F on itself and not the bacterial background is sufficient for adherence [54]. In contrast, 
insertional mutagenesis of the prtF gene resulted in loss of the ability to bind fibronectin 
and reversely could be complemented by the introduction of the respective gene on a 
plasmid [50]. Besides protein F1/SfbI also serum opacity factor mediates fibronectin-
binding [55]. Furthermore, it is known to mediate the opacity reaction in human serum 
[56, 57]. Lbp has been described to bind laminin [58], which is the major noncollagenous 
adhesive glycoprotein in basement membranes [59, 60]. PAM [61, 62] as well as α-
enolase [63], have been reported to bind plasminogen, a key component of the 
fibrinolytic system. The different adhesins expressed in a given environment on the 
surface of S. pyogenes additionally define the preferential adhesion to a certain type of 
cells and therefore are responsible for tissue tropism [34]. In summary, colonization of 
and adherence to epithelial cells represents the first stage of GAS infection mediated by 
the expression of many various surface molecules interacting with their specific ligand 
on host cells. The fate of S.pyogenes, whether it will be cleared, remains surface bound or 
will induce its internalization depends on many host factors, such as receptors and 
immune responses, the strength of physical interaction that occurs between host and 
GAS as well as the signal GAS sends to either stimulate or antagonize internalization. 
3.2.2 Invasion by S. pyogenes of Host Cells 
Binding of host ECM proteins during streptococcal adherence may lead to intracellular 
invasion by GAS of host cells. This is a dynamic process that implies the activation of 
host cell signal transduction pathways by GAS and active participation of the host cell 
cytoskeletal structure. To initiate host cell signalling, GAS interacts with various host 
cellular receptors such as integrins, CD46 or CD44.  
The interaction with integrins on host cells is crucial for skeletal rearrangements to 
induce uptake of adherent S. pyogenes cells by an actin-mediated “zipper phagocytosis”. 
It can be induced by laminin bound to the surface of S. pyogenes [64], but also by plasma-
fibronectin bound either to protein F1 or to M protein [65]. 
The M protein can also bind host CD46, a membrane bound complement regulatory 
protein, related to factor H which serves as a cellular receptor on keratinocytes [66]. This 
contact may also initiate proinflammatory responses during infection [67]. Further 
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signalling events to the host cell are established by binding of streptococcal hyaluronic 
acid capsule to the host CD44 receptor. This interaction contributes to translocation first, 
by disrupting intercellular junctions facilitating the uptake of streptococci into deeper 
tissue and secondly it prevents streptococci from being trapped within epithelial cells 
[68].  
The process of streptococcal invasion is very complex and also involves the secretion of 
various invasins and toxins which may result in the destruction of host cells and allows 
S. pyogenes to spread among tissues by dissolving host fibrin and intercellular ground 
substances [8]. The secreted invasins and toxins act in a variety of ways, leading to lysis 
of eukaryotic cells, including red blood cells and phagocytes and to damage of other 
host macromolecules like enzymes and informational molecules. Examples for such 
virulence determinants are Streptolysin S (SLS) and Streptolysin O (SLO). Both are 
potent cytolytic toxins produced by almost all clinical isolates of group A streptococci 
[69]. SLO is a 540-amino-acid secreted protein toxin that binds to cholesterol in 
eukaryotic cell membranes, where it oligomerizes to produce large transmembrane 
pores leading to cell lysis [70]. Recently, it was demonstrated that SLO acts as a vehicle 
for translocation of a second GAS protein, NAD-glycohydrolase (NADase), into the 
cytoplasm of host epithelial cells [71]. SLS is primarily responsible for beta-hemolysis 
observed surrounding colonies grown on the surface of blood agar media [72, 73]. It can 
exist in intracellular, cell surface-bound and extracellular forms [74] and can damage 
other cell membranes, including those of lymphocytes [75], neutrophils and platelets 
[74] as well as subcellular organelles such as lysosomes [76]. Its toxicity to erythrocytes, 
leukocytes and smooth muscle has qualified it as an accessory virulence factor [76]. 
Streptococcal hyaluronidase plays an important role to aid host tissue invasion and is 
capable of degrading hyaluronic acid, a major component of the extracellular matrix of 
body tissues [77]. GAS are capable of producing 2 types of hyaluronidase, a 
bacteriophage associated enzyme and an extracellular one that is secreted from the cell 
[78]. Two further toxins contribute to the large repertoire of virulence factors used by S. 
pyogenes, Streptodornase and Streptokinase, which possess deoxyribonuclease activity 
and participate in fibrin lysis, respectively [79].  
In summary, the process of invasion by GAS is mediated by a number of streptococcal 
surface proteins which interact with host cellular receptors to induce their uptake into 
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host cells but invasion of the host also involves the expression of various invasins and 
toxins which allow S. pyogenes to spread into deeper tissues resulting in damage and 
destruction of host cells.  
3.2.3 Streptococcal Immune Evasion Mechanisms 
The interaction of streptococcal cells with host cell surfaces and receptors induces 
mechanisms of innate and adaptive immunity. Innate immunity includes for example 
proinflammatory responses, complement activation and phagocytosis. Gram-positive 
bacteria contain peptidoglycan in their cell wall that activates the alternative 
complement pathway. One result of complement activation is opsonization and 
enhanced phagocytosis of the bacteria. Complement by-products such as C5a stimulate 
inflammatory responses by recruiting and activating leukocytes. Phagocytes use various 
surface receptors to recognize appropriately opsonized bacteria and upon activation of 
the phagocytes cytokines are secreted to induce leukocyte infiltration. On the other side 
virulence of bacteria has been linked to a number of mechanisms that mediate resistance 
to innate immunity including antiphagocytic mechanisms and inhibition of complement 
or inactivation of complement products.  
Adaptive immunity on the other hand is mainly mediated by antibodies and represents 
the principle protective immune response to GAS. It functions to block infection, 
eliminate the microbes and neutralize their toxins. The antibody responses against 
bacteria are directed against cell wall antigens, secreted and cell-associated toxins, which 
may be polysaccharides or proteins. Effector mechanisms used by antibodies to combat 
streptococcal infections include neutralization, opsonization and phagocytosis as well as 
activation of the classical complement pathway. Neutralization is mediated by high 
affinity IgG and IgA isotypes, opsonization by IgG1 and IgG3 and complement 
activation by IgM and IgG1 and IgG3 isotypes. Activation of CD4+ helper T cells leads to 
the production of cytokines to stimulate antibody production, to induce local 
inflammation (tumor necrosis factor, lymphotoxin) and to enhance the phagocytic and 
microbicidal activities of macrophages (IFN-γ) and neutrophils which participate in 
defending Streptococcus pyogenes. 
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S. pyogenes has evolved various virulence mechanisms that counteract human host 
defenses which contribute to GAS pathogenesis and guarantee their successful survival 
within its host. These immune evasion mechanisms are briefly described below. 
3.2.3.1 Inhibition of the Alternative Complement System by S. pyogenes 
The complement system represents an important component of the host defense system 
as the first line of defense against invading microorganisms [80]. It consists of a set of 
plasma proteins which interact in a complex cascade of events. The result is the 
generation of bioactive molecules which mediate opsonic, chemotactic and lytic 
functions against invading microorganisms. The capsule of S. pyogenes inhibits 
complement activation and the M protein supports streptococcal infections by binding 
fibrinogen. Interaction of plasma fibrinogen with M protein masks C3b-binding sites on 
the streptococcal surface [81]. Binding of factor H, a serum control protein of the 
alternative complement pathway, leads to the inhibition of the alternative C3b 
convertase [82]. The deposition of large numbers of molecules of complement fragment 
C3b on the surface of microorganisms which thereby become accessible to uptake by 
phagocytic cells is essential for opsonising the bacteria [41, 83, 84]. Binding of fibrinogen 
or factor H prevents complete opsonisation of the Streptococcus. However immune 
opsonisation is not inhibited by either fibrinogen or factor H. 
3.2.3.2 GAS Inhibits Polymorphonuclear Neutrophil Recruitment 
Circulating polymorphonuclear neutrophils (PMNs) are recruited to sites of infection by 
chemokines, cytokines, matrix metalloproteases and products produced by the invading 
microorganisms. Host derived chemotactic factors are critical in the regulation of 
inflammatory responses. Disrupting PMN recruitment is one strategy used by GAS to 
evade innate immunity By the expression of streptococcal C5a peptidase, ScpA, GAS 
attacks complement derived chemotaxins C5a [85]. C5a peptidase is highly specific for 
the alternative complement component C5a and is strategically bound to the bacterial 
surface near the source of C5a which is generated by interaction of streptococci with the 
alternative complement pathway. Although several virulence factors are known to 
attack complement components, they are non-specific and act on a variety of proteins 
[86, 87]. ScpA is unique in that it acts on C5a specifically which delays infiltration of 
phagocytes, retarding clearance of bacteria from mucosal surfaces [88].  
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Besides targeting inflammatory responses by the elimination of C5a at the bacterial 
surface [88], IL-8, the neutrophil activating peptide 1, was recently shown in association 
with necrotizing fasciitis to be targeted for degradation [89]. IL-8 is generally produced 
as a consequence of neutrophil activation which further amplifies the inflammatory 
response [90] by mediating endothelial translocation and subsequent recruitment of 
neutrophils to the site of infection. The cell envelope serine proteinase Spy0416 (ScpC) 
was identified to specifically cleave IL-8 between 59Q and 60R resulting in conversion 
from an 8 kDa to a lower molecular-weight species of 6 kDa [91]. This lead to a paucity 
of neutrophils at the site of infection, because the inactivated form of IL-8 lacks the 
necessary biological activity to promote neutrophil transmigration.  
3.2.3.3 Antiphagocytic Behavior of S. pyogenes 
Phagocytes seem to be very efficient in eliminating streptococci since the bacteria do not 
produce catalase or significant amounts of superoxide dismutase to inactivate the 
oxygen metabolites (e.g. hydrogen peroxide, superoxide) produced by the oxygen-
dependent mechanism of phagocytes. Therefore, pathogens can be quickly killed after 
engulfment by phagocytes. The streptococcal defense must be one to stay out of 
phagocytes [8]. It is well established that group A streptococcus causes diseases 
attributed partially to its ability to resist phagocytosis by human neutrophils due to 
surface exposed M protein and hyaluronic acid capsule. Inhibition of phagocytosis is 
principally due to the ability of M protein to bind fibrinogen [81] or complement control 
protein factor H which inhibits non-immune opsonisation [83]. Furthermore, 
streptococcal cell surface structures including hyaluronic acid capsule contribute to 
resistance to phagocytosis [92]. Hyaluronic acid capsule does not seem to block C3 
deposition on the surface of GAS. Rather, it acts as a physical barrier to prohibit direct 
interaction of PMNs with opsonins on the bacterial surface [93]. 
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Figure 1: Interactions of S. pyogenes with the human host in terms of adhesion, invasion, innate and 
adaptive immunity 
Adhesion processes involve interaction of S. pyogenes M protein and Protein F/SfbI with fibronectin as well 
as Cpa or Scl with collagen. Interaction with plasma glycoproteins (fibrinogen and plasminogen) is 
mediated via the M protein. Invasion processes involve M protein interaction with CD46 cellular receptor 
and/or interaction of M protein and SfbI via plasma fibronectin with integrins to establish signalling events 
into the cell and induce actin-mediated “zipper phagocytosis”. Invasion is supported by secretion of toxins 
by S. pyogenes including streptodornase (S-dornase), streptokinase (S-kinase) involved in fibrin lysis as well 
as potent cytolytic toxins including streptolysin S (SLS) and streptolysin O (SLO).  
To protect itself from innate immunity, proinflammatory actions for the recruitment of phagocytes to the 
infection site are reduced by ScpA and ScpC degrading C5a and IL-8, respectively. The alternative 
complement system is inhibited by M protein that binds factor H, a complement control protein and 
fibrinogen. Adaptive immunity is the principle protective immune response. Factor H binding to 
streptococcal M protein inhibits the classical complement pathway. Antibodies against conserved 
determinants found in the C-terminal region of the M protein, Protein F/SfbI, ScpA and also toxins are 
effective in inducing opsonisation and neutralization, respectively. Humoral immune defenses can be 
avoided by genetic sequence variation of the M protein N-terminal domain. Strong cytokine secretion is 
induced by binding of SpeB (pyrogenic exotoxin) to MHC class II molecules outside the peptide binding 
cleft of APCs (antigen presenting cells) which leads to activation of CD4+ T cells. 
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3.2.3.4 Evasion of Humoral Immune Responses 
The major mechanism used by bacteria to evade humoral immunity is genetic variation 
of surface antigens. An example is the M protein. Type-specific M protein antibodies 
directed to the exposed extreme amino-terminal ends of M protein epitopes result in 
activation of the classical complement pathway through deposition of C3b and 
subsequent phagocytosis [8, 79]. Extreme genetic variation at exactly the amino-terminal 
ends of the M protein protects strains of different M types from being immediately 
eliminated by antibodies. Even in the situation of increased defense by the host S. 
pyogenes again demonstrates adaptation. Furthermore, late complications of humoral 
immune response to bacterial infection can be the generation of disease-producing 
antibodies attributed to the conserved C-terminal region of the M protein. Some of the 
antibodies that target the C-terminus of the streptococcal M protein cross react with 
myocardial sarcolemmal proteins and myosin and are deposited in the heart and 
subsequently cause carditis [94]. 
T cells are targeted by streptococcal pyrogenic exotoxins (SpeA, SpeB, SpeC, SpeD) 
which can trigger and increase cytokine release of T cells. These exotoxins do not require 
processing by antigen presenting cells due to their ability to stimulate T cells by binding 
class II MHC molecules outside the peptide binding cleft. The independence of 
polymorphic differences in MHC leads to a massive detrimental cytokine release [8, 95-
97] promoting injury to surrounding tissues. These exotoxins are powerful toxins as they 
can potentially trigger diseases such as toxic shock and autoimmunity and therefore 
play an important role in S. pyogenes survival within its human host. Cytokines such as 
tumor necrosis factor, IL-1, IL-6, and IFN-γ have been implicated as central contributors 
to tissue destruction and death due to shock triggered by streptococcal infection [79]. 
Primarily chemokines stimulate the activation and migration of neutrophils into tissue 
from peripheral blood.  
 
This summary only briefly described some of the streptococcal immune evasion 
mechanisms used by GAS to successfully establish disease and are not the only ones 
used in the repertoire of Group A streptococcal pathogenesis. There are other 
mechanisms described in literature [79, 98-100] and there might be discovered many 
more in the future. 
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3.3 Treatment and Prevention  
Penicillin, a beta-lactam antibiotic, is to date the drug of choice for treating most GAS 
infections and resistance to penicillin was not reported until today. The primary goal of 
antibiotic therapy for patients with streptococcal pharyngitis is eradication of the 
organism [101]. Nevertheless the evaluation of the efficacy of penicillin for treatment of 
GAS pharyngitis has revealed lower than expected eradication rates from the upper 
respiratory tract [101]. The primary treatment for GAS infections in patients with β-
lactam hypersensitivity or chronic, recurrent pharyngitis due to prior treatment failure 
are thus macrolides and lincosamides. In recent years, resistance to macrolides such as 
erythromycin, the second drug of choice, was reported to emerge [102]. Interestingly, the 
increased use of macrolide antibiotics is correlated with an increased rate of resistance to 
erythromycin among group A streptococcal isolates [103, 104]. In Finland, the rates of 
erythromycin resistance among group A streptococci prompted an intense effort to 
decrease the use of macrolide antibiotics, which in turn led to a dramatic reduction in 
the prevalence of erythromycin-resistant strains [105]. Although there is no resistance to 
penicillin registered so far, reports about increasing antibiotic resistance in different 
bacteria such as Streptococcus pneumoniae [106] or Staphylococcus aureus [107] and also 
recently observed increased properties of insusceptibility to penicillin for example in 
group B streptococci [108] are concerning [109]. Penicillin resistant S. pyogenes strains 
would increase the disease burden dramatically since penicillin is uniquely effective in 
the treatment of GAS infections and still this treatment is not optimal because treatment 
failures do occur [1]. One problem with antibiotic treatment might be the intracellular 
localization of GAS which probably protects the bacteria from β-lactam action and might 
account for recurrent pharyngotonsillitis [110]. In vitro studies show that the ability of 
GAS to persist in the throat following antibiotic therapy is in accordance with their 
capacity to adhere to and be internalized by epithelial cells [1]. For instance, it could be 
shown that the proportion of prtF1-positive strains was significantly higher among 
patients with eradication failure than among those with successful eradication of 
bacteria, thus promoting a carrier state [111]. Neeman’s data indicated that prtF1-
positive strains isolated from carriers enter cultured epithelial cells much more 
efficiently than strains lacking this gene. Inadequately or untreated streptococcal 
pharyngitis can lead to rheumatic fever and rheumatic heart disease which is the case 
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for about 3% of individuals. Even though in the United States for example outbreaks of 
rheumatic fever are relatively rare [13], as many as 1% of school-age children in 
developing countries are estimated to have rheumatic heart disease [112].  
Another problem represents the excessive global usage of antibiotics. Whenever 
symptoms of a sore throat and high fever occur, symptoms are quickly eradicated with 
antibiotics, without careful diagnosis, which increase concerns that penicillin-resistant 
strains may appear since there might occur selective pressure for resistance. Therefore, 
there is a strong motivation and need to develop a safe and effective vaccine against 
group A streptococcal pharyngitis [1].  
3.4 Vaccine Approaches to Protect Against GAS Pharyngitis 
Prevention of severe diseases relies on the diagnosis and efficient treatment with 
penicillin. Although so far S. pyogenes remains susceptible to penicillin, resistance to 
different antibiotics has been reported with an increasing frequency [102, 113-115]. Most 
significantly, GAS pharyngitis contributes to approximately 20% to antibiotic 
prescriptions for acute respiratory illnesses in the Unites States [116]. The eradication or 
at least significant reduction of carriage of S. pyogenes in the human pharynx would have 
profound effect on the dissemination of this organism in the population and on the 
initiation of streptococcal disease. Even in cases of the highly invasive strains of 
streptococci, there is not much evidence that they originate from other than pharyngeal 
sources [1]. Therefore, vaccination clearly constitutes an attractive alternative strategy to 
control GAS infections not only to significantly reduce the burden of invasive and non-
invasive disease, but also to reduce antibiotic use and thus development of resistance in 
group A streptococci. 
Vaccines take advantage of the adaptive immune system which is based on a specific 
repertoire of B cell-derived antibodies and T cell presented receptors that bind to antigen 
of an intruding microbe [117]. The pathogen-specific antigens formulated in vaccines are 
capable of inducing protective B and T cell responses. Traditional vaccines contain 
inactivated/attenuated microbes in which whole microbes seem to deliver the set of 
antigens needed to induce a repertoire of protective antibodies and T cells such as in 
case of vaccines directed against Bordetella pertussis and Vibrio cholerae. These traditional 
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vaccines indeed disclosed that a proper set of antibodies optimally mounted against a 
single antigenic structure like surface carbohydrate or a particular protein can be 
sufficient to provide protective immunity. In case of S. pyogenes it is getting more 
complicated due to the complexity of the pathogen as a single antigen is not sufficient to 
provide protection against the whole range of serotypes. 
3.4.1 M protein Based Vaccine Approaches 
A prime vaccine candidate has been the M protein since it could be shown that M 
protein-specific human and animal antibodies have the capacity to opsonize streptococci 
in preparation for phagocytic clearance [1, 46]. Therefore, studies were designed to 
develop a GAS vaccine focusing on the variable amino-terminal and conserved carboxy-
terminal regions of the M protein [118]. Although the variable N-terminal region of the 
M protein induces opsonic and protective antibodies which overcome the 
antiphagocytic property, protection is only serotype specific. On the other hand, 
vaccines based on conserved domains located in the carboxy-terminal region have been 
reported to evoke protection against strains of heterologous M serotypes, but also may 
induce harmful cross-reacting antibodies [119, 120]. This cross reactivity is based on 
significant sequence homology of M protein with mammalian fibrillar proteins 
including type I keratin, myosin and human α-tropomyosin [121]. B cell epitopes have 
been identified within the M protein that induce antibodies that show cross reactivity 
with human heart tissue, joint but also kidney and brain [120-124].  
Thus multivalent M protein vaccines were designed which contain epitopes from the 
amino-terminal type specific regions of different M proteins in tetravalent, octavalent 
and 26-valent vaccines [125-127]. In the development of type-specific epitope-based 
vaccines, still one has to consider the prevalence of specific serotypes within a 
population [126] and the variability of M protein structures within a serotype [128-130]. 
It is unrealistic to predict that highly complex multivalent M protein based vaccines will 
prevent all group A streptococcal infections [126].  
Vaccine approaches using the conserved C-terminal region of the M protein were also 
taken into consideration [131, 132]. For instance overlapping synthetic peptides of the 
conserved region of the M6 protein were covalently linked to the mucosal adjuvant 
cholera toxin B subunit [131]. Another approach was investigated by Olive and 
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colleagues with a peptide vaccine that contains a conserved M protein B cell epitope and 
lacks a T cell autoepitope which elicited protective immunity at the mucosal level in 
mice [133]. Further attempts using M protein conserved region as a streptococcal vaccine 
were undertaken with vaccinia virus as vector system [1, 134].  
Combination of multiple M protein amino terminal peptides and a conserved region 
peptide demonstrated complete protection in mice parenterally upon challenge with 
different GAS strains [135, 136].  
Although approaches to design multivalent M protein vaccines containing epitopes 
from the amino-terminal type specific regions of different M proteins [127], the 
conserved C-repeat region of this antigen [131, 133] or combinations of them [135-137] 
have proven to be reasonably effective in inducing protective immunity against S. 
pyogenes infections in experimental animal models, individual consideration led to the 
conclusion that they either do not fulfil all the requirements of broad coverage and 
safety or they have failed conferring full protection against a lethal challenge [138]. 
3.4.2 Protective S. pyogenes Antigens Other than M protein 
To circumvent problems that might occur with vaccines solely based on M protein, 
attempts have been made to identify novel protective GAS antigens. Several protective 
antigens were found to induce protective immune responses in animals and were 
therefore considered as vaccine candidates. For example the group A streptococcal C5a 
peptidase, which cleaves the human chemotaxin C5a and prevents its binding to 
polymorphonuclear neutrophils, was targeted as a potential vaccine candidate, since it 
was shown to lack serotypic diversity [118, 139]. The intranasal administration of a 
defective form of streptococcal C5a peptidase molecule to mice showed protection when 
challenged with heterologous serotypes [140]. Furthermore it stimulated significant 
levels of specific salivary secretory IgA which increased clearance of streptococci from 
intranasally infected mice [140]. C5a peptidase antibodies in acute and convalescent sera 
from children with streptococcal pharyngitis were also detected [141]. Studies have also 
shown that more than 70% of adults have measurable IgA directed at C5a peptidase 
(ScpA) in their saliva [142].  
A different strategy was targeted by Musser and his group working on the group A 
streptococcal cysteine protease SpeB [143]. Since it was found that a mutant lacking SpeB 
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expression lost nearly all its ability to cause death in mice they could show that both 
passive and active immunization with rabbit IgG to cysteine protease and cysteine 
protease itself, respectively, foreshortened time to death but did not prevent it. Also 
pyrogenic exotoxin A and C (SpeA and SpeC) are considered as potential vaccine 
candidates. Selected multiple-site mutants of SpeA as toxoids [144] and two toxoid 
mutants of pyrogenic exotoxin C [145] were shown to be protective when used as 
immunogens in rabbits challenged with a lethal dose of wildtype SpeA or wildtype 
SpeC, respectively. Other streptococcal proteins shown to produce protective immunity 
to heterologous streptococcal serotypes are for instance serum opacity factor [146] and 
the fibronectin binding domain of SfbI [147]. SfbI components were even described to 
have immune modulatory properties resulting in improved cellular and humoral 
immune responses at both systemic and mucosal levels [147, 148]. In addition, 
streptococcal cell surface heme-binding protein, Shp, has been shown to induce 
production of anti-Shp antibodies in mice with bactericidal activity [149]. Furthermore 
SLO was found to elicit antibody responses with markedly different subclass profiles 
than seen for the M protein which supports its utility as a vaccine candidate and 
possible implications for IgG subclass regulation [150]. Antibodies to SLO were 
predominantly IgG1 with only minor contributions from other subclasses while M 
protein specific antibodies were distributed between IgG1 and IgG3 subclasses. In recent 
years more and more potential candidates have been identified for a vaccine against 
group A streptococcal infections. Genome sequencing coupled with advances in 
technology has permitted development of rapid strategies to identify potential new 
vaccine candidates. Postgenomic analyses for example led to the identification of 
spy0843 which encodes a cell surface protein and can confer protection against 
intraperitoneal challenge in a mouse model of GAS infection [151]. Attempts to find new 
GAS candidate vaccine antigens among putative lipoproteins were made by Lei and 
colleagues since lipoproteins are a major class of cell surface exposed proteins and play 
critical roles in nutrient uptake, antibiotic resistance, adhesion as well as protein 
secretion [152]. Five extracellular lipoproteins were identified: Spy0385, a lipoprotein 
component of an ABC transporter possibly involved in iron acquisition, Spy1245, part of 
a putative phosphate transporter, Spy1274, a component of a putative amino acid ABC 
transporter, Spy1390, a homologue of the protease maturation protein PrtM of L. lactis  
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and Spy1558, a thioredoxin homologue. All five proteins stimulated the production of 
antibodies that significantly inhibited in vitro growth of GAS in blood as assessed by 
commonly used bactericidal activity assay. Recently another vaccine candidate was 
published, which has also already been identified by our ANTIGENome Technology 
[153]. The IL-8 degrading cell envelope serine proteinase Spy0416 (ScpC) was shown to 
mediate protection against lethal S. pyogenes infection in mice [154]. 
The increasing knowledge about pathogens shows that streptococcal infection is a 
highly complex process and that a vaccine targeting a single antigen might not be 
sufficient to control all pathogenic aspects of the bacteria and protect the host against 
their colonization. A type-specific vaccine which is capable of protecting against a 
streptococcal infection therefore necessitates a multivalent antigen corresponding to 
stable immunodeterminants on serotypes that together account for the majority of 
nasopharyngeal isolates prevalent within the population at a given time and the absence 
of cross reactivity with its host tissue [1]. 
3.5 Antigenome Technology Applied to GAS 
Several approaches were recently applied to identify novel vaccine candidates from GAS 
based on proteomic methodologies, also taking advantage of the availability of several 
genomic GAS sequences [154-156]. These studies have provided evidence for the surface 
localization of numerous group A streptococcal proteins, some of them without 
predictable signatures for surface localization. In spite of these efforts, so far only one of 
the identified surface proteins, Spy0416, was shown to mediate protection against S. 
pyogenes infection [154].  
By the use of the ANTIGENome technology (see Figure 2) protective vaccine candidates 
have already successfully been identified from S. aureus [157], S. pneumoniae [158] and 
several additional bacterial pathogens (unpublished data). This technology was also 
employed to S. pyogenes for the comprehensive identification of novel conserved and 
protective antigens suitable for vaccine development to prevent GAS infections. The 
underlying technology combines genome-derived peptide libraries which comprise 
nearly the complete protein repertoire of a pathogen with comprehensive collections of 
antibodies which derived from individuals exposed to S. pyogenes [117]. For the library 
  Introduction 
Andrea Fritzer  26 
construction the streptococcal strain SF370 was chosen. After randomly shearing the 
pathogen’s genome into 30-300 bp DNA fragments and introduction of the fragments 
into a frame-selection vector system [157, 159] for the elimination of those random 
sequences that possess a stop codon within the expressed reading frame, the library was 
directly and in-frame transferred into a display vector. This allowed efficient 
presentation of fragment-encoded peptides on the surface of Escherichia coli in context of 
outer membrane proteins LamB, FhuA and BtuB [117, 153] which are characterized by 
flexible loops. In this context it could be assumed that the foreign peptides inserted 
within such a loop may potentially adopt a structural configuration that comes close to 
its natural structure. The three genomic libraries were constructed in the LamB, BtuB 
and FhuA platforms, representing 0.5, 0.15 and 0.35 million clones with average sizes of 
40, 100 and 350 bp, respectively, covering the S. pyogenes SF370 genome more than 50 
times [153, 159].  
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Figure 2: Scheme of the antigen identification and validation approach [117] 
Selection procedure of protective streptococcal antigens out of a pool of proteins encoded by the pathogen. 
 
Human sera which provide imprints of pathogen encounters were used to screen the 
previously generated libraries for antigens expressed by the pathogen during infection 
in vivo. Sera have been collected from patients with acute S. pyogenes infections, such as 
pharyngitis, wound infection and bacteraemia (based on medical microbiological tests). 
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As another source for human sera served uninfected healthy adults, since group A 
streptococcal infections are common and antibodies are present as a consequence of 
natural immunization from previous encounters with streptococci. The serum samples 
from patients and healthy individuals respectively were characterized for anti-S. 
pyogenes antibodies by immune assays to select the most appropriate screening reagents. 
For the assessment of anti-bacterial antibody-levels of high affinity (IgA and IgG) ELISA 
was performed using total bacterial extracts or whole cells as well as secreted 
components isolated from culture supernatant. Sera with the best reactivity were further 
used for the antigen identification. This selection process was performed via magnetic 
bead cell sorting (MACS screening) where E. coli cells displaying the genomic peptide 
library from SF370 strain were incubated with purified and biotinylated antibodies from 
previous selections. Those cells that displayed the peptides recognized by the specific 
antibodies were selected by binding to streptavidin coupled paramagnetic beads 
allowing the separation by magnetic force. The antigenicity of the selected bacterial 
clones was then confirmed by western blot analyses. The screens identified 95 antigen 
candidates annotated in the S. pyogenes SF370 genome and 55 peptides that could not be 
assigned to an annotated open reading frame.  
In order to select the most promising candidate antigens for further evaluation in animal 
models of group A streptococcal disease, several independent selection criteria based on 
a variety of in vitro assays were used: 
 
» The presence of the corresponding genes was tested by PCR and sequence analysis in a 
set of 50 clinical GAS isolates encompassing 15 different serotypes.  
» Peptide ELISA served to evaluate the reactivity of antigenic peptides corresponding to 
the identified antigenic epitopes with multiple individual sera to identify the most 
immunogenic epitopes.  
» Surface localization of the antigenic proteins on the pathogen was evaluated by 
bioinformatics and FACS analysis.  
» All antigens were analyzed by bioinformatics, lack of homology with human proteins 
and for their intellectual property status.  
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The described validation steps generated a ranking list of approximately 31 candidates 
that were recombinantly expressed in E. coli to test their potency to protect against S. 
pyogenes in animal models. Three different animal models were established and survival 
of the mice was monitored as readout for protection. These animal models included 
systemic immunization of CD-1 mice 3 times in an interval of 2 weeks with respective 
recombinant antigens applied with CFA/IFA or Aluminum hydroxide and challenge one 
week after the last booster immunization either with S. pyogenes AP-1 intravenously or 
alternatively with S. pyogenes A20-MA intranasally. The third animal model consisted of 
intranasal immunization of BALB/c mice with the recombinant antigen co-administered 
with IC31®-low and challenged with A20-MA intranasally. Based on the data from all 
three animal models nine group A streptococcal proteins have been selected, Spy0269, 
Spy0292, Spy0416, Spy0488, Spy0872, Spy0895, Spy1536, Spy1666 and Spy1727 as the 
most promising candidates for further characterization and vaccination studies. In this 
work the focus is particularly set on Spy0895, Spy1536 and Spy0416. 
In summary, the antigen identification approach thus reduced the complex GAS 
proteome (1752 proteins) to an ‘antigenome’ consisting of a smaller subset of 
approximately 100 antigenic proteins. Among the most frequently identified antigens 
were most of the previously published antigens and protective proteins, such as M1 
protein (Spy2018) [46], C5A peptidase (Spy2010) [160], Streptolysin O (Spy0167) [150] 
and Exotoxin B (Spy2036) [161], Spy0843 [151] as well as in the meantime published 
ScpC (Spy0416) [154]. This latter observation clearly confirmed that the ANTIGENome 
technology selects valuable vaccine candidates and thereby giving credibility to the 
approach [153]. 
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4 STUDY OBJECTIVES 
The aim of the present work was the characterization of protective antigens identified by 
Intercell’s ANTIGENome Technology and selected as candidates for a prophylactic 
vaccine for the prevention of infections caused by group A streptococcus. Out of nine 
promising vaccine candidates, Spy0416, Spy0895 and Spy1536 have been chosen for 
further characterization.  
The further biochemical characterization of Spy0416 was based on the work of my 
diploma thesis [162, 163], where I could demonstrate for the first time in vitro 
degradation of IL-8 by recombinant Spy0416. Particular focus was set on the 
contribution of the distinct C-terminal domains of Spy0416 to IL-8 degradation. 
Additionally, other CXC and CC chemokines were examined as substrate for 
degradation by Spy0416.  
Secondly, by generation of gene deletion mutants I aimed to assess the contribution of 
the encoded Spy0416, Spy0895 and Spy1536 proteins to GAS pathogenesis. Due to the 
large size and complex protein structure of Spy0416 it was speculated that it has 
additional functions besides its IL-8 degradation activity. In case of Spy0895 which is 
annotated as putative histidine protein kinase, I was hoping to reveal a potential 
involvement into a two component system. For Spy1536 on the other hand, annotated as 
conserved hypothetical protein, not even a putative function was assigned so far. 
Therefore, the availability of deletion mutants was expected to facilitate a thorough 
characteristic including the assessment of growth defects under different environmental 
conditions and the contribution of the genes to virulence in mice. Further it was planned 
to investigate the interaction of the mutants with host proteins as well as the effect of 
gene deletion on expression of surface proteins and transcription. 
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5 MATERIALS AND METHODS 
5.1 Materials 
5.1.1 Laboratory Equipment 
Blockheater QBT2  Grant Instruments Ltd, England 
Centrifuges HERAEUS Megafuge 2.0, Kendro Lab. Products, 
England 
HERAEUS Multifuge 3S-R, Kendro Lab. Products, 
England 
HERAEUS Biofuge Fresco, Kendro Lab. Products, 
England 
EPPENDORF Centrifuge 5415 R, Eppendorf, 
Germany 
E. coli Pulser     Bio-Rad, USA 
FluorChem SP Imaging   Biozym, Austria 
System  
GFL Rocking Shaker 3013  Gesellschaft für Labortechnik, Germany 
Hybridization shaker   Amersham,  
Incubator  HERA Cell 150, Kendro Lab. Products, England 
  HERAEUS Kelvitron-T 
Laminar flow HERA Safe Laminar Flow KS12, Kendro Lab. 
Products, England 
Microplate Reader   Tecan Sunrise, Austria 
Microscope    Nikon Eclipse E200, Austria 
Optimax X-Ray Film  Protec Medizintechnik GmbH & Co KG, Germany 
pH-meter  Mettler Toledo Seven-easy, Germany 
Powersupply Power Pac   Bio-Rad, USA   
Power washer PW 96   Tecan, Austria 
Scales     Sartorius TE1502S, Germany 
     Sartorius CP224S, Germany 
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Sonoplus HD2070, UW2070  Bandelin, Germany 
Spectrophotometer -  Amersham Biosciences, England 
Ultrospec 3300 pro  
Synergy2 ELISA reader  BioTek, Germany  
Thermocycler    Biometra T3000, Germany 
     Biometra T3, Germany 
     Biometra T-Gradient, Germany 
Thermomixer compact  Eppendorf, Germany 
Trans-Blot® SD semi-dry  Bio-Rad, USA 
UV Transilluminator   Life Technologies, Germany 
Vacuum pump   Neuberger, KNF Comfort 
5.1.2 Additional Equipment 
AmershamTM CyScribeTM cDNA Post labelling Kit   GE-Healthcare 
BCATM Protein Assay Kit      Thermo Scientific 
Blood Agar plates      BioMerieux 
Bromphenolblue Neolab Migge Laborbedarf 
Vetriebs GmbH 
ChemiglowTM        Alpha Innotech Corp. 
Centrifugal device Nanosep 10K Omega    PALL Life Sciences 
Chang cells (clone 1-5c-4, Wong Kilbourne    ATCC 
Derivative (D) of Chang conjunctiva)  
Detroit 562 cells       ATCC 
DIG Easy Hyb       Roche  
DIG labelled RNA Molecular Weight Marker  Roche  
DIG Wash and Block Buffer Set     Roche 
DNA Molecular Weight Marker II     Roche 
DNaseI, amplification grade     Invitrogen 
ECL detection kits       Amersham Biosciences  
E. coli Pulser® Cuvettes      Bio-Rad 
Electroporation cuvettes, 2mm    Peqlab 
EMEM        BioWhittaker 
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Expand High Fidelity PCR System     Roche 
F-12K Medium (Kaighn’s Modification of    ATCC 
Ham’s F-12 Medium)  
Human collagen I and IV     Sigma 
Human fibrinogen      Sigma 
Human fibronectin      Sigma  
Human haptoglobin       Sigma 
Human laminin      Sigma 
Human plasminogen      Sigma 
iBlot® Gel Transfer Device      Invitrogen 
iBlot® Gel Transfer Stacks (nitrocellulose, regular)  Invitrogen  
IllustraTM CyScribeTM GFXTM      GE-Healthcare 
1 kb Plus DNA Ladder      Invitrogen  
Lane Marker reducing sample buffer    Pierce  
Light Cycler 480 SYBR Green I Master   Roche 
Luminescent Detection Kit and ready to use CSPD  Roche  
Ni-NTA agarose beads      BioRad 
Nitrocellulose membranes (0.45 Micron)   HybondTM  
Page RulerTM Plus Prestained Protein Ladder   Fermentas 
PCR DIG Probe Synthesis kit     Roche  
Poly PrepTM slides       Sigma  
ProLong gold antifade reagent containing DAPI   Invitrogen 
QIAquick Gel Extraction Kit     Qiagen 
QIAquick PCR purification Kit     Qiagen  
QIAprep Spin Miniprep Kit      Qiagen  
Restriction enzymes       New England Biolabs® Inc. 
RiboPure™–Bacteria Kit      Ambion 
SDS-Page PAGEr® Duramide Precast Gels   Cambrex 
Sigma Wide Range marker      Fermentas 
Simply Blue Safe Stain      Invitrogen  
Slide-A-Lyzer dialysis cassette    Pierce 
SOC medium        Invitrogen  
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SuperScript III First-Strand Synthesis System   Invitrogen  
TC Microwell 96F plates      Nunc  
TOPO-TA Cloning Kit      Invitrogen  
Twin.Tec real-time PCR Plates 96     Eppendorf   
Wizard® Genomic DNA Purification kit    Promega 
5.1.3 Chemicals and Reagents  
ABTS        Sigma-Aldrich 
Acetic acid       Fluka 
Aceton       Sigma-Aldrich 
AEBSF        Serva 
Agarose, electrophoresis grade    Invitrogen 
Albumin Bovine Serum (BSA) Fraction V   Biomol 
Ammonium Chloride     Sigma-Aldrich 
Ammonium Hydroxide      Sigma-Aldrich  
Amphotericin B       Invitrogen 
Aprotinin       Sigma-Aldrich 
APS (Ammoniumperdisulfat)    Sigma-Aldrich  
Bestatin       Sigma-Aldrich 
Bromphenol Blue      Sigma-Aldrich 
BugBuster® Protein Extraction Reagent    Novagen  
Calcium carbonate      Sigma-Aldrich 
Complete Freund´s Adjuvant    Difco 
DEPC        Invitrogen 
DMEM (1x) high Glucose     PAA 
E-64        Serva 
EDTA        Sigma-Aldrich 
Ethanol       Merck 
Ethidium Bromide      Fluka 
Erythromycin       Sigma-Aldrich 
Fetal Bovine Serum      Sigma-Aldrich 
FITC Isomer I       Sigma-Aldrich  
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Formaldehyd Lösung, 37% Neolab Migge Laborbedarf 
Vetriebs GmbH 
Formamide  Sigma-Aldrich 
Gentamicin (10 mg/ml), liquid    Invitrogen 
D-(+) Glucose Ultra, 99.5%      Sigma-Aldrich 
Glutaraldehyde      Merck 
Glycerol, 87 %       Fluka 
Glycerol, 99%       Sigma-Aldrich 
Glycine       Fluka 
HBSS        Gibco 
Hydrochloric Acid, 37%, A.C.S. reagent   Fluka 
HEPES       Fluka 
Imidazole       Sigma-Aldrich 
Incomplete Freund´s Adjuvant    Difco 
IPTG        Sigma-Aldrich 
Kanamycin Sulfate      Gibco 
Leupeptin       Serva 
L-Glutamine       Invitrogen 
Lysozyme       Sigma-Aldrich 
Magnesium chloride      Sigma-Aldrich 
MEM nonessential amino acids    Invitrogen 
2-Mercaptoethanol (50 mM)     Invitrogen 
Methanol       Fluka 
MOPS, minimum 99.5 titration    Sigma-Aldrich 
Mutanolysin from Streptomyces globisporus  Sigma-Aldrich 
Ni-NTA-Agarose®      Qiagen 
PEG- Solution       Sigma-Aldrich 
Penicillin-Streptomycin-Glutamine (100 x, liquid)  Invitrogen 
Pepstatin A       Serva 
PMSF        Sigma-Aldrich 
Ponceau Solution       Sigma-Aldrich 
(0.1% (w/v) Ponceau S in 5% (v/v) acetic acid) 
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2-Propanol       Fluka 
Simply Blue Safe Stain Solution    Invitrogen 
Skim Milk Powder      Fluka 
Sodium Acetate      Merck 
Sodium Carbonate      Sigma-Aldrich  
Sodium Chloride      Sigma-Aldrich 
Sodium Dodecyl Sulfate (SDS)    GibcoTM   
Sodium Hydrogen Phosphat     Merck 
Sodium Hydroxide      Sigma-Aldrich 
Sodium Pyruvate      Invitrogen 
TEMED (N,N,N,N-Tetra-methyl-ethylendiamine)  Bio-Rad 
TRIZMA®base, minimum 99.9%    Sigma-Aldrich 
Trypsin, 0.05% (1X) with 0.53 mM EDTA 4Na   Invitrogen 
Tween® 20       Sigma-Aldrich 
Triton X100        Fluka 
UltraPure™ Phenol:Water (3.75:1 v/v)   Invitrogen 
X-Gal (5-Bromo-4-chloro-3-indolyl β-D-galactoside) Sigma-Aldrich 
5.1.4 Buffers 
Binding Buffer 0.5 M NaCl, 20 mM NaH2PO4, 20 mM 
Imidazole/PBS 
Coating buffer:   0.1 M sodium carbonat, pH 9.3 
Deionized formamide 500 ml formamide stirred with 50 g AG 501-X8 ion 
exchange resin, filtrated and stored at RT 
Denaturation solution  0.5 M NaOH, 1.5 M NaCl 
10 x DNA loading buffer 250 mg bromphenol blue dissolved in 40 ml water 
containing 20 g sucrose in a total volume of 50 ml 
Electroporation buffer  0.3 M glucose in PBS 
Electrophoresis/TAE buffer: 196 mM glycine, 0.1% SDS in 50 mM Tris-HCl pH 
8.3 for one liter 
High Stringency buffer  0.5x SSC, 0.1% SDS or 0.1% SSC, 0.1% SDS 
Low Stringency buffer  2x SSC, 0.1% SDS 
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10x MOPS buffer 200 mM MOPS, 50 mM sodium acetate, 20 mM 
EDTA, pH 7 
Neutralization solution  0.5 M Tris-HCl pH 7.5, 1.5 M NaCl 
PBS-T  PBS/ 0.1% Tween-20 
PIC I (100x) Leupeptin (10 mg/ml), Pepstatin A (1 mg/ml in 
EtOH), Aprotinin (5 mg/ml in HEPES, pH 8.0) 
PIC II (100x)  4 mM Bestatin, 1 mM E-64, 10 mM AEBSF  
SDS-running buffer 1xPBS/ 0.1% SDS 
20x SSC    3 M NaCl, 0.3 M sodium citrate 2H2O 
Western blot transfer buffer 39 mM glycine, 48 mM TRIZMA®base, 0.037% SDS, 
20% methanol  
5.1.5 Antibodies 
Dilutions used in Western blot and Immunofluorescence experiments are indicated in 
brackets. 
 
Penta-His antibodies (1:5,000)    Qiagen 
Polyclonal goat anti-human CXCL8/IL-8 (1:1000)  R&D Systems 
Polyclonal goat anti-human CXCL11/I-TAC (1:1000) R&D Systems 
Polyclonal goat anti-human IP-10 (1:1000)   R&D Systems 
Polyclonal goat anti-human MCP-1 (1:1000)  Santa Cruz Biotechnology 
Polyclonal goat anti-S. pyogenes SpeB (1:1000)   Santa Cruz Biotechnology 
Polyclonal mouse anti-M1, -M23, -Spy0269, -Spy1666  in house 
serum (1:25 or 1:1000) 
Secondary goat anti-mouse IgG/HRP (1:5,000)  Amersham Biosciences 
Secondary rabbit anti-goat IgG/HRP (1:5,000)  DakoCytomations 
Texas Red dye conj. AffiniPure goat anti-mouse (1:100) JacksonImmunoResearch 
        Laboratories 
5.1.6 Cytokines 
CXCL8/IL-8       R&D Systems 
MCP-1        PeproTech Inc. 
IP-10         PeproTech Inc. 
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I-TAC        PeproTech Inc.  
5.2 General Methods of Molecular Biology 
5.2.1 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was carried out for analytical purposes to separate DNA 
according to its size and for isolation of specific DNA fragments. Corresponding to the 
size of the DNA, 0.8-1% agarose gels were prepared with TAE buffer. DNA was 
visualized with 0.5 µg/ml ethidiumbromide added to the liquid agarose. A DNA gel 
loading buffer was added to the DNA sample and the 1 kb Plus DNA Ladder was used 
as standard size marker. For cloning procedures DNA fragments were excised from the 
gel and purified using the QIAquick Gel Extraction Kit. 
5.2.2 SDS Polyacrylamid Gel Electrophoresis 
For the separation of proteins according to their size SDS-PAGE was carried out using 4-
20% gradient PAGEr® Duramide Precast Gels. Protein samples were mixed with 5 µl 
Lane Marker reducing sample buffer and heated for 5 minutes to 95°C or for 20 minutes 
to 75°C. Sigma Wide Range marker or Page RulerTM Plus Prestained Protein Ladder 
served as a molecular weight markers. The proteins were separated at 150 V for 1 hour 
or at 200 V for 45 minutes. The gradient gels were further used either for Western blot 
analysis (see 5.2.3) or were stained with Simply Blue Safe Stain Solution. 
5.2.3 Western Blot 
Proteins were separated by one dimensional SDS-PAGE as described under 5.2.2 and 
were transferred onto a HybondTM nitrocellulose membrane via a semi-dry transfer 
system (Trans-Blot® SD) using western blot transfer buffer or via dry blotting utilizing 
iBlot® Gel Transfer Device and iBlot® Gel Transfer stacks according manufacturer’s 
instructions. After the proteins have been transferred on the nitrocellulose membrane 
they were visualized with Ponceau S. Membranes were blocked with 5% milk in PBS or 
PBS-T at room temperature for one hour or at 4°C overnight. Primary antibodies were 
diluted in 5% milk in PBS or PBS-T for 1 hour at room temperature (see 5.1.5). The 
membranes were washed three times for 15 minutes with PBS-T and were incubated 
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with horseradish-peroxidase (HRP) conjugated secondary antibodies in PBS or 5% milk 
in PBS-T for one hour at room temperature. Prior to detection, the membranes were 
washed with PBS-T and PBS. For detection either the ECL detection kit was used where 
the membranes were exposed to a HyperfilmTM ECL in an X-ray film cassette for 3-15 
minutes or ChemiglowTM  served as substrate for the measurement of 
chemiluminescence with the FluorChem SP Imaging System with a CCD digital camera. 
5.2.4 Southern Blot 
For the generation of DIG-dUTP labelled probes labelled M49591 S. pyogenes genomic 
DNA served as template. The probes were amplified with Expand High Fidelity Kit 
under standard conditions with primers (see Table 3, Appendix I) 6074 and 6075 
resulting in a 313 bp, with 6076 and 6077 resulting in a 117 bp fragment. Additionally 
pGhost5 served as template for amplification of a specific probe with primers 6333 and 
6334 resulting in a 1032 bp PCR product. After purification using QIAquick Gel 
Extraction Kit the PCR products served as templates for the DIG labelling PCR reaction 
using PCR DIG Probe Synthesis Kit. DIG labelling required the following PCR 
conditions: 1.5 mM MgCl2 and a ratio of 1 to 2 of 1.5 mM dNTPs and PCR DIG probe 
synthesis mix. 
Genomic DNA was isolated using Wizard® Genomic DNA Purification kit (as described 
under 1.8) and was digested for 8 hours at 37°C with EcoRI or EcoRV restriction 
enzymes to generate an average size of 5000 bp fragments. The digested genomic DNA 
(0.5 µg/ sample) was separated on a 0.8% agarose gel at 80 V for 5 hours. The DIG-
labelled DNA Marker II served as DNA ladder. All incubations were carried out at room 
temperature unless otherwise stated. For the transfer of the DNA on the nylon 
membrane the agarose gel was submerged twice for 15 minutes in Denaturation 
solution. The gel was rinsed with sterile water and immediately submerged twice for 15 
minutes in Neutralization solution. Finally the gel was equilibrated in 20x SSC for at 
least 10 minutes. Capillary transfer of DNA on a nylon membrane was carried out 
overnight using 20x SSC. For DNA crosslinking the wet membrane was exposed for 3 
minutes to UV light with DNA site up. Further steps were adapted from Roche using 
DIG Easy Hyb and DIG Wash and Block Buffer Set. Pre-hybridization and hybridization 
steps were carried out at 42°C using DIG. DIG labelled probes were diluted 1:10 in 
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ddH2O for hybridization. Post-hybridization washes with Low and High Stringency 
Buffer were carried out twice under constant agitation for 5 minutes at room 
temperature and for 15 minutes at 65°C, respectively. Visualization was carried out 
using DIG Luminescent Detection Kit according to the manufacturer’s instructions.  
5.2.5 Northern Blot 
For Northern blot analysis all steps were carried out under RNase free conditions using 
DEPC treated water. The probes that have been generated for Southern blot were used 
and additional probes were generated using primers listed in Table 3 (see Appendix I). 
For probe amplification M49591 S. pyogenes genomic DNA (see 5.8) served as template 
DNA. Amplification was carried out using primers 7268 and 7269 resulting in a 419 bp 
fragment, 7270 and 7271 resulting in a 152 bp PCR product, and 7272 combined with 
7273 generating a 258 bp PCR fragment. PCR conditions of the DIG labelling PCR 
reactions were the same as described for the Southern blot probes (see 5.2.4). 
RNA was isolated from mid-exponential growth phase (OD600nm ~0.5) using RiboPure™– 
Bacteria Kit (see 5.9) and was separated on a 1-2% agarose gel in 1x MOPS buffer 
containing 2% formaldehyde. DIG labelled RNA Molecular Weight Marker was used as 
Marker. Transfer of RNA on the positively charged nylon membrane was carried out the 
same way as for Southern blot (see 5.2.4). Further steps were adapted from Roche using 
DIG Easy Hyb and DIG Wash and Block Buffer Set, as described under 1.2.4. Exceptions 
were the increase of pre-hybridization and hybridization temperatures to 50°C and post-
hybridization wash with High Stringency Buffer was carried out at 50°C. Visualization 
of specific probes again proceeded the same way as described under 5.2.4 using DIG 
Luminescent Detection Kit. 
5.3 Bacterial Strains and Plasmids 
The following S. pyogenes strains were used for in vitro and in vivo studies 
» AP-1: M1 serotype, procured from Dr. Lars Björck, Department of Cell and Molecular 
Biology, Section for Molecular Pathogenesis, Lund University, Lund, Sweden 
» SF370: M1 serotype 
» A20-MA: M 23 serotype 
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» M49591: M49 serotype, received from Bernd Kreikemeyer, University of Rostock 
Medical Faculty Inst. of Med. Microbiology, Virology and Hygiene Dept. of Med. 
Microbiology and Hospital, Rostock, Germany  
The following E. coli strains were utilized for cloning and expression of recombinant 
proteins: 
» Competent ElectroMAX™DH5α-E™ (genotype F-φ80ΔlacZΔM15(lacZYA-argF) U169 
recA1 hsdR17(rk-, mk+)gal- phoA supE44λ-thi-1gyrA96 relA1): Invitrogen 
They were used for transformation via electroporation and plasmid maintainance. The 
ElectroMAX™DH5α-E™ host is particularly suitable for cloning because of a high 
plasmid yield and quality due to the endA1 mutation besides high transformation 
efficiency. Additionally, the stability of inserts is ensured due to the recA1 mutation. 
» One Shot® TOP10 chemically competent E. coli cells (genotype F-mcrA Δ(mrr-hsdRMS-
mcrBC) φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(araleu) 7697 galU galK rpsL (StrR) endA1 
nupG): Invitrogen 
TOP10 chemically competent cells do not require IPTG for induction of the lac operon. 
For blue white screening only 40 µl of 40 mg/ ml X-Gal in dimethylformamide is 
required. 
» BL21 StarTM (genotype F-ompT hsdSB (rB-, mB-) gal dcm rnel31, DE3): Stratagene 
They were used for the expression of recombinant proteins. Besides the λDEЗ lysogen, 
which allows high-level expression of T7-regulated genes, BL21 StarTM contains the 
rne131 mutation which enhances the expression capability of the strain. The rne gene 
encodes the RNase E enzyme which is usually involved in rRNA maturation and mRNA 
degradation. The rne131 mutation encodes a truncated RNase E not able to degrade 
mRNA. Consequently the RNase E-defective BL21 StarTM strain exhibits upon induction 
increased mRNA stability. 
» BL21-CodonPlus® (DE3)-RIPL (genotype B F– ompT hsdS(rB– mB–) dcm+ Tetr galλ(DE3) 
endA Hte ): Stratagene 
They produce an increased supply of rare E. coli tRNAs that correspond to codons used 
more frequently by other organisms which helps to overcome expression problems due 
to codon bias. 
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The following plasmids were used for cloning procedures and gene deletion (see 
Appendix II): 
» pET28b(+) and pET28bn-His: Novagen and Intercell construct 
They were used as vectors for expression of recombinant proteins. The pET28(+) 
expression vector carries a C-terminal His-Tag/thrombin/T7-Tag configuration and an 
optional N-terminal His-Tag sequence. Transcription is carried out by T7 RNA 
polymerase. When heterologous genes are expressed from T7-based expression vectors, 
the yields of recombinant proteins increase. Vector pET28bn-His is a modification of 
pET28b(+) and carries an N-terminal His-Tag. This vector expresses a His-tag at the N-
terminus of the recombinant protein. 
» pGhost5:  
This temperature sensitive shuttle vector was used for the generation of gene deletion 
mutants in M49591 S. pyogenes strain. It harbours an erythromycin resistance cassette for 
selection in E. coli and S. pyogenes as well as an origin of replication (pBR322) for 
maintenance and propagation in E. coli at 37°C. It was kindly provided by Prof. Dr. 
Dieter J. Reinscheid, Bonn-Rhein-Sieg University of Applied Sciences, 53359 Rheinbach, 
Germany. 
5.4 Cloning of Genes and Expression of Proteins 
5.4.1 Preparation of Insert DNA by PCR 
The gene fragment of interest was amplified from S. pyogenes SF370 or M49591 genomic 
DNA (see 5.8) using the Expand High Fidelity PCR System. Gene specific primers for all 
amplified DNA fragments were designed with Vector NTI and are presented in 
Appendix I. PCR products obtained were digested with the respective enzymes at 37°C 
for 1-3 hours, unless otherwise stated. After digestion the DNA was purified using the 
QIAquick PCR purification or Gel Extraction Kit from Qiagen according to 
manufacturer’s instructions. 
5.4.2 Ligation of DNA Fragments into Plasmids 
The digested, purified plasmids (pET28b(+), pET28bn-His and pGhost5) and generated 
PCR fragment were ligated containing maximum 50 ng pET28b(+) or pET28bn-His and 
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50-100 ng insert DNA fragment, 2 µl ligase buffer, 1 unit T4 DNA Ligase and 1 µl 
distilled H2O. In case of pGhost5 cloning procedures a minimum of 200 ng vector and 
250 ng insert were used. The ligation was carried out for 16 hours at 16°C. Prior to 
transformation into E. coli (see 5.4.4) the Ligation reaction was precipitated by adding 
distilled water to a total volume of 100 µl. To the 100 µl 0.1 volumes 3 M sodium acetate 
(pH 5.3), 0.015 volumes glycogen and 2 volumes of chilled ethanol (100%) were added. 
The mixture was vortexed and incubated for 10 minutes at 80°C. This was followed by 5 
minutes centrifugation at 15,700 g. The received pellet was washed with 200 µl 70% 
ethanol and again centrifuged for 2 minutes at 15,700 g. The pellet was dried at 37°C to 
remove ethanol and finally it was resuspended in 1-10 µl water. 
5.4.3 TOPO Cloning 
To facilitate cloning into pET28b(+), pET28bn-His or pGhost5 PCR selected amplified 
DNA fragments have been subcloned into the TOPO® vector from Invitrogen’s TOPO-
TA Cloning Kit. The procedures were carried out according to the manufacturer’s 
instructions. The TOPO vector with its insert was transformed into One Shot® TOP10 
chemically competent E. coli cells via heat shock (see 5.4.4). 
5.4.4 Transformation of Electrocompetent and Chemically Competent E. coli Cells 
Transformation was done in pre-chilled electroporation cuvettes with a 0.1 cm electrode 
gap. Electrocompetent E. coli cells (DH5-α-E™, BL21 StarTM and BL21-CodonPlus® (DE3)-
RIPL competent cells, see 5.3) were thawed on ice, and aliquotes of 19 µl were gently 
mixed with 1 µl ligation mixture (5-50 ng DNA) by tapping. After transfer to chilled 
cuvettes the cells were electroporated with an E. coli Pulser setting the voltage to 2.0 kV. 
Cells were immediately resuspended in 1 ml SOC medium and incubated shaking for 60 
minutes at 37°C.  
Chemical transformation was carried out with One Shot® TOP10 chemically competent 
E. coli cells via heat shock. Therefore one aliquot of E. coli cells was gently mixed by 
tapping with 5-50 ng DNA and incubated on ice for 30 minutes. The heat shock was 
carried out for 30 seconds at 42°C and the cells were immediately put on ice, 
resuspended with 250 µl SOC medium and incubated at 37°C shaking for 1 hour. 
Transformants were selected by plating on LB plates containing 50 µg/ml Kanamycin for 
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pET28b(+), pET28bn-His and TOPO® vector (also X-gal for selection) or in case of 
pGhost5 500 µg Erythromycin. Presence of recombinants was ascertained by colony 
PCR. Plasmid isolation from recombinant colonies was done with the QIAprep Spin 
Miniprep Kit and inserts were checked by restriction digestion and sequencing. For 
restriction enzyme mapping, an aliquot of 0.05 - 0.2 µg was digested with the 
appropriate enzymes for 2 hours at 37°C. The size of the restriction fragments was 
confirmed on a 0.8-1% agarose gel (see 5.2.1). 
5.4.5 Analysis of Protein Expression  
After plasmids were transferred into the expression host E. coli BL21 StarTM (see 5.4.4), 
expression was tested in small scale with IPTG induction. Bacteria grown overnight in 
LB medium supplemented with 50 µg/ml Kanamycin at 37°C were diluted 1:4 and 
cultured until an OD600nm 0.6 was reached. Cells were induced with 1 mM IPTG for 2 
hours at 37°C. Cells were pelleted and lysed by incubation with 100 µl Bug BusterTM 
lysis buffer for 1 hour at room temperature. After centrifugation for 5 minutes at 15,700 
g, the culture supernatant (soluble fraction) was taken off and analysed by SDS-PAGE 
(see 5.2.2). The expressed proteins were visualized with Simply Blue Safe Stain and 
Western blot analysis using Penta-HisTM antibodies (see 5.2.3). 
5.4.6 Expression of Recombinant S. pyogenes Proteins 
For expression of recombinant proteins, E. coli cells (BL21 StarTM One Shot® or BL21-
CodonPlus® (DE3)-RIPL competent cells) which harbour the pET28b(+) or pET28bn-His 
vector with the respective gene as insert were cultivated as a starter culture in 25 ml LB 
medium supplemented with Kanamycin (50 µg/ml) at 37°C shaking overnight. The 
overnight culture was diluted 1:40 in one litre LB-Kanamycin (50 µg/ ml) at a starting 
OD600nm ~0.01 and the E. coli cells were further incubated until they reached an OD600nm of 
0.8. Recombinant protein expression was induced by adding IPTG (final concentration of 
0.5 mM) and an additional growth period of 3 hours was necessary to produce sufficient 
protein for purification. Following induction, the cells were harvested by centrifugation 
for 40 minutes at 1,800 g at 4°C. The cell pellets were collected, resuspended in PBS and 
pellets from two liters of culture were combined. After an additional centrifugation step 
to decant the supernatant efficiently, the cells were frozen at -80°C overnight. In the 
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pET28b(+) and pET28bn-His vectors all recombinant proteins are expressed with a tag of 
six histidines at the C-terminus and the N-terminus respectively. Purification was 
carried out by affinity chromatography using Ni-NTA-Agarose® bead.  
5.4.7 Purification of Recombinant S. pyogenes Proteins 
For purification of the expressed recombinant proteins E.coli cell pellets generated 
previously (see 5.4.6) were thawed and resuspended in 25 ml BugBuster® Protein 
Extraction Reagent. This liberates intracellular proteins by disrupting the E. coli cell wall. 
Protease inhibitor cocktail I and II (PIC I and PIC II, see 5.1.4) as well as PMSF (1 mM 
final concentration) were added to avoid protein degradation by proteases. The cell 
lysates were incubated rotating 45 minutes at room temperature. Meanwhile a 1.5 ml 
aliquot of Ni-NTA-Agarose® beads was washed twice with 1 ml distilled water. After 
the washing step the beads were washed two times with binding buffer (0.5 M NaCl, 20 
mM NaH2PO4, 20 mM Imidazol in PBS) and centrifuged for 2 minutes at 4°C at 1,300 g. 
To separate soluble and insoluble fractions of the E. coli lysates the suspension was 
centrifuged and the supernatant was kept as soluble fraction. Furthermore, it was mixed 
with Ni-NTA-Agarose® beads in binding buffer and after addition of 0.1% Tx100 it was 
incubated rotating for at least 2-3 hours at room temperature. The mixture of cell lysate 
and Ni-NTA-Agarose® beads was applied on a column and its flow through was 
collected. The tube which had contained the lysate-bead mixture was rinsed with 2 
column volumes of 50 mM Tris/HCl (pH 8.0), 150 mM NaCl, 0.1% TX100 and 0.5 mM 
DTT and the rinse was poured onto the column, to loose as little as possible of the 
recombinant protein.  
The column was subsequently washed with the following buffers: 
» 2 column volumes of 50 mM Tris/HCl (pH 8.0), 150 mM NaCl, 0.1% TX100 and 0.5 mM 
DTT   
» 10 column volumes using 50 mM Tris/HCl (pH 8.0), 150 mM NaCl and 0.5 mM DTT  
» 5 column volumes using 20 mM Imidazol in 50 mM Tris/HCl pH 8.0, 150mM NaCl and 
0.5 mM DTT 
» 5 column volumes using 40 mM Imidazol in 50 mM Tris/HCl pH 8.0, 150mM NaCl and 
0.5 mM DTT 
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Proteins bound to the Ni-NTA-Agarose® were harvested in 4 elution steps using the 
following buffers: 
» 3 column volumes of 500 mM imidazole, 20 mM NaH2PO4, 0.5 mM NaCl in 50 mM 
Tris/HCl pH 8.0 
» 3 column volumes of 500 mM imidazole, 20 mM NaH2PO4, 0.5 mM NaCl in PBS pH 7.4 
» 3 column volumes of 500 mM imidazole, 20 mM NaH2PO4, 0.5 mM NaCl in 50 mM 
HEPES pH 7.0 
» 3 column volumes 500 mM imidazole, 20 mM NaH2PO4, 0.5 mM NaCl in 50 mM 
HEPES pH 6.2 
In order to remove everything that was bound to the Ni-NTA agarose beads a final wash 
using 3 column volumes of 500 mM imidazole, 8 M urea in Tris/HCl pH 8.0 with 0.5 mM 
DTT was carried out.  
The efficiency of protein purification was analysed by SDS-PAGE (see 5.2.2) using 
between 1 and 5 µl of soluble fraction, wash or flow through and eluate fractions and 
visualized with Simply Blue Safe Stain. The fractions containing overexpressed proteins 
were pooled and dialyzed against PBS. The amount of recombinant protein was 
evaluated by SDS-PAGE using BSA as quantitative standard. 
5.5 Cultivation of S. pyogenes Strains 
S. pyogenes strains were grown overnight in THY medium in a humidified atmosphere at 
37°C and 5% CO2 without shaking. The cultures grown overnight were diluted 1:20 in 
the respective growth medium. For the determination of the growth behaviour of the 
different strains a growth curve was generated. Therefore the optical density of the S. 
pyogenes strains was measured at 600 nm every hour except during logarithmic growth 
phase (around OD600nm ~0.5) when the optical density was measured every 30 minutes. 
To evaluate the colony forming units at an optical density of 0.5 serial dilutions of the 
bacteria were plated in triplicates on blood agar plates.  
5.6 Generation of Competent S. pyogenes Cells 
For the generation of electrocompetent M49591 S. pyogenes cells the bacteria were grown 
overnight in 3 ml THY supplemented with 20 mM glycine. After a 1:10 dilution in 30 ml 
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fresh THY medium containing 20 mM glycine the bacteria were grown until they 
reached an optical density of ~0.2 and were incubated on ice for 10 minutes. The bacteria 
were pelleted by centrifugation at 1,300 g for 10 minutes and washed twice in ice cold 
electroporation buffer. The washed pellet was taken up in 500 µl cold electroporation 
buffer and left on ice until the competent S. pyogenes cells were used for electroporation. 
5.7 Preparation of S. pyogenes Subcellular Fractions for SDS-PAGE and 
Western Blot Analysis 
S. pyogenes strains were grown as described under 1.5 and the bacterial pellets of a 50 ml 
mid-exponential (OD600nm ~0.5) or late stationary (overnight culture) culture were 
harvested by centrifugation at 1,800 g for 15 minutes. The pellets were washed once with 
PBS and stored overnight at -80°C. After being frozen the bacterial cell pellets were 
taken up in 10 mM Tris HCl, pH 7.6 and lysed by sonication (6x 30 seconds, pulse 5, 
100%). Lysates were centrifuged and the supernatants containing cytoplasmic proteins 
were concentrated using Centrifugal device Nanosep 10K Omega. The pellet from the 
lysate was washed twice with 10 mM Tris/HCl pH 7.6, resuspended in 50 mM Tris, 5 
mM EDTA, 10 mM NaCl, pH 8.1, containing 250 µg Lysozym and 50 U Mutanolysin, 
and was incubated at 37°C for 4 hours. After centrifugation, cell wall proteins contained 
in the supernatant were concentrated the same way as the cytoplasmic fractions. The 
protein concentration of lysates, cytoplasmic and cell wall fractions was measured using 
the BCATM Protein Assay Kit. 
5.7.1 TCA Precipitation of Culture Supernatants 
For concentration of proteins that were secreted into the culture supernatant, TCA-
precipitation was selected as procedure. First 100% TCA was added to each supernatant, 
to give a final concentration of 12% and the mixture was incubated on ice for one hour. 
After incubation on ice the samples were centrifuged at 1,800 g for 40 minutes at 4°C. 
The harvested pellets were washed twice with freeze cold acetone (-20°C) and the 
supernatant after centrifugation at 1,800 g for 15 minutes at 4°C was removed carefully. 
The samples were dried at 37°C until all the acetone was completely evaporated. The 
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precipitated samples were dissolved in PBS and kept for further use at -20°C. The 
protein concentration was measured using the BCATM Protein Assay Kit. 
5.8 Preparation of S. pyogenes Genomic DNA 
Genomic DNA of S. pyogenes strains was purified using Wizard® Genomic DNA 
Purification kit following the manufacturer’s instructions except that the double amount 
of lysozyme was used and lytic enzyme was not used at all. The isolated genomic DNA 
was further used for PCR or Southern blot analysis (see 5.2.4). 
5.9 Isolation of S. pyogenes RNA  
RNA was isolated from S. pyogenes strains for Northern blot analysis (see 5.2.5), 
Microarray analysis (see 5.21) and Real Time RT-PCR (see 5.22) using RiboPure™-
Bacteria Kit. Therefore, overnight cultures of S. pyogenes strains were diluted 1:50 in 
fresh THY medium and grown until they reached mid-exponential phase at OD600nm ~0.5. 
All steps were carried out as described in the kit’s protocol for RNA used in Northern 
blot experiments including DNase treatment.  
As for transcriptome analyses a higher concentration of high quality RNA was desirable 
the protocol was slightly changed: The pellet of a 50 ml culture was taken up in 1.4 ml 
RNAwiz and portioned on 4 provided tubes containing zirconia beads. The 10 minutes 
step where bacteria are lysed by the zirconia beads during vortexing was increased to 20 
minutes. The RNA was eluted in 2x 25 ml elution buffer and DNase treatment was 
carried out using 1 U DNaseI, amplification grade, from Invitrogen per microgram 
RNA. This reaction was inactivated by addition of 2.5 M EDTA and heating to 65°C for 
10 minutes. Absence of DNA was verified by PCR. The RNA of one 50 ml pellet was 
pooled and precipitated. For precipitation UltraPure™ Phenol:Water (3.75:1 v/v) was 
added 1 to 1 and centrifuged for 5 minutes at 15,700 g. LiCl (5 M) was added to the 
supernatant 1 to 1 followed by incubation overnight at 4°C. The RNA was harvested by 
centrifugation (15,700 g for 15 minutes) and washed with ice cold 70% ethanol. The 
dried pellet was taken up in 50 µl DEPC-treated H2O. RNA was checked for degradation 
by agarose gel electrophoresis (see 5.2.1). Additionally, RNA quality was examined 
using SuperScript® III First-Strand Synthesis System which was also used for the reverse 
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transcription of RNA into cDNA. RNA was reverse transcribed as suggested by the 
manufacturer and degraded by RNaseH. Controls were treated the same way but 
missing the reverse transcriptase leading to the fact that during the RNase treatment 
potential DNA contaminants are left in the samples that are amplified during PCR and 
visualized on the agarose gel. 
5.10 Generation of Polyclonal Antibodies 
Polyclonal mouse antibodies have been generated and mainly used for Western blot 
analysis (see 5.2.3) as well as immunofluorescence analysis (see 5.20). 
For the production of antigen specific antibodies ten 6-8 weeks old CD-1 mice were 
immunized with 50 µg recombinant protein emulsified with 1% Alum as adjuvant in 
their flank after taking pre-immune sera from their tail vein. After 14 and 28 days the 
mice received a booster dose through the same route with the same dose of Alum. Seven 
days after the second boost immune sera were taken, pooled and tested for total IgG by 
ELISA and for antigen specific antibody levels by Western blotting. Presence of protein 
specific antibodies was tested either using 1-5 µg of recombinant protein or lysates 
comprising 20-30 µg protein via Western blot analysis (see 5.2.3). All studies were done 
according to the local animal ethics guidelines (Tierschutzgesetz BGBl. Nr. 501/1989). 
5.11 Intraperitoneal Murine Challenge Model 
For the comparison of virulence between various S. pyogenes strains, bacteria were 
grown overnight in THY medium and diluted 1:50 in fresh THY medium at 37°C and 
5% CO2. The bacterial cultures were pelleted after they have reached an optical density 
of ~0.5 by centrifugation at 1,800 g for 10 minutes. The pellet was taken up in ice cold 
PBS to reach a final concentration of 5x108 cfu/ 100 µl. CD-1 mice were challenged 
intraperitoneally with 5x108 cfu/ 100µl and the survival of the CD-1 mice was monitored 
over a period of 2 weeks. Serial dilutions of the bacterial suspension used for challenge 
were plated from 1:10 to 1:10-6 in triplicates on blood agar plates. 
  Materials and Methods 
Andrea Fritzer  49 
5.12 CXC Chemokine Degradation Assay 
The assay for chemokine degradation was always carried out at 37°C. Interleukin 8 was 
used at a final concentration of 6.6 µg/ ml in PBS containing 0.1% BSA. This corresponds 
to an amount of 150 ng chemokine per assay sample (22.8 µl). BSA, present in the IL-8 
solution at 100 µg/ ml (228 ng per sample), served as a standard showing the use of 
equal amounts of IL-8. MCP-1, IP-10 and I-TAC were utilized at a final concentration of 
8.8 µg/ ml corresponding to an amount of 200 ng chemokine per assay sample (22.8 µl). 
The Spy proteins Spy0416A, Spy0416B, Spy0416BFn2Fn3, Spy0416BFn2´Fn3´, Spy0416BY, 
Spy0416BFn2´Fn3´+Y and Spy0416BΔFn1 were used at a concentration of 44 µg/ ml each or in 
combination at a concentration of 22 µg/ml, unless otherwise stated. Chemokine 
degradation was visualized via semi-dry Western blot analysis (see 5.2.3.) using the 
respective primary and secondary antibodies listed under 1.1.5.  
5.13 Protein Interaction Studies by Surface Plasmon Resonance (SPR) 
Interaction studies were performed in collaboration with Andreas Kungl (Department of 
Pharmaceutical Sciences, University of Graz and ProtAffin Biotechnologie AG, 8020 
Graz, Austria) as described in Fritzer et al., 2009 [162]. In brief, BIAcore X–100 biosensor 
system was used to perform binding experiments. FC2 (flow cell 2) of a BIAcore C1 
sensor chip–surface was initially activated with a mixture of 0.4 M EDC and 0.1 M NHS. 
IL–8 was immobilized via amine coupling at a concentration of 25 µg/ ml in 10 mM 
acetate puffer pH 5.5. At a flow rate of 10 µl/ minute and a temperature of 25°C the 
injection time was 7 minutes, resulting in an immobilization level of 342 RU after 
blocking for 7 minutes with ethanolamine. FC1 served as control surface that underwent 
the same chemistry except immobilization of IL–8. Analyses were performed by 
injecting different concentrations of Spy0416A, Spy0416B, Spy0416A1 and Spy0416AΔ 
(ranging from 0 – 1 µM in PBST buffer) over the IL-8 surface for 3 minutes at a flow rate 
of 30 µl per minute. Considering the high stability of the formed complexes, the 
dissociation time was set to 7 minutes, followed by a regeneration step with 0.5% SDS at 
the end of each cycle. The sensorgrams were analyzed using the BIAcore X-100 
evaluation software. Therefore reference subtracted association and dissociation phases 
of all binding curves were simultaneously fitted to different binding models. 
  Materials and Methods 
Andrea Fritzer  50 
5.14 Isothermal Fluorescence Titration (IFT) 
Isothermal Fluorescence Titration was performed in collaboration with Andreas Kungl 
(Department of Pharmaceutical Sciences, University of Graz and ProtAffin 
Biotechnologie AG, 8020 Graz, Austria) as described in Fritzer et al., 2009 [162]. In brief, 
39 nM of Spy0416A or Spy0416B were titrated with IL-8 in the presence of 1 µM bis-
ANS. Excitation was set at 395 nm and fluorescence emission spectra were collected 
between 450 nm and 550 nm. Fluorescence quenching of bis-ANS emission was detected 
due to competition of IL-8 for Spy0416 binding. The excitation-/ emission slit widths 
were set to 15 nm and 20 nm, respectively; the temperature was adjusted to 22°C and a 
430 nm cut off filter was inserted into the emission path to avoid stray light. After 
background correction of the spectra, areas were integrated and mean values of the 
fluorescence intensity, F, resulting from two independent experiments plotted against 
the volume corrected concentration of the IL-8 ligand. The resulting binding isotherms 
were analysed by nonlinear regression as described previously [164, 165]. The fitted 
parameters were Fmax and KD. 
5.15 Preparation of Human Neutrophils and Intracellular [Ca2+]-Measurement 
Preparation of human neutrophils and intracellular [Ca2+]-measurement was performed 
in collaboration with Andreas Kungl (Department of Pharmaceutical Sciences, 
University of Graz and ProtAffin Biotechnologie AG, 8020 Graz, Austria) as described in 
Fritzer et al., 2009 [162]. Human whole blood was obtained from healthy volunteers by 
venipuncture into tubes containing K3EDTA. Neutrophils were isolated by Ficoll-Paque  
centrifugation (400x g, 30 minutes, 4°C) followed by dextran sedimentation of the red 
blood cell (RBC) pellet containing PMNs for 1 h at RT. The PMN-rich supernatant was 
aspired, washed twice with HBSS(-) at 600x g for 10 minutes followed by hypotonic lysis 
of the RBCs and 2 further washing steps. Finally the cells were diluted with HBSS(+) at 
107 cells/ml, taking into account that only 60% of the counted cells were neutrophils. 
Fluorescence measurements were performed on a Perkin Elmer LS50B fluorometer. The 
diluted neutrophils were supplemented with 0.5% BSA and loaded with 3 µM FURA-
2AM for 30 minutes at 37°C in the dark. Subsequently, the cells were washed twice with 
HBSS(+) (500x g, 4 minutes) and stored in HBSS(+)/ 0.5% BSA. Immediately before 
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measurement, 1 ml aliquots were centrifugated for 3 minutes at 500x g and resuspended 
in 1 ml HBSS(+). The cells were placed in a continuously stirred cuvette maintained at 
37°C. After an equilibration period of 10 minutes, a stable fluorescence signal was 
reached. The fluorescence was monitored at an excitation of 345 nm and an emission of 
495 nm, as determined in an initial measurement. The excitation/emission slits were set 
at 10/4. Cells were stimulated with 100 nM protein 60 sec after pre-equilibration, and 
maximum and minimum fluorescence were determined using the following solutions: 
Minimum buffer (100x): 0.18 M EGTA, 1.4 M Tris, 10% Triton X-100 and Maximum 
buffer (100x): 1M HCl, 0.5M CaCl2.  
5.16 Generation of Gene Deletion Mutants in Strain M49591 using pGhost5 
Construction of gene deletion mutants using the temperature sensitive shuttle vector 
pGhost5 was adapted from Biswas et al. [166]. In brief, 150 µl of competent S. pyogenes 
cells (see 5.6) and 1 µg of pGhost5 vector were used for each transformation. 
Electroporation was carried out at 2 kV. The transformed cells were kept on ice for 5 
minutes and incubated for 5 hours in prewarmed THY medium at 28°C, the temperature 
at which the shuttle vector pGhost5 is maintained extra-chromosomally. S. pyogenes 
Cells were plated on THY agar plates containing 5 µg/ ml Erythromycin and incubated 
at 28°C with 5% CO2. For the integration of the construct into the chromosome of S. 
pyogenes, cells were grown in THY containing 5 µg/ml Erythromycin overnight at 28°C 
and 5% CO2 and diluted 1:100 in THY without Erythromycin until they reached an 
optical density (600 nm) between 0.3 and 0.5. A temperature shift from 28°C to 37°C for 
150 minutes induced integration of the vector into the GAS chromosome and serial 
dilutions of cells were plated on THY containing 5 µg/ml Erythromycin and incubated 
overnight at 37°C and 5% CO2. Successful integration of the vector into the chromosome 
was confirmed via PCR. After verification of pGhost5 integration into the chromosome, 
another temperature shift back to 28°C overnight induced excision of pGhost5. Cells 
were plated on agar plates with and without Erythromycin for the selection of 
erythromycin sensitive cells with the desired recombination event and hence gene 
deletion. Positive cells were identified by PCR. Gene deletion was further verified by 
sequencing and Southern blot analysis (see 5.2.4). 
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5.17 Electron Microscopy of S. pyogenes Cells 
S. pyogenes strains were grown overnight in THY medium at 37°C and 5% CO2. The 
cultures were diluted in fresh THY medium and grown till they reached an optical 
density of 0.5. The cell pellets were harvested by centrifugation at 1000 g for 15 minutes 
and washed twice with PBS. The cell pellets were resuspended in PBS and fixed using of 
5% paraformaldehyde, 5% glutaraldehyde and 5 mM CaCl2 in PBS for 1 hour at room 
temperature. S. pyogenes cells were finally visualized with an analytical high-resolution 
scanning electrone microscope of the type FEI Quanta 200F with a 50,000 and a 100,000 
fold magnification at the Technical University of Vienna. 
5.18 Adhesion Assay for Human Detroit 562 and Chang cells 
Detroit 562 cells were grown in EMEM supplemented with 10% fetal bovine calf serum 
(heat inactivated), 50 µM 2-Mercaptoethanol, 1% MEM nonessential amino acids, 1% 
gentamicin (10 mg/ ml, liquid) and 1% sodium pyruvate giving the complete growth 
medium. For Chang cells F-12K Medium (Kaighn’s Modification of Ham’s F-12 
Medium) supplemented with 10% heat inactivated fetal bovine calf serum, 100 units 
penicillin G, 0.25 µg/ml amphotericin B and 100 µg/ml streptomycin was used. Passage 
of Detroit 562 and Chang cells was carried out every 3-4 days. Therefore the cells were 
washed twice with HBSS containing 10 mM glucose and were trypsinized for 7 minutes 
at 37°C and 5% CO2 using Trypsin, 0.05% (1X) with 0.53 mM EDTA 4Na. The trypsinized 
cell suspension was taken up in fresh complete medium and was washed once. Cells 
were harvested by centrifugation at 1000 g for 7 minutes and diluted 1 to 5 in fresh cell 
culture medium. Before the adherence assay, cells were passaged into antibiotic-free 
medium. 
For the adhesion assay cells were seeded into wells of 24-well tissue culture plates at a 
density of 2.5x 105 cells per well in 1 ml antibiotic-free medium containing 10% FCS and 
incubated overnight or for 2 days at 37°C and 5% CO2 to reach about 95% confluence. 
Meanwhile, S. pyogenes strains were cultured overnight at 37°C and 5% CO2 without 
shaking. On the next day the bacterial cells were harvested and washed once with PBS. 
Bacteria were taken up either in EMEM or F-12K medium supplemented with 10% FCS 
without antibiotics, to reach 3.4x 108 cfu/ ml. For infection 100 µl of the previously 
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prepared bacterial cell suspension was added to the washed Detroit 562 or Chang cells 
and incubated for 2 hours at 37°C and 5% CO2. 
After incubation, medium was decanted followed by intensive washing with PBS to 
remove unbound bacteria. The Detroit 562 and Chang cells together with the attached 
bacterial cells were trypsinized with 100 µl trypsin for 5 minutes and taken up in 400 µl 
H2O or directly taken up in 500 µl H2O and incubated for 10 minutes at room 
temperature. Immediately, 100 µl of serial dilutions from 1:10 to 1:10-6 were plated in 
triplicates on blood agar plates and incubated overnight at 37°C and 5% CO2. To 
consider also bacterial growth during the process of attachment a control consisting of S. 
pyogenes strains incubated in wells which did not contain Detroit 562 or Chang cells was 
used. Afterwards the suspension was plated also on blood agar plates, using 100 µl of 6-
fold serially diluted bacteria in PBS. 
5.19 Protein Binding Assays 
Human plasma- and extracellular matrix-proteins (fibronectin, fibrinogen, laminin, 
collagen type I and type IV, plasminogen and haptoglobin) were coated on 96 well 
plates (10 µg in 100 µl) using 100 mM NaHCO3/Na2CO3, 50 mM NaCl (pH 9.2) as coating 
buffer and incubated overnight at 4°C. The plates were washed once with PBS and 
blocked with 10% BSA in PBS for 2 hours at 37°C. For labelling with Fluoreszein 
Isothiocyanate (FITC) Isomer I overnight cultures of S. pyogenes strains were washed 
once with PBS and incubated with 1 ml FITC Isomer I (1 mg/ ml Na2CO3) for 20 minutes 
at room temperature in the dark. After incubation, the culture was washed with PBS 
until the supernatant appeared transparent again and 6x 107 cfu/100 µl were incubated 
with the previously coated human proteins on the 96 well plates for 1 hour at 37°C. A 
control of 6x 107 cfu/100 µl FITC-labelled bacteria was incubated for the same time 
separated to take bacterial growth during the incubation time into account. Finally, the 
plates were washed 4 times with 0.1% Tween20 in PBS and measured with the BioTek 
Synergy2 ELISA reader using the following settings: Excitation at 485/20 nm, Emission 
560/60 nm, Gain: 72, 80, 75, 77. 
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5.20 Immunofluorescence Analysis using Confocal Microscopy 
Immunostaining was adapted from Harry et al. [167]. In brief, bacterial cells from an 
overnight culture were harvested by centrifugation at 1000 g for 10 minutes and washed 
once with PBS. After the cells were fixed for 15 minutes at room temperature and 45 
minutes on ice using 5 ml 3% (v/v) paraformaldehyde, 30 mM sodium phosphate (pH 
7.5), they were washed three times using 100 mM glycine in PBS and once with PBS 
only. For the detection of streptococcal proteins on the bacterial surface, cells were 
resuspended in 50 mM glucose, 20 mM Tris-HCl pH 7.5, 10 mM EDTA and ~5x 107 
cfu/100 µl were transferred immediately onto poly L-lysine coated Poly PrepTM slides 
and allowed to settle for 15 minutes. The slides were washed twice with PBS and dipped 
in 0.1% Triton X100 in PBS for 5 minutes. After another wash with PBS the slides were 
blocked overnight at 4°C with 2% BSA in PBS. For the one hour-incubation with the 
primary antibody at room temperature, M23, M1, Spy0269 and Spy1666 specific hyper-
immune mouse sera (see 5.1.5) generated in CD-1 mice (see 5.10) were diluted 1:25 in 100 
µl 1% BSA in PBS. Slides were washed three times for 5 minutes with 0.1% Tween 20 in 
PBS, dried and incubated with Texas Red dye conjugated AffiniPure goat anti mouse 
antibody, diluted 1:100 with 1% BSA in PBS for 1 hour in the dark at room temperature. 
Slides were washed three times with 0.1% Tween 20 in PBS for 5 minutes followed by 
another 3 washes with PBS for 5 minutes. Control cells were stained with DAPI by 
mounting the slides with ProLong gold antifade reagent containing DAPI. 
Polymerization was allowed for 24 hours at room temperature in the dark. 
Immunostaining was visualized with a Zeiss Axiovert 200M microscope equipped with 
a Zeiss LSM510META confocal laser-scanning unit, a Plan-Fluor 100x1.45 oil  or a Plan-
Apochromat 63x1.40 oil DIC MC27 (aperture, 0.19 mm) objective (Zeiss, Germany). 
5.21 Microarray Analysis 
In order to evaluate differential gene expression between different strains, dual colour 
microarray hybridization analysis was chosen. Microarray chips were obtained from 
Bernd Kreikemeyer (Department of Medical Microbiology, Virology and Hygiene, 
University Hospital Rostock, Germany). The whole S. pyogenes genome DNA arrays 
contained 50-mer 5’ amino-oligonucleotides and were designed and produced by MWG 
  Materials and Methods 
Andrea Fritzer  55 
Biotech. As sequence information for the target selection served the published M1 S. 
pyogenes sequence comprising 1964 ORFs, a partial genome sequence of the serotype 
M18 strain 818 ORFs of 1889 ORFs and the partial serotype M49 [168]. 
5.21.1 Generation and Purification of Cy3- and Cy5-Labelled cDNA 
RNA from three independent isolations as described under 1.9 was prepared for 
hybridization: First, 25 µg of RNA were precipitated overnight at -20°C using 0.1 
volume of 4 M LiCl (pH 7.0) and 2.5 volumes of 100% ethanol. This was followed by 
centrifugation at 15,700 g for 10-15 minutes at 4°C and resuspension of the dried pellet 
in 9 µl RNase-free water. The generation of CyDye labelled cDNA was carried out in 
two steps, the first one involves the incorporation of amino allyl-dUTP (AAdUTP) 
during cDNA synthesis using an optimized nucleotide mix and the second step involves 
chemically labeling of the amino allyl modified cDNA. Therefore the Amersham™ 
CyScribe Post labelling Kit was utilized according to manufacture’s instructions. 
Synthesis of cDNA and indirect labelling via aminoallyl integration was performed as 
follows: Random primers with the previously precipitated RNA were heat denatured for 
5 minutes at 70°C to eliminate secondary structures and incubated for 10 minutes at 
room temperature for annealing a mixture of anchored oligo(dT) and random nonamer 
primers. Immediately a mix of 5x CyScribe buffer, 0.1 M DTT, dNTP mix, aminoallyl-
dUTPs and CyScribe Reverse transcriptase as described by the manufacturer were 
added and heated for 90 minutes at 42°C. For the purification of aminoallyl-labelled 
cDNA to remove RNA from the single stranded cDNA, mRNA is degraded into short 
oligomers by the treatment with 2 µl of 2.5 M NaOH and incubated at 37°C for 15 
minutes. Neutralization was induced by the addition of 10 µl 2 M HEPES. The newly 
synthesized cDNA was precipitated by the addition of 0.1 volume 4 M LiCl (pH 7.0), 2.5 
volumes of 100% ethanol and 1 µl acrylamid (Ambion) and incubation at -20°C for 30 
minutes. The pellet harvested by centrifugation at 15,700 g for 15 minutes was 
resuspended in 120 µl Na2CO3 (pH 9.0). cDNA concentration was measured and 20-30 
µg were expected for optimal incorporation of Cy3- and Cy5-labelled nucleotides into 
the cDNA. GE Healthcare’s Illustra™ CyScribe™ GFX purification kit was utilized for 
the post-labelling coupling reaction which was carried out as described by the 
manufacturer except that 4 M hydroxylamine/HCl was increased from 15 µl to 30 µl. To 
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minimize hybridization background and improve the sensitivity of detection of low 
abundance targets unincorporated CyDye molecules were removed with the Illustra™ 
CyScribe™ GFX purification kit. 
5.21.2 Preparation of Microarray Chips and Data Analysis 
For the preparation of the chips, unspecific probe binding was prevented by blocking 
the slides with 4x SSC, 1% BSA and 0.5 % SDS at 42°C for 45 minutes. The chips were 
washed five times with sterile water and dried by centrifugation at 1000 g for 3 minutes. 
For the dual colour microarray hybridization the Cy3- and Cy5- labelled probes (Cy3-
labelled M49591 wildtype and Cy5-labelled gene deletion mutant per chip and vice 
versa) were denatured for 5 minutes at 99°C and immediately cooled in an ice bath. The 
probes were pipetted carefully on the microarray chips and covered by a plastic foil. 
Hybridization was performed at 42°C overnight in the dark. Chips were washed in the 
dark with 2x SSC, 0.1% SDS for 5 minutes at 42°C, with 1x SSC for 5 minutes at 42°C and 
finally with 0.1x SSC for 5 minutes at room temperature, rinsed with water and dried by 
centrifugation. Each experiment was performed in triplicates including separate sample 
preparation as well as labelling and hybridization. Hybridization was detected with a 
DNA Microarray Scanner from Agilent Technology instrument (Affymetrix). Data 
analysis was carried out using GeneSpring GX Software also from Agilent. Data for 
individual genes (values) was expressed as the fold change of normalized wildtype/ 
experimental signal (gene deletion mutant).  
5.22 Real Time RT-PCR 
Real Time RT-PCR was performed to verify the previously generated microarray data. 
The mRNA expression was analyzed from two independent RNA isolations as 
described under 1.9 and reverse transcribed into cDNA with random hexamer primers 
using the SuperScript® III First-Strand Synthesis System following the manufacturer’s 
instructions. Gene-specific oligonucleotide primers (see Table 6, Appendix I) were 
designed using Vector NTI (Invitrogen) and were tested in PCR using M49591 genomic 
DNA and standard conditions to determine amplification specificity. PCR analyses were 
performed using Real Time PCR LightCycler® 480 SYBR Green I Master for the 
incorporation of SYBR Green I dye into double-stranded DNA during each phase of 
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DNA Synthesis. 5 µl of 1:25 diluted cDNA were used for one PCR reaction. Real Time 
RT-PCR was carried out in twin.tec real-time PCR using the Mastercycler from 
Eppendorf with the following conditions: 95°C for 5 minutes to activate the FastStart 
Taq DNA polymerase, 40 cycles running 95°C for 10 seconds, primer annealing at 55°C 
for 15 seconds, elongation at 72°C and SYBR Green I fluorescence was measured at 72°C 
for 10 seconds after every cycle. In the end 95°C for 20 seconds was followed by a 
melting curve analysis where the temperature was increased stepwise from 60-95°C for 
30 minutes and finally 95°C for 15 seconds. The temperature at which the amplified 
DNA is separated into single strands which leads to the loss of the fluorescent SYBR 
Green is characteristic for each PCR product. The housekeeping gene mutS-mRNA 
(encoding DNA mismatch repair protein) expression was used as internal control as it 
produced more stable results than using gki (glucose kinase) or recP (transketolase) as 
internal controls. Data analysis was supported by the Eppendorf RealPlex software and 
quantitative differences for each sample were determined using the 2-(ΔCTsample-
ΔCTcalibrator) method [169]. 
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6 RESULTS 
6.1 Selection of Nine Protective Antigens from Streptococcus pyogenes 
Identified via Intercell’s ANTIGENome Technology 
In order to identify novel group A streptococcal antigens for vaccine development the 
ANITGENome technology was employed using human sera collected from uninfected 
healthy adults [153, 159]. Bacterial surface display screens led to the identification of 95 
antigen candidates as annotated by the S. pyogenes SF370 genome and 55 peptides that 
could not be assigned to an annotated open reading frame [153]. The most promising 
candidate antigens for further evaluation in animal models of group A streptococcal 
disease were selected by in vitro assays such as peptide ELISA with human sera and 
gene conservation analysis. Three different animal models were performed to reduce the 
number of identified candidates to the most promising ones. Mice were either 
immunized with the adjuvant CFA/IFA followed by intravenous challenge with S. 
pyogenes AP-1 or with Aluminum hydroxide following intranasal challenge with S. 
pyogenes strain A20-MA and the third immunization was carried out via the intranasal 
route with the adjuvant IC31™ before challenging with A20-MA. The data from all three 
animal models provided ample evidence for the selection of nine group A streptococcal 
proteins, Spy0269, Spy0292, Spy0416, Spy0488, Spy0872, Spy0895, Spy1536, Spy1666 and 
Spy1727 as the most promising candidates for further vaccine development.  
The nine selected vaccine candidates had not been characterized previously in more 
detail at the time I started this work. While this work was performed, Spy0416 was 
shown to possess IL-8 degrading activity [89, 91, 162]. The other eight proteins have 
either been assigned no or only a putative function so far (see Figure 3). Spy0488, 
Spy1536, Spy1666 and Spy1727 were described as hypothetical or conserved 
hypothetical proteins and show very limited similarity to proteins with known 
functions. However, Spy0269 was described as a putative surface exclusion protein and 
possesses a short 130 amino acid region showing similarity with the EzrA protein that 
interacts with the cell-division protein FtsZ [170]. Spy0292 was annotated as Penicillin 
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binding protein, but no beta-lactamase activity was yet reported for this protein. The 
Spy0872 protein shows similarity to secreted 5'-nucleotidases, enzymes located at the 
cell surface, such as UshA of E. coli [171], with an important function in nucleotide 
salvage or growth on nucleosides as carbon source. Spy0895 displays weak similarity 
with several proteins and was thus annotated as putative histidine kinase and 
transcription regulator LytR, none of which functions was so far experimentally 
confirmed. Due to this very limited knowledge about the proteins the aim was to gain 
more information about their potential function and contribution to streptococcal 
virulence and pathogenesis.  
Spy0269 873 aa
SP EzrA
Spy0416 1647 aa
Spy0488 331 aa
Spy0292 410 aa
SP PBP5-CBeta-lactamase superfamily
Spy0895 262 aa
Cas-Csm6
Spy0872 670 aa
5-nucleotid-C
UshASP LPXTG
345aaSpy1536
Lon-CPDZSP
Spy1666 337 aa
NADB-Rossmann
Spy1727 263aa
PKc-like
APH
PA-C5a
LPXTGDUF 1034Peptidase S8, Subtilase familySP
 
Figure 3: Structural features of the nine protective candidates 
The schematic drawings are based on the protein sequences encoded by the SF370 genome. SP, Signal 
peptide; EzrA, septation ring formation regulator EzrA; PBP5-C, Penicillin-binding protein 5, C-terminal 
domain; PA-C5a, Protease-associated domain of C5a-like proteins; DUF1034, Domain of Unknown 
Function; LPXTG, cell wall anchor motif; UshA, 5'-nucleotidase/2',3'-cyclic phosphodiesterase and related 
esterases; 5-nucleotid-C, C-terminal domain of 5'-nucleotidases; Cas-Csm6, CRISPR (Clustered regularly 
interspaced short palindromic repeats) -associated protein; PDZ, PDZ ('post synaptic density disc-large zo-
1') domain, also called DHR (discs-large homologous region); Lon-C, Lon protease (S16) C-terminal 
proteolytic domain; NADB-Rossmann, Rossmann-fold of NAD(P)(+)-binding proteins; PKc-like, catalytic 
domain of protein kinase C superfamily; APH, Aminoglycoside-2"-phosphotransferase enzyme family.  
6.2 Focus on Three of the Nine Candidates Spy0416, Spy0895 and Spy1536 
The three candidates Spy0416, Spy0895 and Spy1536 have been chosen for further 
characterization for several reasons. 
Spy0416 was selected for more detailed characterization prior to its description as the IL-
8 degrading cell envelope serine proteinase ScpC [89, 91, 162], because this antigen was 
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among those candidates with the widest and highest range of immune reactivity with 
human sera. Further it showed high levels of protection in several mouse models against 
streptocococcal infection. In addition the sequence of the spy0416 gene displayed at least 
98% amino acid sequence identity in genomes of 50 GAS isolates encompassing 15 
different serotypes and bioinformatic analysis revealed a C-terminal LPXTG motif 
predictive of surface localization of Spy0416. Biochemical characterization had already 
started during my diploma thesis where I could demonstrate that the recombinantly 
expressed form of Spy0416 cleaved IL-8 in vitro in a site-specific manner which led to 
inactivation of the chemokine [162, 163]. Interestingly, IL-8 degradation was only 
observed in presence of both, the catalytic N-terminal domain and the accessory C-
terminal domain, for which a function could not be demonstrated so far. Therefore, I 
continued my work on the characterization of Spy0416 by evaluating possible 
contributions of the predicted individual domains within Spy0416B to IL-8 degradation. 
A collaboration with Bernd Kreikemeyer (Rostock, Germany) was established on the 
generation of spy0416, spy0872 and spy0292 gene deletion mutants. For my thesis I 
further focused on the generation of deletion mutants for two additional candidates, 
spy1536 and spy0895 in order to assess their possible contribution to streptococcal 
virulence and pathogenesis. The first set of candidates spy0416, spy0872 and spy0292 for 
gene deletion was selected based on their high protection observed in the mouse models 
and their location on the GAS genome as independently transcribed genes. In contrast, 
spy0895 and spy1536 are located within an operon flanked by one and two genes, 
respectively (see Figure 14B and 14C, page 74). Spy0895, annotated as putative histidine 
protein kinase, Spy1536, a conserved hypothetical protein which is similar to the ATP-
dependent proteinase La, were selected due to their consistent protection in the animal 
models and high conservation in the GAS genome - Spy0895 with more than 98.9% 
amino acid sequence identity and Spy1536 with more than 99.1% amino acid sequence 
identity in 13 GAS strains of 10 different M serotypes [153].  
6.3 Characterization of Spy0416 
The identification of the Spy0416 protein as a prominent antigen [153] using the 
ANTIGENome technology [172] together with the at that time recent reports showing 
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that the Spy0416 protein of invasive S. pyogenes strains possesses human chemokine 
degrading activity [89, 91], has prompted us to further investigate the function of this 
putative serine proteinase. Several attempts to express and purify the full length 
recombinant protein failed. Apart from the fact that correct amplification of the gene 
sequence was not possible, cloning into an E. coli expression vector was not successful 
[162]. Therefore I generated two subfragments, Spy0416A & B overlapping with 132 
amino acids (see Figure 4) for the analysis of IL-8 degradation. The design of these 
fragments was supported by bioinformatic analyses to avoid hindrance of efficient 
expression. It also revealed that the Spy0416 protein consists of multiple domains of 
which the C-terminal region entails several domains with unknown functions (see 
Figure 4). We could previously demonstrate that Spy0416 cleaves IL-8 in a site specific 
manner that leads to inactivation of the chemokine in vitro [162]. Furthermore, site 
directed mutagenesis revealed that the amino acid residues, Asp151, His279 and Ser617, 
predicted to form the active site in the N-terminal domain of Spy0416 (see Figure 4) in 
analogy to Subtilisin-like proteinases [173], are essential for enzymatic activity. The 
abolishment of IL-8 degradation activity by the elimination of the PA and Fn1 domain in 
Spy0416A also indicated a contribution of these two domains. As we could show that 
the C-terminal domain of Spy0416 is also required for proteolytic activity we wanted to 
further investigate the contribution of the individual domains to IL-8 degradation. 
6.3.1 Recombinant Spy0416 Possesses IL-8 Cleavage Activity  
IL-8 degradation could be reconstituted in vitro with the two generated subfragments 
Spy0416A and Spy0416B, as already published [162, 163]. We could further show that 
IL-8 degradation was dependent on enzyme concentration and degradation time 
visualized by immunoblotting since only active IL-8 was detected with anti CXCL-8 
antibodies. 
In order to confirm this data and provide a more detailed kinetic on the process, a 
degradation assay was performed based on the measurement of chemiluminescence.  
Therefore, Spy0416A and Spy0416B were incubated in increasing concentrations for each 
protein with IL-8 for various time intervals at 37°C and IL-8 was quantified on a 
nitrocellulose membrane using FluoreChem SP Imaging System and a CCD digital 
camera. 
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Figure 4: Schematic representation of the domain architecture of serine proteinase Spy0416 and Spy0416B 
subconstructs 
SP, signal peptide; X, Y, low complexity regions; PA, protease associated domain; RI, RII, repeat regions; 
Fn1-3, Fn2’, Fn3’, Fibronectin type III (Fn) domains; LPXTG, cell wall anchor motif. Predicted active site 
residues within Spy0416 are depicted by asterisk. Spy0416A and Spy0416B show a sequence overlap of 132 
amino acids located in the Fn1 domain. Spy0416B subconstructs Spy0416BΔFn1 (Phe819-Ala1600), Spy0416BFn2Fn3 
(Phe819-Thr1127), Spy0416BFn2`Fn3` (Leu1128-Asp1390), Spy0416BY (Leu1391-Ala1600) and Spy0416BFn2`Fn3`Y (Leu1128-
Ala1600) have also been generated. 
 
As shown in Figure 5A, after approximately 1.5 hours 50% of the chemokine was 
degraded by Spy0416A and Spy0416B. Approximately 80% of IL-8 was degraded after 
2.5 hours which was only barely detectable on the immunoblot. Degradation of IL-8 was 
not only dependent on the time of incubation with the cell envelope serine proteinase, 
but also depending on the enzyme concentration (see Figure 5B). At a concentration of 
44 µg/ml Spy0416A and Spy0416B approximately 40% of IL-8 was degraded. At an 
enzyme concentration of 110 µg/ml, inactivation of 100% of IL-8 could be observed 
already after 30 minutes of incubation. These data confirm the dependence of IL-8 
degradation on incubation time and Spy0416 concentration. 
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Figure 5: Time and concentration dependent degradation of IL-8 by Spy0416A and Spy0416B 
(A) Time dependent IL-8 degradation using each 22 µg/ml Spy0416A and Spy0416B incubating at various 
time intervals from 0 – 2.5 hours and constant amounts of IL-8 (6.6 µg/ml). IL-8 was quantified by the 
measurement of chemiluminescence using the FluorChem SP Imaging System. (B) Concentration dependent 
IL-8 degradation after 30 minutes at 37°C using increasing amounts of Spy0416A and Spy0416B (0 – 132 
µg/ml) and constant amounts of IL-8 (6.6 µg/ml). IL-8 was quantified as described under A. 
6.3.2 Binding of IL-8 by Spy0416 is Mainly Mediated by the N-terminal Domain 
In order to further evaluate the essential contribution of Spy0416B to the enzymatic 
activity of Spy0416A, we assessed whether IL-8 binding occurs via the catalytic 
Spy0416A domain or the catalytically inert Spy0416B domain. Our immunoprecipitation 
studies with IL-8 and IL-8 antibodies failed for technical reasons (non-specific binding of 
IL-8 to Protein G beads used for IgG binding). Therefore, in collaboration with Andreas 
Kungl from the Karl-Franzens University in Graz, Austria, we applied isothermal 
fluorescence using soluble proteins and the fluorophore bis-ANS in order to evaluate 
binding of IL-8 to Spy0416A and B proteins. Titration of IL-8 to the samples containing 
Spy0416A or B and bis-ANS, should induce displacement of the fluorophore upon 
binding of IL-8 to S. pyogenes proteins, resulting in fluorescence quenching of bis-ANS 
emission. These analyses showed that both proteins bind IL-8, however Spy0416A had 
an approximately 20 times higher affinity for IL-8 (KD
 
= 2.7x 10-7 M) compared to 
Spy0416B (KD
 
= 1.2x 10-6 M) (see Figure 6A). In order to confirm the large differences in 
affinities of Spy0416A and Spy0416B towards its IL-8 ligand, we performed Surface 
Plasmon Resonance (SPR) experiments in which IL-8 was immobilised via amine 
coupling to a BIAcore C1 chip. By this means, a kinetically-derived KD
 
value of 13.1 nM 
was determined for the interaction of Spy0416A with IL-8, but no interaction of IL-8 
with Spy0416B was detected in this set-up. We also evaluated the binding of the 
Spy0416A1 mutant protein to IL-8 and detected a 70-fold lower, but still significant KD
 
value of 926 nM for the interaction of the chemokine with Spy0416A1 (see Figure 6B). 
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The difference in KD
 
values for Spy0416A interacting with IL-8 derived by the two 
different methods (Isothermal fluorescence titration and Surface plasmon resonance) 
relates to the fact that potentially induced oligomerisation and/or cooperative structural 
effects induced by protein-protein binding lead to different results, if one of the 
interacting partners is immobilised. 
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Figure 6: Binding of IL-8 to Spy0416 as measured by Isothermal Fluorescence Titration and Surface 
Plasmon Resonance (SPR) analysis  
(A) Isothermal fluorescence titrations of 39 nM Spy0416A (■) or 39 nM Spy0416B (□) was measured in the 
presence of 1 µM bis-ANS. Excitation was set at 395 nm and fluorescence emission spectra were collected 
between 450 nm and 550 nm. The fluorescence quenching of bis-ANS emission upon addition of increasing 
IL-8 concentrations was background corrected and normalised for generation of the binding isotherms. KD
 
values were fitted by non linear regression as described in Materials and Methods. (B) Sensorgram overlay 
of Spy0416 variants binding to immobilized IL-8. Spy0416A (■) or Spy0416A1 (○) were injected over an IL-8 
sensorchip at 0, 50, 100, 250, 500, 750, 1000 nM concentration for 3 min at 30 µl/min flow rate. The RU 
(resonance unit) response was recorded as a function of time and kinetic rates were calculated from both 
association and dissociation phases. 
6.3.3 The Interaction of Spy0416A and Spy0416B Competes with Binding of 
Spy0416A to IL-8  
Since the isothermal fluorescence experiment was performed by an indirect 
displacement using a non-covalently attached fluorophore, we were not able to measure 
the interaction of three proteins – Spy0416A, Spy0416B and IL-8 – in one assay. As both, 
Spy0416A and Spy0416B were required for proteolytic activity we applied again in 
collaboration with Andreas Kungl a gel depletion assay to investigate how the two 
fragments of Spy0416 influence each other’s binding to IL-8. In this assay, binding of the 
Spy0416 protein to IL-8 would shift the resulting complex towards the opposite charge-
flow direction as compared to IL-8 alone, resulting in depletion of IL-8 from the gel. 
Despite the intermediate binding affinity between IL-8 and the Spy0416 domains (low 
micromolar range), we were able to detect significant shifts due to the chemokine’s 
quaternary structure that tends to increase from a dimeric to an oligomeric structure 
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upon ligand binding. A 1:10 molar ratio of the Spy0416 proteins and IL-8 used in the gel 
depletion assays led to chemokine oligomerisation and thus to a complete depletion of 
IL-8 by the stronger binding to Spy0416A (see Figure 7, lane 1), whereas Spy0416B alone 
was not capable of fully depleting the chemokine (see Figure 7, lane 2). The 
Spy0416AD151A protein, which was shown to be devoid of catalytic activity [162], was also 
able to deplete IL-8, indicating significant binding to the chemokine even in the absence 
of proteolytic activity (see Figure 7, lanes 3 & 4). Interestingly, in the presence of 
Spy0416B, Spy0416A and Spy0416AD151A
 
were unable to completely deplete IL-8 from the 
gel (see Figure 7, lanes 5 & 6) suggesting that the interaction between the N- and C-
terminal parts of Spy0416 modulates substrate binding. 
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Figure 7: Interaction of Spy0416 variants and IL-8 evaluated by gel depletion assay  
Western blot analysis of IL-8/ Spy0416-protein complexes after 15% native-PAGE (3 hrs, 100 V). lane 1: 5.2 
µM Spy0416A + 54 µM IL-8; lane 2: 4.9 µM Spy0416B + 54 µM IL-8; lane 3: 5.2 µM Spy0416A-D151A + 54 
µM IL-8; lane 4: 2.6 µM Spy0416A + 3.5 µM Spy0416A-D151A + 54 µM IL-8; lane 5: 4.9 µM Spy0416B + 3.5 
µM Spy0416A-D151A + 54 µM IL-8; lane 6: 2.6 µM Spy0416A + 4.9 µM Spy0416B + 54 µM IL-8; lane 7: 54 
µM IL-8. 
6.3.4 Influence of IL-8 Degradation by Spy0416A/B on Ca2+-Release of Neutrophils  
It was shown recently that cleavage of IL-8 by Spy0416 reduces the migration of 
neutrophils in response to the cytokine [89]. As it was previously also described that one 
can distinguish between IL-8 mediated activation and migration of neutrophils [174, 
175] we investigated in collaboration with Andreas Kungl whether IL-8 cleavage by 
Spy0416 also abrogates human neutrophil activation. We thus assessed the Ca2+-release 
of neutrophils before and after pre-incubation of the chemokine with Spy0416A/B. 
Neutrophils showed the expected Ca2+-release after injection of native IL-8 (see Figure 
8A). However, prior incubation of IL-8 with Spy0416A/B had no effect on neutrophilic 
Ca2+-release (see Figure 8B). A signal of similar intensity could even be detected after an 
incubation time of IL-8 with Spy0416A/B of 3.5 hours, indicating that the degradation 
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product of IL-8 (devoid of the C-terminal 13 amino acids) is able to stimulate 
neutrophils, most probably due to the ELR motif at N terminus of the protein which is 
mainly responsible for receptor recognition and activation via CXCR1 (CXC chemokine 
receptor 1) and CXCR2 (CXC chemokine receptor 2). 
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Figure 8: Ca2+- release by neutrophils 
Neutrophils were isolated as described under Materials and Methods. IL-8 was incubated with Spy0416A 
and Spy0416B in PBS at 37°C and degradation was stopped every 30 minutes for 3.5 hours by freezing the 
sample at -20°C. Immediately before measurement, 1 ml aliquots were thawed, centrifuged for 3 minutes at 
500 g and resuspended in 1 ml HBSS(+). Fluorescence was monitored for app. 3 minutes and cells were 
stimulated with 100 nM protein 60 seconds after pre-equilibration, and maximum and minimum 
fluorescence were determined. (A) Calcium-release by neutrophils following injection of undigested IL-8 
(840 ng) after 60 seconds (arrow). (B) Calcium-release of neutrophils after IL-8 (840 ng) injection previously 
incubated for 3.5 hours with Spy0416A/B (described as IL-8d in this Figure). 
 
6.3.5 Mutation of Single Residues of IL-8 Reduces Degradation by Spy0416 
The G protein-coupled (GPC) receptor binding activity of the chemokine IL-8 has been 
assigned to the N-terminal amino acid residues Glu4-Leu-Arg6
 
[165, 174], whereas the 
cleavage by Spy0416 was reported to occur between residues Gln59
 
and Arg60 of mature 
IL-8 (see Figure 9A) [89]. It was thus of interest to determine whether the cleavage 
activity of Spy0416 could be influenced by mutations within IL-8 and whether the 
specificity could be assigned to the cleavage residues itself or residues outside of the 
cleavage site. Recently, Skelton et al. have shown that the interaction of IL-8 with the 
GPC receptor peptide derived from CXCR1 involves the phenylalanine residues at 
position 17 and 21 of the chemokine [176]. Interestingly, the degradation of the 
Interleukin 8 mutant IL-8F17K,F21K is abolished as compared to wild type IL-8 (see Figure 
9B). Other IL-8 mutants containing amino acid substitutions at the Phe17
 
and Phe21
 
positions other than Lys residues (for example Arg residues) exhibited a similar 
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reduction in cleavage by Spy0416 (data not shown), indicating that changes within IL-8 
distinct from the cleavage site strongly influence the interaction with Spy0416. 
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Figure 9: Degradation of the IL-8 mutant IL-8F17K,F21K
 
 
(A) Ribbon drawing of the IL-8 backbone structure; shown in ball and stick representation are the amino 
acids targeted by the Spy0416 enzyme as well as the sites which are, in addition, required for processing by 
Spy0416. (B) The mutant form of IL-8, IL-8F17K,F21K,
 
was used in a concentration of 6.6 µg/ml and tested for 
degradation by Spy0416A and Spy0416B (22 µg/ml each) at 37°C from one up to 72 hours. The control (C) 
represents chemokine without Spy0416A and Spy0416B incubated at 37°C for 72 hours. IL-8F17K,F21K was 
visualized by Western blot analysis as described in materials and methods.  
6.3.6 Deletion of spy0416 Delayed Virulence in an Intraperitoneal Murine 
Challenge Model 
The spy0416 gene deletion mutant, ΔSpy0416 was generated in collaboration with Bernd 
Kreikemeyer (Rostock, Germany). In order to evaluate the role of Spy0416 in 
streptococcal pathogenesis we investigated the effect of spy0416 gene deletion in an 
intraperitoneal murine challenge model and survival of mice was monitored over a 
period of 2 weeks. As it is shown in Figure 10 ΔSpy0416 showed a reduced or delayed 
virulence compared to the M49591 wild type strain which confirmed the recently 
published reduced virulence of the Spy0416 mutant [91]. In an attempt to confirm the 
emm type of the ΔSpy0416 mutant, it was later found that it showed a deviation in emm 
type. Instead of the expected M49 serotype, the M gene sequencing revealed an emm 
type 102. For this reason no further experiments were performed with the mutant. 
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Figure 10: Virulence of ΔSpy0416 in an intraperitoneal murine challenge model 
CD-1 mice were challenged with 5x 108 cfu of S. pyogenes strains M49591 wild type and ΔSpy0416 applied 
intraperitoneally. Survival of mice was monitored over a period of 16 days.  
6.3.7 Generation of Spy0416 Subconstructs 
The spy0416 gene comprises 4944 base pairs and encodes a protein with a calculated 
molecular weight of 181 kDa. The generation of the two subfragments, Spy0416A and 
Spy0416B, was already described previously [162, 163]. The Spy0416A protein (Mw = 
94.52 kDa), encompasses the Subtilisin-like protease domains intervened by a protease 
associated domain (see Figure 4, page 62). The Spy0416B protein (Mw = 103.11 kDa) 
encompasses the entire C-terminal fragment of Spy0416, devoid of 50 amino acids 
cleaved off due to anchoring in the cell wall by the LPXTG motif. I could show that the 
N-terminal domain Spy0416A alone, did not reveal any IL-8 degrading activity [162, 
163]. IL-8 degradation could only be reconstituted by the addition of Spy0416B as 
separate recombinant protein. Therefore I wanted to continue my work on the 
evaluation of distinct domains contributing to IL-8 degradation.  
The C-terminal region Spy0416B, entails two repetitive regions of unknown function, RI 
and RII, each of which consists of two domains identified in C5A peptidase as Fn2/Fn3 
and Fn2’/Fn3’, respectively, postulated to contribute to regulation of enzymatic activity 
[177]. The Y region located at the C terminus between Fn3´and the LPXTG motif shows 
homology to similar regions in proteinases such as CspA of S. agalactiae [177] and to 
sigma A factors of Flavobacteriaceae (app. 30% identity with the N-terminal 100 amino 
acids). Based on this I generated the following Spy0416 subconstructs: Spy0416BFn2Fn3 
(Phe819-Thr1127), Spy0416BFn2´Fn3´ (Leu1128-Asp1390), Spy0416BY (Leu1391-Ala1600), 
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Spy0416BFn2´Fn3´Y (Leu1128-Ala1600), Spy0416AΔFn2 (Ala34-Gln818) and Spy0416BΔFn1 (Leu1128-
Ala1600). The latter ones lack the Fn2 and the Fn1 domains, respectively, which led to the 
elimination of the overlap between recombinant Spy0416A and Spy0416B (see Figure 4, 
page 62). Sequences were amplified from SF370 (primers listed in Table 4, Appendix I) 
since this was the S. pyogenes strain used for the generation of genomic libraries. All 
proteins were expressed by E. coli from expression vector pET28b(+) with a tag of six 
histidines at their C-terminus for purification except for Spy0416BΔFn1. Its expression 
could only be observed in pET28bn-His resulting in a N-terminal His-tag. The hexa-His-
tagged fusion proteins were isolated from the soluble fraction only since insoluble 
recombinant proteins are usually purified using 8M urea which might result in loss of 
their original protein conformation and thus in enzymatic activity. 
The expressed and purified recombinant Spy0416 proteins were assessed for purity by 
SDS-PAGE as presented in Figure 11.  
Spy0416BFn2´Fn3 (Mw 28.9 kDa), Spy0416BY (Mw 23.1 kDa) and Spy0416BFn2´Fn3´Y (Mw 52 
kDa) recombinant proteins do not show any major degradation products. By the use of 
BSA as quantitative standard a final protein amount of ~32.5 mg, 15 mg and 30 mg was 
calculated as product obtained from a shaking E. coli culture of 1 litre, respectively. 
Spy0416BΔFn1 (85.9 kDa) shows increased purity and less degradation than the 
recombinant Spy0416B full length protein which was prone to degradation [162, 163].  
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Figure 11: Analysis of recombinant Spy0416B subconstructs by SDS-PAGE 
Recombinant proteins Spy0416AΔFn1, Spy0416BFn2Fn3, Spy0416BFn2’Fn3’, Spy0416BY and Spy0416BFn2’Fn3’Y were 
expressed in BL21-CodonPlus® (DE3)-RIPL E. coli cells using pET28b(+) and Spy0416B ΔFn1 was expressed 
using pET28bn-His. (A) SDS-PAGE of 1 µl Spy0416BFn2’Fn3’, of 1µl Spy0416BY and Spy0416BFn2’Fn3’Y and 5 µl of 
Spy0416B ΔFn1 deriving from elution using 15 ml of 500 mM imidazole, 20 mM NaH2PO4, 0.5 mM NaCl in 50 
mM Tris/HCl pH 8.0 after dialysis against PBS. BSA served as a quantitative standard using 0.5, 1, 2, 3, 4 and 
5 µg for comparison. (B) SDS-PAGE of 1 µl Spy0416AΔFn2 and Spy0416BFn2Fn2 deriving from elution using 15 
ml of 500 mM imidazole, 20 mM NaH2PO4, 0.5 mM NaCl in 50 mM Tris/HCl pH 8.0 after dialysis against 
PBS. BSA served as a quantitative standard using 0.5, 1, 2, 3, and 4 µg. 
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The final protein amount from a 1 litre E. coli culture was ~3 mg. In contrast, 
Spy0416BFn2Fn3 (34.8 kDa) could not be purified with the same purity and quantity as the 
other Spy0416 subconstructs. For this recombinant protein only 0.188 mg could be 
purified (see Figure 11B). Spy0416AΔFn2 with a calculated molecular weight of 87.3 kDa 
could not be expressed in full length (see Figure 11B). 
6.3.8 The Entire Spy0416 C-terminal Region is Required for IL-8 Degradation  
The entire C-terminal domain was shown to be required for IL-8 degradation which 
indicated an essential function of Spy0416B possibly modulating and/or contributing to 
the N-terminal protease activity. In order to find out whether any of the domains can be 
deliniated, distinct domains generated as separate recombinant proteins were tested for 
their contribution to IL-8 degradation in combination with Spy0416A. As it is shown in 
Figure 12A Spy0416BΔFn1 combined with Spy0416A degraded IL-8 with the same 
efficiency as seen with the full length Spy0416B protein. In contrast, for none of the three 
proteins Spy0416BFn2Fn3, Spy0416BFn2´Fn3´ and Spy0416BFn2´Fn3´Y in combination with 
Spy0416A we could observe IL-8 degradation (see Figure 12B). Also Spy0416A 
combined with Spy0416BFn2Fn3, and Spy0416BFn2´Fn3´ or Spy0416BFn2Fn3 and Spy0416BY or 
Spy0416BFn2Fn3 and Spy0416BFn2´Fn3´Y (see Figure 12C) did not reveal cleavage of IL-8.  
These results suggested that all the domains of Spy0416 need to be present for enzymatic 
activity.  
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Figure 12: Degradation of IL-8 by Spy0416A combined Spy0416B subconstructs 
Western blot analysis of active human IL-8 using goat anti-human CXCL8/IL-8 specific antibodies (1:1000 
dilution) and secondary rabbit anti-goat IgG/HRP (1:5,000) for detection. (A) Spy0416A and Spy0416BΔFn1, 
were individually (44 µg/ml) and in combination (22 µg/ml) incubated with IL-8 (6.6 µg/ml) at 37°C for up 
to 3 hours. (B) IL-8 (6.6 µg/ml) was incubated with 22 µg/ml Spy0416A combined with 22 µg/ml 
Spy0416BFn2Fn3 or Spy0416BFn2`Fn3` or Spy0416BY or Spy0416BFn2`Fn3`Y. (C) IL-8 (6.6 µg/ml) was incubated with 
14.5 µg/ml Spy0416A combined with 14.5 µg/ml Spy0416BFn2Fn3 and 14.5 µg/ml Spy0416BFn2’Fn3’ or 
Spy0416BFn2Fn3 and Spy0416BY or Spy0416BFn2Fn3 and Spy0416BFn2`Fn3`Y.  
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6.3.9 IP-10, MCP-1 and i-TAC are Not Degraded by Spy0416 In Vitro 
So far human IL-8, GCP-2 (granulocyte chemoattractant protein 2) and GRO-α (growth-
related oncogene alpha) as well as murine KC (keratinocyte-derived chemokine) and 
murine MIP-2 (macrophage inflammatory protein 2) were the cytokines that have been 
reported to be degraded by ScpC (Spy0416) from culture supernatants [91, 178]. These 
CXC chemokines are responsible for acute neutrophil priming and/or mobilization and 
migration in their respective species. In contrast, RANTES, which is responsible for T-
cell and monocyte chemotaxis, was not degraded at all [91]. Therefore, we wanted to 
analyse further human chemokines of the CXC family for activity exerted by the 
recombinantly produced Spy0416. As GRO-α was also degraded by Spy0416 in vitro 
[162], the chemokines IP-10 (Interferon-inducible protein 10) and I-TAC (IFN-inducible 
T-cell alpha-chemoattractant) were selected to evaluate whether they can also be 
degraded by Spy0416. Although they are involved in the recruitment of activated T-cells 
they were selected for the degradation assay as they belong to the same chemokine 
(CXC) family and display very similar overall three-dimensional folds as seen in Gro-α. 
Furthermore MCP-1 was selected from the CC-chemokine family. The conditions 
applied during the degradation assay were the same as used for IL-8 degradation, 
except that the concentration of IP-10, I-TAC and MCP-1 was increased to 8.8 µg/ ml. As 
can be seen in Figure 13 the combined Spy0416A & B domains were not capable of 
readily degrading the human CXC chemokines IP-10 and I-TAC or the CC chemokine 
MCP-1 tested, despite their similar three-dimensional structure. 
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Figure 13: Degradation of MCP-1, I-TAC and IP-10 by Spy0416A combined Spy0416B  
Western blot analysis of active human MCP-1, I-TAC and IP-10 using respective polyclonal goat anti-human 
antibodies diluted 1:1000 and secondary rabbit anti-goat IgG/HRP diluted 1:5,000 for detection. Spy0416A 
and Spy0416B were in combination (22 µg/ml) incubated with MCP-1, I-TAC and IP-10, utilized at a final 
concentration of 8.8 µg/ ml at 37°C for up to 3 hours.  
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6.4 Generation of spy0895 and spy1536 Gene Deletion Mutants 
The two genes encoding Spy0895 and Spy1536 were targeted for the generation of gene 
deletion mutants. Spy0895 is annotated as putative histidine protein kinase and Spy1536 
is a conserved hypothetical protein with a C-terminal Lon protease domain. Both 
proteins showed consistent protection in animal experiments. No function or possible 
contribution to pathogenesis of S.pyogenes was reported and they do not show a high 
degree of identity to other known proteins allowing to predict a function. The spy0895 
and spy0894 genes (spy0894 encodes a putative purine nucleoside phosphorylase) 
constitute a two gene operon with overlapping open reading frames of 8 bp. The spy1536 
gene is located with spy1537, encoding a putative 3-deoxy-D-manno-octulosonic-acid 
transferase, and with a conserved hypothetical protein encoded by spy1538 in a three 
gene operon (14B, page 74). 
The purpose of the generation of gene deletion mutants was to assess the function by 
analyzing their phenotype in terms of growth defects and virulence in mice as well as by 
in vitro assays, transcriptome analyses and interaction with host proteins. 
Initially, generation of gene deletions was attempted in S. pyogenes AP-1 since this was 
the strain used for protection studies in the mouse model. However, all attempts to 
transform this strain with pGhost5, our shuttle vector of choice failed. Therefore, we 
decided to use strain M49591 that was kindly provided by Bernd Kreikemeyer (Rostock, 
Germany) and which had successfully been transformed previously [166]. 
6.4.1 Design of Gene Deletion Constructs 
The first step for generation of gene deletion mutants was the generation of knock out 
constructs consisting of N- and C-terminal flanking regions of spy0895 and spy1536 
ligated to one another. The purpose of the knock out constructs is to serve as 
recombination sites for vector integration into the chromosome which in the ideal case 
leads to gene deletion after excision. The design of knock out constructs also defines the 
size of the generated deletion within spy0895 and spy1536. The fact that spy0895 and 
spy1536 are located in a two and a three gene operon, respectively, complicates gene 
deletion since the flanking genes must not be affected by the deletion in terms of 
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transcription. This was taken into consideration for the design of the knock out 
constructs. 
A 3-step PCR strategy was employed for the generation of knock out constructs (see 
Figure 14A) using primers listed in Table 5 (Appendix I). 
For spy0895, first a 662 bp fragment was amplified using primers 5412 and 5413 
containing 120 bp of spy0895 gene specific sequence. The second 621 bp fragment was 
amplified using primers 5414 and 5415 containing 66 bp of the spy0895 gene. In a third 
PCR the two fragments were ligated using primers 5412 and 5415 resulting in a 1273 bp 
fragment. This design of the knock out construct would allow a deletion of 606 bp from 
the 792 bp full length spy0895 (see Figure 14B), leaving spy0894 gene untouched. In case 
of transcription of the remaining spy0895 gene sequence, a transcript of 132 bp due to 
stop codons within the ORF could be expected which could result in the expression of a 
mutant protein with a calculated molecular weight of 5 kDa. 
For the spy1536 gene an N-terminal fragment of 589 bp was amplified using primers 
5416 and 5417 and the C-terminal 284 bp fragment was amplified using primers 5418 
and 5419. The ligated fragments constitute the spy1536 knock out construct and would 
result in a deletion of 501 bp (see Figure 14C) in the M49591 strain. The design of this 
construct was also based on the GC content, thermodynamic properties and palindromic 
sequences of the primers. For this reason, 537 bp of the spy1536 gene would be still 
found on the chromosome of the respective mutant strain. Due to the generation of stop 
codons within the ORF of spy1536, a transcript of 138 bp could result in a mutant protein 
of 5.5 kDa. The spy0895 and spy1536 knock out constructs were finally transferred into 
the pGhost5 vector resulting in vectors pGhost5-0895 and pGhost5-1536, respectively. 
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Figure 14: Design and generation of spy0895 and spy1536 gene deletion constructs  
(A) Schematic representation of 3 step-PCR strategy for generation of knock out constructs. N- and C-
terminal regions of the gene of interest were amplified first. In a third PCR the two flanking regions were 
ligated giving the final knock out construct for cloning into pGhost5. (B) Design of knock out construct for 
spy0895: 120 bp and 66 bp of the spy0895 gene were included into N- and C-terminal flanking regions, 
respectively resulting in a knock out construct of 1273 bp carrying 186 bp of the spy0895 sequence. This 
would lead to a deletion in ΔSpy0895 of 606 bp (C) Design of knock out construct for spy1536: 420 bp and 
117 bp of the N- and C-terminal region, respectively, resulting in a knock out construct of 873 bp carrying 
537 bp of the spy1536 sequence. This would lead to a deletion of 501 bp in ΔSpy1536.  
6.4.2 Generation of Gene Deletion Mutants ΔSpy0895 and ΔSpy1536 in Three Steps 
Three steps were required to delete the sequences in spy0895 and spy1536, defined by the 
designed knock out constructs using the temperature sensitive shuttle vector pGhost5. 
The first step included the transformation of pGhost5-0895 and pGhost5-1536 into the 
M49591 parental strain. The resulting erythromycin resistant strains M49pGhost5-0895exc 
and M49pGhost5-1536exc, harboured pGhost5-0895 and pGhost5-1536 
extrachromosomally, respectively. In the second step a temperature shift to 37°C 
induced homologous recombination either via the N- or C-terminal fragment contained 
within the knock out constructs in vectors pGhost5-0895 and pGhost5-1536 (see Figures 
15A and 16A). This led to the integration of pGhost5-0895 and pGhost5-1536 into the 
operon regions of spy0895 and spy1536 resulting in strains M49pGhost5-0895int and 
M49pGhost5-1536int, respectively.  
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Before continuing with step 3, the excision of the vector from the chromosome, proper 
integration of pGhost5 in strains M49pGhost5-0895int and M49pGhost5-1536int had to be 
confirmed by PCR using oligos (see Table 5, Appendix I) that flanked the insertion sites 
of the vector. For this confirmation two scenarios had to be taken into consideration.  
As shown in Figures 15A and 16A pGhost5 integration can either occur via the N- or the 
C-terminal regions flanking the spy0895 and spy1536 genes. This results in two different 
scenarios of vector integration in the respective operons presented in Figures 15B and 
16B. Consequently for each scenario caused by either recombination via the N- or the C-
terminal flanking regions different PCR fragments are expected to be amplified. 
Analysis of different erythromycin resistant clones of M49pGhost5-0895int using oligos 
(see Table 5, Appendix I) flanking the insertion site of pGhost5-0895 showed that two 
different recombination scenarios occurred. In strain M49pGhost5-0895int-N 
recombination occurred via the N-terminal fragment as presented in Figure 15B. The use 
of primers 6005 and 6007 as well as primers 6006 and 6008 (see Table 5, Appendix I), 
designed to amplify sequences across the borders of pGhost5-0895 integration, indeed 
showed the expected size in PCR. As shown in Figure 15C, primers 6005 and 6007 
resulted in a fragment of 1863 bp and primers 6006 and 6008 amplified the expected 
2374 bp. In strain M49pGhost5-0895int-C on the other hand the recombination occurred 
via the C-terminal region of spy0895 which resulted in the generation of a 2647 bp and a 
1767 bp product using the same set of primers as above (see Figure 15B and 15C). For 
the two strains M49pGhost5-0895int-N and M49pGhost5-0895int-C correct integration of 
pGhost5-0895 in the spy0895 gene region could be confirmed. 
Different clones of M49pGhost5-1536int also showed that integration of pGhost5-1536 
construct either occured via the N- or C-terminal flanking regions (Figure 16A). This 
resulted in strains M49pGhost5-1536int-N and M49pGhost5-1536int-C. In strain 
M49pGhost5-1536int-N recombination occurred via the N-terminal fragment as 
presented in Figure 16B. The use of primers 6007 and 6009 as well as primers 6006 and 
6010 (see Table 5, Appendix I), designed to amplify sequences across the borders of 
pGhost5 integration, indeed showed the expected size in PCR. As shown in Figure 16C 
primers 6007 and 6009 resulted in a fragment of 1794 bp and primers 6006 and 6010 
amplified the expected 1198 bp. In strain M49pGhost5-1536int-C the recombination 
occured via the C-terminal region of spy1536 which resulted in the generation of 1294 bp 
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and 1698 bp using the same set of primers as above (see Figure 16B). Also for the two 
strains M49pGhost5-1536int-N and M49pGhost5-1536int-C correct integration of pGhost5-
1536 in the spy1536 operon was confirmed by PCR (see Figure 16C). 
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Figure 15: pGhost5-0895 integration into the spy0895 operon 
(A) Schematic representation of pGhost5-0895 that recombines with the N-terminal region of the spy0895 
gene. (B) Schematic representation of pGhost5-0895 integrated into the spy0895 operon by recombination via 
the N-terminal and C-terminal spy0895 regions resulting in strains M49pGhost5-0895int-N and M49pGhost5-
0895int-C, respectively. Primer binding sites are indicated as arrows and corresponding PCR products are 
indicated in red. (C) PCR analysis of M49pGhost5-0895int-N and M49pGhost5-0895int-C with primer pairs 
6005 and 6007, 6006 and 6008. 
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Figure 16: pGhost5-1536 integration into the spy1536 operon 
(A) Schematic representation of pGhost5-1536 that recombines with the N-terminal region of the spy1536 
gene. (B) Schematic representation of pGhost5-1536 integrated into the spy1536 operon by recombination via 
the N-terminal and C-terminal spy1536 regions resulting in strains M49pGhost5-1536int-N and M49pGhost5-
1536int-C, respectively. Primer binding sites are indicated as arrows and corresponding PCR products are 
indicated in red. (C) PCR analysis of M49pGhost5-15365int-N and M49pGhost5-1536int-C with primer pairs 
6007 and 6009 and 6006 with 6010. 
 
After confirmation of correct insertion of pGhost5-0895 and pGhost5-1536, the third step, 
excision of the vector from the S. pyogenes chromosome, was carried out. In this last step 
pGhost5 excision was induced by a temperature shift back to 28°C. For this I continued 
for the spy0895 and spy1536 gene deletion with both strains that had been generated, 
M49pGhost5-0895int-N and M49pGhost5-0895int-C as well as M49pGhost5-1536int-N and 
M49pGhost5-1536int-C, respectively. This was due to the probability that in one of the 
two strains, where integration happened either via the N- or the C-terminal flanking 
region, the excision might be favored to lead to the desired recombination event - the 
deletion of spy0895 and spy1536. Excision of pGhost5 results in an erythromycin 
sensitive S. pyogenes phenotype which can either be wild type M49591 or a gene deletion 
mutant. PCR was used to identify those erythromycin sensitive clones which harboured 
the desired gene deletion.  
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As shown in Figure 17A by the example of strain M49pGhost5-0895int-N, the excision of 
pGhost5-0895 is explained. Recombination via the N-terminal regions of spy0895 results 
in the parental wild type strain while recombination via the C-terminal regions in 
ΔSpy0895. Approximately 550 erythromycin sensitive clones were randomly picked 
from both strains, M49pGhost5-0895int-N and M49pGhost5-0895int-C subjected to the 
temperature shift, which then have been analysed by PCR. Primers 6005 and 6008 (see 
Figure 17A and Table 5 in Appendix I) in strains converted back to wild types amplified 
2772 bp, while in strains where gene deletion occurred a PCR fragment 606 bp smaller in 
size was obtained (see Figure 17B). A difference between excision of pGhost5 in strains 
M49pGhost5-0895int-N and M49pGhost5-0895int-C resulting in gene deletion could not 
be observed. Among ~550 erythromycin sensitive clones analyzed ~ 300 clones were 
identified as spy0895 deletion mutants. The success rate was approximately 55% 
In case of spy1536 gene deletion the example of pGhost5-1536 excision using strain 
M49pGhost5-1536int-C is presented (see Figure 18A). In this case recombination via the 
C-terminal regions of spy1536 results in the parental wild type strain, recombination via 
the N-terminal regions of spy1536 leads to gene deletion, resulting in strain ΔSpy1536. 
Approximately 500 erythromycin sensitive clones of M49pGhost5-1536int-N and 
M49pGhost5-1536int-C were subjected to PCR analysis. Indeed PCR analysis with 
primers 6009 and 6010 (see Figure 18A and Table 5 in Appendix I) identified one clone 
which showed the 1461 bp PCR product instead of the 1962 bp fragment found in the 
M49591 wild type strain (Figure 18B). The success rate for spy1536 gene deletion was 
about 0.2%. The gene deletion mutant ΔSpy1536 was among the erythromycin sensitive 
clones deriving from strain M49pGhost5-1536int-C.  
To sum up, the three steps of gene deletion, transformation of pGhost5-0895 and 
pGhost5-1536, integration into the S. pyogenes spy0895 and spy1536 operons as well as 
excision, successfully led to the generation of ΔSpy0895 and ΔSpy1536.  
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Figure 17: Gene deletion by excision of pGhost5 from the spy0895 operon region 
(A) Schematic representation of pGhost5 excision in strain M49pGhost5-0895int-N. Primer binding sites are 
indicated as arrows and corresponding PCR products are indicated in red. Recombination via the N-
terminal spy0895 region leads to the parental wild type strain, recombination via the C-terminal region 
results in gene deletion. (B) PCR results of erythromycin sensitive S. pyogenes phenotypes after pGhost5-
0895 excision from the spy0895 operon obtained from amplification with primers 6005 and 6008. 
6.5 Confirmation of spy0895 and spy1536 Gene Deletion 
In order to confirm spy0895 and spy1536 gene deletions, sequencing of the regions where 
the deletion occurred was carried out with oligos that flanked the insertion site. 
Sequencing successfully confirmed spy0895 and spy1536 deletions as presented in the 
Appendix III. Additionally Southern blot analysis and Northern blot analysis were 
carried out to verify complete removal of pGhost5 from the S. pyogenes genome and 
evaluate whether a transcriptional influence of spy0895 and spy1536 gene deletion on the 
genes located within the same operon occurred (see Figure 14B and 14C, page 74). 
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Figure 18: Gene deletion by excision of pGhost5 from the spy1536 operon region 
(A) Schematic representation of pGhost5 excision in strain M49pGhost5-1536int-C. Primer binding sites are 
indicated as arrows and corresponding PCR products are indicated in red. Recombination via the C-
terminal spy1536 region leads to the parental wild type strain, recombination via the N-terminal region 
results in spy1536 gene deletion. (B) PCR results of erythromycin sensitive S. pyogenes phenotypes after 
pGhost5-1536 excision from the spy1536 operon obtained from amplification with primers 6009 and 6010. 
6.5.1 Confirmation of spy0895 and spy1536 Gene Deletion by Southern Blot 
Analysis 
Although gene deletion was verified by sequencing, we considered it indispensable to 
be sure that the pGhost5 vector was completely removed from the genome and hence 
Southern blot analysis was performed. Therefore genomic DNA was isolated from the 
M49591 wild type strain and from all strains generated during the three steps of gene 
deletion, M49pGhost5-0895exc, M49pGhost5-1536exc, M49pGhost5-0895int-N, and 
M49pGhost5-1536int-C as well as of the identified gene deletion mutants ΔSpy0895 and 
ΔSpy1536. 
In case of spy0895 gene deletion genomic DNA of the M49591 wild type, M49pGhost5-
0895exc, M49pGhost5-0895int-N and ΔSpy0895 was digested with EcoRI. DIG-labeled 
probes have been generated for specific detection of pGhost5, spy1536 and of the deleted 
sequence in ΔSpy0895. As presented in Figure 19A pGhost5 could only be detected with 
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the specific DIG labeled probe in the S. pyogenes strains M49pGhost5-0895exc and 
M49pGhost5-0895int-N at 9997 bp and a very strong signal was obtained when purified 
pGhost5 was detected. In ΔSpy0895 elimination of pGhost5 from the chromosome was 
confirmed by the absence of a signal. The spy0895 DIG labeled probe specific for the 
sequence deleted in ΔSpy0895 resulted in a signal of 4748 bp in the wild type strain as 
well as in strain M49pGhost5-0895exc. In strain M49pGhost5-0895int-N the fragment size 
increased corresponding to the size of integrated pGhost5-0895. Successful spy0895 gene 
deletion was confirmed with the spy0895 specific probe since no signal was detected. 
Furthermore the spy1536 DIG labeled probe was used which resulted in the wild type 
strain as well as in strains M49pGhost5-0895exc, M49pGhost5-0895int-N and ΔSpy0895 in 
a signal of the same size. 
In case of spy1536 gene deletion genomic DNA from the wild type strain and strains 
M49pGhost5-1536exc, M49pGhost5-1536int-C and ΔSpy1536 was digested with EcoRV 
and pGhost5, spy1536 and spy0895 specific probes were used for detection of the 
digested DNA fragments. As it is shown in Figure 19B use of the pGhost5 specific DIG-
labeled probe resulted in a very strong signal in strain M49pGhost5-1536exc and in strain 
M49pGhost5-1536int-C a signal at 7359 bp was detected. In ΔSpy1536 like its parental 
wild type strain no pGhost5 detection was observed which confirmed successful 
excision and removal of pGhost5 from the ΔSpy1536 chromosome. For detection of the 
spy1536 sequence deleted in ΔSpy1536 the same specific signal in strain M49591 and 
M49pGhost5-1536exc was detected and an increase of fragment size corresponding to the 
size of integrated pGhost5-1536 was observed in M49pGhost5-1536int-C. In ΔSpy1536 the 
lack of a specific spy1536 signal confirmed successful deletion of this sequence. In 
contrast with the spy0895 specific probe in both the wild type strain and ΔSpy1536 a 
fragment size of ~9400 bp was detected. 
By the use of Southern blot it was confirmed that spy0895 and spy1536 were successfully 
deleted in strains ΔSpy0895 and ΔSpy1536, respectively. Furthermore complete removal 
of shuttle vector pGhost5 was shown.  
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Figure 19: Southern blot analysis of ΔSpy0895 and ΔSpy1536 
(A) Schematic representation of the spy0895 operon region in M49591 wild type and ΔSpy0895 showing 
EcoRI restriction enzyme recognition sites. Southern blot analysis of 0.5 µg EcoRI digested genomic DNA 
deriving from strains M49591 wild type, M49pGhost5-0895exc, M49pGhost5-0895int-N and ΔSpy0895. 
Detection with DIG labeled probes specific for pGhost5, spy0895 gene sequence deleted in strain ΔSpy0895 
and for spy1536. (B) Schematic representation of the spy1536 operon region in M49591 wild type and 
ΔSpy1536 showing EcoRV restriction enzyme recognition sites. Southern blot analysis of 0.5 µg EcoRV 
digested genomic DNA deriving from strains M49591 wild type, M49pGhost5-1536exc, M49pGhost5-1536int-
C and ΔSpy1536. Detection with DIG labeled probes specific for pGhost5, spy1536 gene sequence deleted in 
strain ΔSpy1536 and for spy0895. 
6.5.2 Confirmation of spy0895 and spy1536 Gene Deletion by Northern Blot 
Analysis 
Spy0895 and Spy1536 are located on the streptococcal chromosome as part of an operon. 
In order to verify that deletion of the spy0895 and spy1536 gene sequences did not affect 
transcription of spy0894, spy1537 and spy1538 Northern blot analysis was carried out.  
As it is presented in Figure 20 DIG-labeled probes specific for spy0895 and spy0894 did 
not give any signal at the expected 1506 bp in the M49591 wild type strain and 900 bp in 
the gene deletion mutant (see Figure 14, page 74) which leads to the assumption that 
spy0895 is not expressed under the in vitro growth condition. This result was somehow 
expected as Western blot analysis had previously shown that Spy0895 protein is not 
expressed in vitro [163]. However, DIG labeled probes being specific for spy1536, spy1537 
  Results 
Andrea Fritzer  83 
and spy1538 detected the wild type transcript at the expected 2070 bp (see Figure 14, 
page 74). In the ΔSpy1536 mutant the transcript decreased in size corresponding to the 
501 bp deletion resulting in a signal at 1569 bp with spy1537 and spy1538 specific probes. 
No signal was observed with the spy1536 specific probe. 
To sum up, Northern blot analysis indicates lack of in vitro transcription of the spy0895 
operon, but did confirm lack of spy1536 gene transcription without an effect on 
transcription of spy1537 and spy1538. 
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Figure 20: Northern blot analysis of ΔSpy0895 and ΔSpy1536 
Five microgram of RNA derived from a mid-exponential growth phase (OD600nm ~0.5) separated by agarose 
gel electrophoresis were used for detection of spy0895, spy0894, spy1536, spy1537 and spy1538 transcripts 
with respective DIG labeled probes. A probe specific for the transcript of the emm gene encoding the M 
protein served as control. 
6.6 Characterization of spy0895 and spy1536 Gene Deletion Mutants 
In order to identify a potential function of Spy0895 and Spy1536 for streptococcal 
virulence or pathogenesis the gene deletion mutants were examined for a specific 
phenotype which might help leading the way to a more precise characterization of the 
two vaccine candidates. As their annotation did not really indicate where to start 
searching for a phenotype, first a more general characterization including the 
examination of growth at different environmental conditions as well as virulence in CD-
1 mice and the bacteria’s shape were performed. A more specific characterization by 
evaluating the effects of gene deletion in terms of transcription was possible within the 
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collaboration with Bernd Kreikemeyer where I could perform microarray analysis. 
Furthermore since the process of interaction with and adherence to epithelial cells 
during the course of streptococcal infection represents an important step in the initiation 
of disease the binding of ΔSpy0895 and ΔSpy1536 to human proteins was analyzed as 
well.  
6.6.1 ΔSpy0895 and ΔSpy1536 Cells Have No Major Growth Defects under In Vitro 
Growth Conditions 
During an infection bacteria are subjected to different environmental conditions in their 
human host such as the environment of the throat or the blood. Although growth of 
bacteria under varying in vitro conditions will differ from in vivo growth conditions due 
to the highly artificial environment of growth, the current study was done to analyze the 
mutants for potential growth defects. Therefore growth of ΔSpy0895 and ΔSpy1536 cells 
was compared to wild type cells at different temperatures, glucose levels, NaCl levels in 
medium ranging from 3 mM to 1 M and different iron levels from 1 µM up to 40 µM. 
Additionally, they were subjected to growth in acidic (pH 5.1 and 6) and basic (pH 8.5) 
medium. 
Growth under standard conditions in THY medium at 37°C with 5% CO2 as well as 
decreased and increased temperatures of 28°C and 42°C did not show a difference 
between M49591 wild type and the two mutants, ΔSpy0895 and ΔSpy1536. The growth 
of bacteria in NaCl which increases stress and changes hyper or hypotonicity in the 
medium did not reveal either altered growth of ΔSpy0895 and ΔSpy1536 when 
compared to wild type cells. ΔSpy0895 and ΔSpy1536 subjected to an excess of iron 
which can be toxic for the bacteria also showed the same growth as their parental wild 
type strain. The same was the case for growth in acidic pH (5.1 and 6.0) as well as basic 
pH (8.5). To evaluate the effect of glucose which on the one hand represents a source of 
energy and on the other hand can be a growth retarding component due to increase of 
osmolarity, the three streptococcal strains were grown in THB medium containing 1%, 
2% and 3% glucose. In large scale and shaking (80 rpm), the bacteria did not show a 
difference in growth behavior. Interestingly, when grown in 96-well plates the ΔSpy1536 
cells showed a reproducible altered growth behavior (see Figure 21). While the M49591 
wild type and ΔSpy0895 cells reached OD600nm of 0.7 after approximately 7 hours of 
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growth and stopped growing at that time maybe due to the small amount of medium 
and used up nutrients, ΔSpy1536 increased its optical density from 0.5 to 1.3 within 1 
hour (see Figure 21). 
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Figure 21: Growth of M49591, ΔSpy0895 and ΔSpy1536 in THB supplemented with 2% glucose 
Optical density at 600 nm was measured in 96-well plates using Synergy 2 ELISA reader. Results of four 
independent experiments represented. 
6.6.2 Deletion of spy0895 and spy1536 Did Not Decrease Virulence in Mice 
The effect of spy0895 and spy1536 gene deletion was also investigated in vivo in an 
intraperitoneal murine challenge model. Although in case of GAS there are no models 
available in mice that entirely mimick human disease and only a few strains can 
establish infection in mice, the mouse model still has been extensively used for studies in 
streptococcal pathogenesis [47, 179-181]. As the M49591 wild type strain was found not 
to be very virulent in mice 5x 108 cfu/100 µl had to be applied intraperitoneally to see an 
effect on the survival of the mice which was monitored over a period of 2 weeks. As it is 
shown in Figure 22 a decrease of virulence could be observed neither for ΔSpy0895 nor 
for ΔSpy1536 in this mouse model. It is possible that an effect on virulence as 
consequence of gene deletion might be observed in a different mouse model for instance 
an intranasal or a subcutaneous challenge model. 
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Figure 22: Virulence of M49591, ΔSpy0895 and ΔSpy1536 in an intraperitoneal murine challenge model 
CD-1 mice were challenged with 5x 108 cfu of S. pyogenes strains M49591 wild type, ΔSpy0895 and ΔSpy1536 
applied intraperitoneally. Survival of mice was monitored over a period of 15 days. 
 
6.6.3 Electron Microscopy Did Not Reveal a Conspicuous Change of Bacterial Shape 
in the Gene Deletion Mutants 
In order to examine whether spy0895 or spy1536 gene deletion affects the overall shape 
or potentially the surface of the streptococcal chains, the cells were visualized by 
scanning electron microscopy. From the pictures represented in Figure 23 it is not 
possible to determine whether the gene deletion mutants differ in their phenotype 
compared to the wild type, since even the shape of the wild type cells seems to be 
damaged. The reason might be the preparation of bacterial cells before the pictures had 
been taken. The fixed bacteria were dried with vacuum which might have been a too 
aggressive method as even the remnants of the fixation solution are visible surrounding 
the bacteria. 
Observation of the ΔSpy0895 and ΔSpy1536 cells compared to wild type cells did not 
reveal a change of bacterial surface or shape. 
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Figure 23: Scanning electron microscopy of wild type, ΔSpy0895 and ΔSpy1536 cells 
S. pyogenes wild type and mutant cells were fixed and visualized with an analytical high-resolution scanning 
electron microscope of the type FEI Quanta 200F. GAS cells are shown with 50,000 and 100,000 fold 
magnification. 
6.6.4 ΔSpy1536 Showed Significantly Reduced Binding to Human Plasma and 
Extracellular Matrix Proteins 
As we could neither observe any reduced virulence for ΔSpy0895 and ΔSpy1536 nor was 
any significant in vitro growth defect determined I assessed the possible role of both 
proteins for the interaction with host proteins. Since GAS possesses many proteins 
involved in interaction with human host proteins, deletion of spy0895 or spy1536 could 
influence this interaction. Both proteins, Spy0895 and Spy1536, were identified with 
human sera. This means that they are recognized by the human immune system and are 
accessible for antibodies. Their lack on the bacterial surface could possibly influence 
human protein interactions because Spy0895 or Spy1536 themselves interact with 
human components or their deletion influences other surface proteins involved in host 
protein binding. 
Binding of FITC-labeled M49591 wild type, ΔSpy0895 and ΔSpy1536 cells to selected 
human plasma- and extracellular matrix-proteins was therefore analyzed in vitro by an 
ELISA based assay. Using the fluorescent dye FITC, that unspecifically stains bacterial 
cell surfaces, bacteria can easily be labeled and their binding behaviour to immobilized 
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proteins can be evaluated by the measurement of fluorescence emitted by the bacteria 
bound to the immobilized proteins.  
As it is shown in Figure 24, ΔSpy1536 cells showed significantly (p-value < 0.005, 2 
clones tested in 3 independent experiments) reduced binding to human fibronectin, 
fibrinogen, laminin, plasminogen and collagen type I coated on ELISA plates compared 
to wild type and spy0895 gene deletion mutant cells. In contrast, wild type cells and both 
gene deletion mutants were not able to bind to haptoglobin and collagen type IV. The 
reduced binding of ΔSpy1536 cells was accompanied by a 2 to 3-fold increase in 
fluorescent light emission of FITC labeled ΔSpy1536 cells measured at 560 nm in 
comparison to M49591 wild type and ΔSpy0895 cells, indicating changes in the 
composition of the cell surface of the mutant ΔSpy1536 GAS cells. As ΔSpy1536 could no 
longer bind to the listed human plasma and extracellular matrix proteins, I found it 
interesting to evaluate whether this reduced ability to adhere to human proteins would 
also result in a reduced binding to Detroit 562 cells, which are pharynx carcinoma cells. 
These experiments unfortunately did not show any consistency as already adherence of 
wild type GAS to Detroit 562 cells fluctuated. An imprecise use of bacterial cfu per 
experiment could be excluded as the relation between bacteria used for infection of the 
Detroit 562 cells and the controls was always correct. Nevertheless it was not possible to 
prove that ΔSpy1536 was consistently adhering less to the Detroit 562 cells than the wild 
type strain. The same results were obtained with Chang cells, which derive from normal 
conjunctiva and are similar to human pharynx cells. Such binding assays were 
previously performed [182, 183]. For sure optimization of the adhesion and 
internalization assays would have been required but unfortunately time was restricted 
in the end. In literature human cells have been treated differently for lysis. Manetti and 
colleagues used saponin but also Triton X-100 [184] was used to lyse cells. In my 
experiments water was used which might have led to partial lysis and resulted in the 
inconsistent results. 
The significantly reduced binding of ΔSpy1536 cells to human proteins indicated a 
change on the bacterial surface possibly due to a defect in peptidoglycan synthesis or in 
surface protein anchoring. 
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Figure 24: M49591 wild type, ΔSpy0895 and ΔSpy1536 binding to human plasma and extracellular matrix 
proteins in vitro 
Binding ability of M49591 wild type and spy0895 and spy1536 gene deletion strains was tested using an 
ELISA based assay. Human fibrinogen, fibronectin, laminin, haptoglobin, plasminogen, collagen type I and 
IV were coated in an amount of 10 µg on 96-well plates. The FITC-labeled S. pyogenes strains were tested for 
their adherence to the human proteins by measuring their emission of fluorescent light using BioTek 
Synergy2 ELISA reader with the following settings: Excitation at 485/20 nm, Emission 560/60 nm, Gain: 72, 
80, 75, 77. 
6.6.5 In Absence of spy1536 Surface Expression of M protein and Spy0269 is 
Reduced on S. pyogenes Cells 
The reduced binding of ΔSpy1536 cells to selected human proteins prompted me to 
investigate whether this reduction is due to changes of the exposure of group A 
streptococcal proteins on the bacterial surface. Therefore the surface localization of the 
major virulence factor of S. pyogenes, M protein, and of two candidate antigens, Spy0269 
and Spy1666, was assessed by immunostaining.  
First M protein surface localization was assessed. For the visualization of M protein on 
the bacterial surface M1 and M23 specific polyclonal mouse antibodies were used to 
specifically detect M protein on the bacterial surface as there was no access to M49 
specific polyclonal mouse serum. Due to the fact that polyclonal antibodies are known to 
be specific for both, the variable and the conserved region of the M protein, we expected 
a M protein specific signal also with antibodies other than M49 specificity. M1 and M23 
specific mouse antibodies resulted in the same surface staining and therefore results 
generated using M23 specific antibodies are not demonstrated here.  
As can be seen in Figure 25 wild type and ΔSpy0895 cells showed localization of M 
protein at the streptococcal cell septum. In contrast, ΔSpy1536 cells displayed no M 
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protein specific staining when visualized under the same conditions as performed for 
wild type and ΔSpy0895 cells. Similarly, we could observe a strong reduction in surface 
localization of the Spy0269 protein on the surface of ΔSpy1536 cells while surface 
localization of the Spy1666 protein was not affected by mutation of the spy1536 gene (see 
Figure 26). 
These results indicate that Spy1536 affects surface expression of distinct GAS proteins. 
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Figure 25: Localization of M protein on the surface of M49591 wild type, ΔSpy1536 and ΔSpy0895 
S. pyogenes cells of an overnight culture of wild type, ΔSpy1536 and ΔSpy0895 cells were subjected to 
immunofluorescence analysis with M23 specific polyclonal mouse antibodies (1:25), Texas Red-dye 
conjugated goat anti-mouse antibodies (1:100) and with DAPI, following microscopic visualization with a 
Zeiss Axiovert 200M microscope equipped with a Zeiss LSM510META confocal laser-scanning unit and a 
Plan-Apochromat 63x1.40 oil DIC MC27 (aperture, 0.19 mm) objective (Zeiss). 
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Figure 26: Localization of Spy0269 and Spy1666 on the surface of M49591 wild type, ΔSpy1536 and 
ΔSpy0895 cells 
S. pyogenes cells of an overnight culture of M49591, ΔSpy1536 and ΔSpy0895 gene deletion mutants were 
subjected to immunofluorescence analysis. Primary Spy0269 and Spy1666 specific polyclonal mouse 
antibodies and Texas Red-dye conjugated goat anti-mouse antibodies were used in 1:25 and 1:100 dilutions, 
respectively. DAPI was used for staining DNA. Microscopic visualization was carried out with a Zeiss 
Axiovert 200M microscope equipped with a Zeiss LSM510META confocal laser-scanning unit and a Plan-
Apochromat 63x1.40 oil DIC MC27 (aperture, 0.19 mm) objective (Zeiss). 
6.6.6 Deletion of spy1536 Does Not Affect emm-Gene Transcription 
Since M protein and Spy0269 were no longer detected on the surface of ΔSpy1536 cells 
the next logical step was to determine whether this interesting observation was the 
result of a transcriptional or translational modulation caused by spy1536 deletion. 
Therefore cell fractions generated from the wild type strain and the two gene deletion 
mutants, ΔSpy0895 and ΔSpy1536 were subjected to Western blot analysis for the 
detection of M protein, Spy0269 and Spy1666. Interestingly, this showed that M protein 
can be detected in the bacterial lysates of M49591, ΔSpy0895 and ΔSpy1536 and it is still 
expressed at similar levels in the cytoplasm of all cells (see Figure 27A), indicating that 
the lack of M protein on the bacterial surface is not due to any influence of the spy1536 
deletion on the transcription or translation of the M protein encoding gene. Also in the 
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cell wall fractions of wild type and ΔSpy0895 cells M protein is still detectable. In 
contrast, the cell wall fraction for ΔSpy1536 cells showed a reduced presence of M 
protein, in agreement with the immunofluorescence data. In contrast, for Spy0269 (see 
Figure 27B) and Spy1666 (see Figure 27C) no differential expression in lysates, 
cytoplasmic and cell wall fractions of wild type and ΔSpy0895 and ΔSpy1536 cells could 
be observed. Besides that, a high background was observed in case of Spy0269 and 
Spy1666 detection. 
These results demonstrate that the reduced surface localization of GAS protein signal on 
ΔSpy1536 cells is not the consequence of a transcriptional or translational modulation. 
At least for the M protein there is an indication that the transport of the protein to the 
bacterial cell surface is affected by spy1536 deletion, since it is no longer detectable in 
ΔSpy1536 cell wall fractions. 
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Figure 27: Detection of M protein, Spy0269 and Spy1666 in subcellular fractions of M49591, ΔSpy1536 
and ΔSpy0895 
Western blot analysis of M protein, Spy0269 and Spy1666 detected in cell fractions of M49591 wild type, 
ΔSpy1536 and ΔSpy0895 cells showing total lysate (L), cytoplasmic fraction (C) and cell wall fraction (W). 
For all fractions approximately 30 µg as measured by BCA assay were loaded. (A) Detection with M1 
protein specific polyclonal mouse antibodies diluted 1:1000 and secondary goat anti-mouse IgG/HRP 
(1:5,000). (B) Detection with Spy0269 polyclonal mouse serum (1:1000) and secondary goat anti-mouse 
IgG/HRP (1:5,000). Spy0269 is expected at a size of 94.7 kDa. (C) Detection with Spy1666 polyclonal mouse 
serum (1:1000) and secondary goat anti- mouse IgG/HRP (1:5,000). Spy1666 is expected at a size of 37 kDa. 
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6.6.7 ΔSpy1536 Cells Secrete Mainly Inactive Pyrogenic Exotoxin B in their Culture 
Supernatant 
Since M protein is still expressed by ΔSpy1536 cells and detectable in the cytoplasm but 
no longer on the bacterial surface I wanted to further evaluate the reasons for this 
observation. The question was whether the absence of surface expressed M protein is the 
result of a defect in transport or anchoring to the cell wall or might be the consequence 
of overexpression of proteases secreted by the mutant cells. SpeB, pyrogenic exotoxin B, 
was reported to release biologically active fragments from the streptococcal surface 
including M protein [185]. Therefore the expression of SpeB was analysed in the culture 
supernatant of wild type, ΔSpy0895 and ΔSpy1536 cells. 
Western blot analysis revealed that in culture supernatant of wild type and ΔSpy0895 
cells SpeB was mainly detected at a size of 28 kDa, the size of the active form of this 
enzyme (see Figure 28). Interestingly, we found out that in the culture supernatant of 
ΔSpy1536, SpeB was not overexpressed as we expected. SpeB could only be detected as 
the enzymatically inactive precursor (40 kDa) with the corresponding anti-SpeB 
antibody. However, the inactive 40 kDa SpeB secreted by ΔSpy1536 could be partly 
activated using 10 mM DTT. DTT did not have any effect on the active SpeB of M49591 
wild type and ΔSpy0895 cells. Active SpeB deriving from the wild type supernatant in 
contrast did not activate inactive SpeB.  
The detection of mainly inactive SpeB in ΔSpy1536 culture supernatant indicates that 
lack of M protein on the bacterial surface is not the result of degradation by SpeB. 
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Figure 28: Detection of secreted SpeB of M49591, ΔSpy1536 and ΔSpy0895 cells 
Western blot analysis of TCA precipitated supernatants deriving from M49591 wild type, ΔSpy1536 and 
ΔSpy0895 cells. Equal amounts of protein (7 µg) were loaded for each strain and SpeB was specifically 
detected with 1:1000 diluted polyclonal goat anti-S. pyogenes SpeB antibodies and secondary rabbit anti-goat 
IgG/HRP (1:5,000). For activation of inactive SpeB (40 kDa) culture supernatant proteins (7 µg) were treated 
with 10 mM DTT as reducing agent for 30 minutes at 37°C. 
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6.6.8 Deletion of spy1536 Causes Transcriptional Upregulation of hasA and 
Downregulation of Adhesin Encoding Genes 
In order to identify a potential effect of spy0895 and spy1536 gene deletion on the 
transcription of GAS genes, a genome wide analysis of the transcriptome was carried 
out using Microarray and Real Time RT-PCR. 
6.6.8.1 Transcriptome Analyses by Microarray 
In collaboration with Bernd Kreikemeyer (Rostock, Germany) it was possible to analyse 
the spy0895 and spy1536 gene deletion mutants for differential gene expression. In order 
to identify potentially up- or down-regulated genes as a consequence of spy0895 or 
spy1536 gene deletion I performed dual colour microarray hybridization analysis in 
Bernd Kreikemeyer’s lab. The DNA microarrays that were used contained 50mer oligos 
and were designed from open reading frame sequences of a partial serotype M49 
genome sequence (NZ_AAFV00000000) and complete serotypes M1, M3 and M18 
sequences [168].  
The microarray data was read from the Agilent Technology instrument from Affymetrix, 
normalized and analyzed using GeneSpring GX Software by Jana Normann (Rostock, 
Germany). From these data, the selection of genes for further analysis by Real Time RT-
PCR was based on an at least two fold change of up- or down-regulation and 
identification as such in two of three independent experiments unless otherwise stated. 
An overview of the genes being selected the way mentioned above can be seen in Table 
2 (page 97).  
In case of the spy0895 gene deletion mutant, 9 genes were found to be differentially 
expressed compared to the wild type M49591 in 2 of the 3 independent experiments. 
Among these candidates were 2 conserved hypothetical proteins, spy0441 and spy1691, 
that showed according to the microarray data a 2.1-2.3 fold upregulation in the spy0895 
gene deletion mutant. Additionally, spy0570, a putative drug resistance protein, spy1718, 
a putative esterase, spym49b0400, a putative DNA-damage-inducible protein P and 
spym49c0816 which is similar to spy1364 (DNA polymerase iii subunits gamma) were all 
found to be upregulated between 2.3-2.5 fold. Downregulation was observed for the 
genes spy1031, a putative dihydrolipoamide dehydrogenase, spy180822, a hypothetical 
protein, spym49b0627, which is annotated as 50S ribosomal protein rpmF and 
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spym49c1025, a putative biotin carboxyl carrier protein. The gene spym180822 in contrast 
to the other genes was also listed and selected for further analysis by Real Time RT-PCR 
not because it was identified in 2 of the 3 microarray experiments but because it showed 
a ~25 fold decreased transcription in ΔSpy0895 compared to the M49591 wild type 
strain. 
In the ΔSpy1536 strain 12 genes showed a differential gene expression in 2 of the 3 
independent experiments. Among these 12 candidates was for example spy2010, 
annotated as C5a peptidase precursor scpA, that was identified a second time as 
spym31726. This was possible since some genes were represented more than just once 
whenever it was not possible to design a common oligo for the four serotypes. Also 
spym49c1149 was detected a second time by a different oligo representing the same gene 
(spym49b0494). From the 12 candidates that were represented as up- or down-regulated 
genes in 2 independent experiments six were further analyzed by Real Time RT-PCR. 
First of all because twice the same genes with two different oligos on the microarray 
chip were identified, second because strain M49 derived gene sequences encoded 
proteins with unknown functions (e.g. spym49b1334, spym49b0529 and spym49b0495) or 
they did not show homology to known GAS proteins. The genes would probably not 
contribute to identify a role for Spy1536. Oligos specific for spy2010 amplified only 
unspecific PCR products from genomic DNA. Design of another primer pair did not 
change this which is the reason that this gene was not further analysed by Real Time RT-
PCR. Therefore the following six genes were analyzed: spym49b0963, a conserved 
hypothetical protein similar to Spy0587, spym49b1739, encoding a collagen like-protein 
ScIB, spym49s0005 similar to fcrA protein precursor and spym49s0078, encoding a protein 
similar to serum opacity factor as well as spy0611, which encodes a putative translation 
elongation factor tufA. All of the genes showed according to the microarray data a 
decreased transcription between 2.1-4.8 fold except spy0611 which was 2.3 fold 
upregulated. Due to the fact that among the candidates the transcription of the two 
genes, spym49b1739 and spym49c1149, encoding putative collagen-like proteins ScIB and 
ScIA, respectively, have been found, I searched among all 2 fold differentially regulated 
genes of the microarray data for other potential virulence factors being differentially 
expressed that are involved in S. pyogenes pathogenesis such as genes encoding proteins 
binding to human plasma and extracellular matrix proteins like the already identified 
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putative collagen-like proteins binding to collagen. This led to the selection of 4 
additional genes to be tested in Real Time RT-PCR: spy0738 encoding a streptolysin S 
associated protein, spy1642 that encodes a protein similar to autoinducer-2 production 
protein LuxS, spy2200 that encodes hyaluronate synthase for the production of 
hyaluronic acid capsule and spym49s0079 encoding the fibronectin-binding protein 
SfbX49. Microarray analysis revealed that spy1642 and spy2200 were approximately 2 
fold increased in their transcript level resulting probably from the spy1536 gene deletion, 
while spy0738 and spym49s0079 showed a decrease in transcription of ~4 and ~2 fold, 
respectively.  
6.6.8.2 Transcriptome Analyses by Real Time RT-PCR 
The microarray analysis has identified several genes in the spy0895 and spy1536 gene 
deletion mutants that showed a change on the level of transcription compared to the 
M49591 wild type strain. To verify the data for the selected genes in the microarray 
experiments Real Time RT-PCR was performed.  
First, gene specific primers (see Table 6, Appendix I) were designed to amplify 100-200 
bp of the genes that have been selected based on the data obtained from microarray 
analysis. All primers were designed to have a melting temperature between 54.3-55.8°C 
and tested in PCR using genomic DNA of M49591 wild type strain. First experiments 
were carried out with different dilutions of cDNA ranging from 1:5 to 1:125. As the best 
dilution for amplification in 40 cycles was 1:25, for all PCR reactions 5 µl of this dilution 
was used. SYBR Green I served as fluorescent dye during the amplification of the cDNA 
binding to amplified double stranded DNA. Increase of the measured fluorescent signal 
corresponds to an increase of amplicons. The melting curve, a stepwise increase from 60-
95°C, was performed for visualization of PCR product specificity because the 
temperature at which the amplified DNA is separated into single strands leading to the 
loss of fluorescent SYBR Green is characteristic for each PCR product. The housekeeping 
gene mutS (encoding DNA mismatch repair protein) and its mRNA expression was used 
as internal control as it produced more stable results than using gki (glucose kinase) or 
recP (transketolase) transcripts as internal controls.  
The obtained Real Time data was analyzed using the 2-(ΔCTsample-ΔCTcalibrator) 
method [169] to reveal quantitative differences in transcript levels between wild type 
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and gene deletion mutants. Results in Table 2 and Figure 29 are presented as ratio 
between the mutant and the wild type strain from two independent experiments.  
In the ΔSpy0895 mutant none of the genes showed a differential gene expression in Real 
Time RT-PCR as the ratio between ΔSpy0895 and M49591 wild type was in a range 
between ~0.5-1. Only spy1718 showed a slight increase in transcript levels (see Table 2).  
 
Table 2: List of genes being differentially expressed in ΔSpy0895 and ΔSpy1536 as assessed by 
Microarray analysis and Real Time RT-PCR 
Genes that were identified to be differentially regulated in ΔSpy0895 and ΔSpy1536 by microarray analysis 
are listed. Microarray results are listed as fold change (F. c.) of mutant vs. wild type strain. Values derive 
from 2 independent experiments except for spym180822 in the ΔSpy0895 mutant and spy0738, spym49s0079, 
spy1642 and spy2200 in the ΔSpy1536, where the values derive from one experiment only. Real Time RT-
PCR results are presented as ratio between mutant and wild type transcript levels calculated using the 2-
(ΔCTsample-ΔCTcalibrator) method. The ratio values derive from 2 independent experiments. 
 
  Microarray 
ΔSpy0895 
Real Time RT-PCR 
ΔSpy0895 
Genes  Annotation F. c. Regulation Ratio Regulation 
spy0441 conserved hypothetical protein 2.131 up 0.532 - 
spy0570 similar to Spy0570, putative drug 
resistance protein;  
2.394 up 0.946 - 
spy1031 similar to Spy1031, putative 
dihydrolipoamide dehydrogenase, 
component e3; acol  
2.461 down 0.615 - 
spy1691 Spy1691, conserved hypothetical 
protein 
2.394 up 1.609 - 
spy1718 putative esterase 2.133 up 0.994 - 
spym180822 hypothetical protein, epuA 25.720 down 0.804 - 
spym49b0400 putative DNA-damage-inducible 
protein P, dinP,  
3.222 up 0.751 - 
spym49b0627 50S ribosomal protein L32, rpmF 2.231 down 0.830 - 
spym49c0816 similar to Spy1364 DNA 
polymerase iii subunits gamma/ 
tau; dnax  
2.547 up 0.804 - 
spym49c1025 putative biotoin carboxyl carrier 
protein, accB 
2.306 down 0.729 - 
 
 
  
Microarray 
ΔSpy1536 
 
Real Time RT-PCR 
ΔSpy1536 
Genes  Annotation F. c. Regulation Ratio Regulation 
spy0611 putative translation elongation 
factor EF-Tu, tufA 
2.345 up 0.751 - 
spy0738 similar to Spy0738, streptolysin s 
associated protein; sagA  
4.042 down 0.575 - 
spy1642 similar to Spy1642, autoinducer-2 
production protein; luxS  
2.261 up 0.586 - 
spy2200 hyaluronate synthase, hasA  2.068 up 1.755 up 
spym49b0963 similar to Spy0587, conserved 
hypothetical protein;  
2.519 down 0.664 - 
spym49b1739 collagen-like protein SclB, sclB 3.264 down 0.140 down 
spym49c1149 putative collagen-like protein, sclA 4.823 down 0.065 down 
spym49s0005 similar to NF004459_41, fcrA 
protein precursor  
2.682 down 0.004 down 
spym49s0078 similar to NF004451_15, Serum 
opacity factor   
2.143 down 0.831 - 
spym49s0079 similar to NF004466_21, 
Fibronectin-binding protein, 
SfbX49  
2.147 down 0.011 down 
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For ΔSpy0895 the Real Time RT-PCR could not verify the data obtained from microarray 
analysis.  
In contrast, Real Time data generated with ΔSpy1536 looked very promising for some 
genes. As it is presented in Figure 29 among the 10 tested genes selected by microarray 
analysis 5 genes, spy0611, spy0738, spy1642, spym49cb0963 and spym49s0078 did not seem 
to be affected by spy1536 gene deletion as detected by Real Time RT-PCR and therefore 
microarray results could not be confirmed. However, five genes showed a different gene 
expression, confirming at least for those genes the observations in the microarray 
analysis. One of the candidates, namely spy2200 (hasA) is slightly upregulated (see 
Figure 29A). The gene hasA, part of the hasABC operon, encodes membrane associated 
hyaluronate synthase and adds alternating N-acetyl-D-glucosamine and D-glucuronic 
acid residues to form the linear hyaluronic acid polymer for hyaluronic acid capsule 
production [186]. The other 4 genes, also potential virulence factors, spym49b1739 (scIB) 
and spym49c1149 (scIA), both encoding putative collagen-like proteins, as well as 
spym49s0005 and spym49s0079 encoding an fcrA protein precursor and the fibronectin-
binding protein SfbX49, respectively, showed significant downregulation (see Figure 
29B).  
The two genes encoding the collagen-like proteins ScIA and ScIB, which are reported to 
act as adhesins as a consequence of their extracellular location and collagen-like 
structure [49] showed a ratio of 0.065 and 0.140 between mutant and wild type strain 
(see Table 2) which equates with 5-10 fold decreased transcription. The genes that 
encode the fcrA protein precursor (spym49s0005) and SfbX49 (spym49s0079), encoding a 
fibronectin-binding function and linked to serum opacity factor in one operon [187], 
showed even a more decreased transcript level, resulting in a ratio between ΔSpy1536 
and wild type of 0,004 and 0,011, which equates with ~100 fold downregulation of 
transcription. FcrA encodes an M protein-related Ig-binding protein and is usually 
clustered on the streptococcal chromosome with M protein and C5a peptidase [188-190].  
In summary, the verification of the transcriptome analysis using Microarray chips by 
Real Time RT-PCR was successful for the ΔSpy1536 strain. The data strongly indicate 
that surface proteins binding to collagen (ScIA and ScIB) or fibronectin (SfbX49) are 
strongly downregulated which is in agreement with the protein binding studies in vitro 
where binding to human proteins including fibronectin and collagen was significantly 
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reduced by deletion of spy1536 (see Figure 24, page 89) and with the 
immunofluorescence analysis (see Figures 25 and 26, pages 90 and 91) which revealed a 
reduced exposure of M protein and Spy0269 on the bacterial surface. 
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Figure 29: Differential gene expression in ΔSpy1536 as assessed by Real Time RT-PCR 
Representation of up- and down-regulated genes from ΔSpy1536 cells of mid-log phase analysed by Real 
Time RT-PCR. Real Time data analysis was supported by the Eppendorf RealPlex software and quantitative 
differences for each sample between wild type and ΔSpy1536 were determined using the 2-(ΔCTsample- 
ΔCTcalibrator) method. The housekeeping gene mutS served as internal control. Data of two independent 
experiments is presented. (A) Fold change of transcript level between wild type and spy1536 gene deletion 
mutant. (B) Logarithmic view of fold change analyzed in ΔSpy1536 giving a better view of downregulated 
genes.  
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7 DISCUSSION 
The observation that M protein-derived GAS vaccines can induce cross-reactive 
antibodies in humans causing rheumatic fever [79] and the existence of more than one 
hundred different group A streptococcal serotypes have recently focused vaccine 
development efforts on novel protein antigens from S. pyogenes. While a number of 
individual antigens, such as C5A peptidase and SfbI, were identified by traditional 
technologies, large scale proteomic approaches building on the available genomic 
sequence information have recently identified novel candidates from S. pyogenes on a 
broader scale [154-156]. Severin and colleagues for example employed a method to 
identify surface antigens of S. pyogenes by generating peptides of surface exposed 
proteins using trypsin digestion and analyses of these peptides by multidimensional 
tandem mass spectrometry. This approach led to the identification of 79 proteins on the 
bacterial surface. Among them were 14 out of 17 predicted peptidoglycan-attached 
proteins, 12 out of 27 predicted lipoproteins, 9 secreted proteins, 22 membrane proteins, 
1 bacteriophage-associated protein and 21 proteins commonly identified as cytoplasmic 
proteins, thus providing guidance in the development of a novel vaccine to prevent 
infections caused by S. pyogenes. Lei and his colleagues focused on a systematic analysis 
of culture supernatant proteins by two-dimensional Western blot analyses of GAS 
strains grown in vitro [155]. In order to identify supernatant proteins expressed in the 
course of host pathogen interactions, sera from mice with experimentally induced soft 
tissue infections and sera from humans with pharyngitis, acute rheumatic fever and 
severe invasive diseases were utilized. This approach identified 5 new candidates, 
Spy0385, Spy1245, Spy1274, Spy1390 and Spy1558. Active immunization of mice with 
the recombinant forms of these proteins stimulated the production of antibodies which 
significantly inhibited growth of GAS assessed by bactericidal activity assay. 
Nevertheless the mentioned strategies to identify new potential vaccine candidates may 
miss potential vaccine candidates due to limitations of in vitro expression of proteins. In 
order to avoid any potential shortcomings by lack of in vitro expression or proper 
bioinformatic annotation of protein function, we have applied the ANTIGENome 
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technology [157, 158, 172] to select novel protective GAS vaccine candidates on a 
genomic scale for the purpose of designing and developing subunit vaccines directed 
against GAS disease that cannot be properly mastered by present vaccination strategies 
[153]. Using this technology, 95 antigenic proteins have been identified from S. pyogenes, 
including most of the known protective antigens. Among the 8 most frequently selected 
antigens in our screens were thus 5 published protective proteins, confirming the 
strength of the technology to identify relevant candidates. Applying several in vitro 
assays and three different murine infection models, nine proteins capable of providing 
protection against GAS infection have been identified. The aim of my work was to 
further characterize some of these candidates to support their utilization as vaccine 
candidates. Based on their protectivity in the murine challenge models and the location 
on the bacterial chromosome as single genes or as part of an operon I focused on three of 
the nine candidates, namely on Spy0416, which was one of the most frequently selected 
antigens, as well as on Spy0895 and Spy1536. While Spy0416 was also identified recently 
by a proteomic approach and shown to provide protection against an M23 S. pyogenes 
strain in mice [154], Spy0895 and Spy1536 as well as the other 6 selected proteins have 
not previously been recognized to be capable of providing protection against GAS 
infection, nor have they been characterized in more detail in regard to their biochemical 
function or role in streptococcal pathogenesis. 
7.1 Role of Spy0416 in Group A Streptococcal Pathogenesis 
Our studies aiming at the identification of novel candidates for a Group A streptococcal 
vaccine have selected the cell envelope serine proteinase Spy0416 (ScpC) as one of 
several protective antigens. The evidence that IL-8 cleavage activity is mediated by 
Spy0416 [91] and that it is assumed to prevent recruitment of polymorphonuclear 
leukocytes to the site of infection as well as its selection as vaccine candidate by the 
ANTIGENome technology [153] warranted further characterization.  
First, it was necessary to establish an in vitro system to measure IL-8 cleavage activity of 
Spy0416. Using recombinant Spy0416 protein, I could show in my previous work that it 
mediates indeed proteolysis of IL-8 in vitro and that the predicted active site residues are 
essential for enzymatic activity [162]. In the same study I also found out, that the 
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predicted catalytic domain alone (Spy0416A) was not sufficient to provide enzymatic 
activity. Instead activity could only be restored by supplying the C-terminal region of 
Spy0416 (Spy0416B) as separate recombinant protein. Therefore, I was interested in the 
possible contribution of the predicted distinct domains of Spy0416 to IL-8 degradation 
activity and in the interaction between the protease and IL-8, as well as in possible other 
substrates targeted for degradation. 
7.1.1 Contribution of PA, Fn1 and Fn2 Domains to Spy0416 Catalytic Activity  
Although many of the known cell envelope proteinases consist of multiple domains 
[191] for most of them the functions have not been elucidated so far. Therefore, we 
investigated the contribution of the PA, Fn1 and Fn2 domains to Spy0416 catalytic 
activity. We were already able to show that the PA domain, which in the C5a peptidase 
of S. agalactiae may be involved in recognition of a cellular receptor thus triggering 
enzymatic activity [177], and the Fn1 domain - both located in the N-terminal region of 
Spy0416 - contribute to enzymatic activity [162]. In our publication we were further able 
to show that upon deletion of the Fn1 domain within the Spy0416A protein, IL-8 
degradation was abolished. In this regard the 131 bp region of the Fn1 domain 
represented the overlap between Spy0416A and Spy0416B. At that time we 
hypothesized that the Fn1 domain might be involved in mediating interactions with 
Spy0416B and therefore be essential for IL-8 cleavage activity. In this work I 
demonstrated that the Fn1 sequence overlap between Spy0416A and Spy0416B is not 
essential, because IL-8 degradation is exerted by both Spy0416A and Spy0416BΔFn1. Only 
a short 48 bp sequence overlap within the Fn2 domain remains between Spy0416A and 
Spy0416BΔFn1 that might be involved in mediating the interaction between Spy0416A and 
Spy0416B. The important role for the Fn2 and PA domain in ScpC may be explained by a 
model that was recently published for ScpA interacting with its substrate C5a. Since 
Spy0416 and ScpA show a high sequence homology, homologous domains may exert 
similar functions. Based on the crystal structure of ScpA from S. pyogenes it was 
postulated that the PA and Fn2 domains are involved in substrate selectivity and 
binding [95, 177]. It was suggested that the access to the ScpA catalytic site is restricted 
by the presence of PA and Fn2 domains and that electrostatic interaction is the potential 
driver in substrate recruitment by ScpA. Interactio
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RGD motif with integrins may stabilize conformational changes required for substrate 
binding [177]. The model of the C5a-ScpA complex presented by Kagawa et al., places 
the core of C5a on the Fn2 domain and the C5a C-terminal tail making contact to the 
catalytic, Fn2 and PA domains. In this case the interaction between C5a and the Fn2 
domain would be electrostatic in nature due to charge complementarity between Fn2 
and C5a and thus predicts that both interactions in the active site, but also interactions 
on the Fn2 domain, would contribute to the selectivity of ScpA. A similar way of 
interaction between Spy0416 and its substrate might occur, but this is just speculation. 
To date we also do not know whether the sequence overlaps between Spy0416A and 
Spy0416B are indeed necessary for IL-8 degradation, because the generation of 
recombinant Spy0416ΔFn2 failed due to lack of expression in E. coli.  
7.1.2 Essential Function of Ancillary C-terminal Spy0416 Domains 
We found out that the predicted catalytic domain alone (Spy0416A) was not sufficient to 
provide enzymatic activity but was dependent on the presence of the ancillary C-
terminal domains. Therefore, we wanted to evaluate the essential function of Spy0416B 
for enzymatic activity in terms of interaction with Spy0416A and IL-8 but also the 
contribution of distinct Spy0416B domains to enzymatic activity.  
First we addressed how Spy0416 interacts with IL-8 using isothermal fluorescence 
analyses. The data from isothermal fluorescence studies indicated that binding of IL-8 
was mainly mediated by the proteinase domain of Spy0416, but it also showed that the 
Spy0416B protein could contribute to binding of IL-8. In agreement with its higher 
affinity, only Spy0416A but not Spy0416B was capable of significant binding to IL-8 as 
determined by a gel depletion and surface plasmon resonance assays. However, when 
both proteins, Spy0416A and Spy0416B, were supplied together in the gel depletion 
assay, it was observed that Spy416B reduced binding of Spy0416A to IL-8. Apparently, 
under these conditions, the interaction of Spy0416A and Spy0416B dominates over 
Spy0416A binding to IL-8. Since Spy0416A binds with significantly higher affinity to IL-
8 (yet without exhibiting proteolytic activity), we hypothesise that in the full-length 
Spy0416 protein, IL-8 binds predominantly to the A domain which causes a 
conformational change leading the B domain to ´´lock´´ the IL-8 substrate in the catalytic 
site, which then triggers enzymatic activity. Under gel depletion conditions, however, 
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Spy0416B prevents binding of IL-8 to Spy0416A by a strong interdomain (A-B) 
interaction which is somehow leaky in the case of the Spy416A-D151A mutant. The 
reduced binding of IL-8 by Spy0416A in the presence of Spy0416B may also indicate 
Spy0416B-induced changes in structure or binding of Spy0416A resulting in the 
observed reduction in IL-8 binding.  
The lack of proteolytic activity of the individual domains and participation of the non-
catalytic domains of Spy0416B to CXC chemokine degradation in vitro also argues for 
the essential contribution of several, if not all of the domains of Spy0416 for enzymatic 
activity and thus for its contribution to virulence. This most likely also explains the high 
sequence conservation level that we determined for this large cell envelope proteinase 
throughout the entire amino acid sequence. PCR analyses showed that Spy0416 is 
present in at least 98% of more than 300 tested Group A streptococcal strains. 
Subsequent sequencing of the Spy0416 gene from more than 60 strains, including 26 
distinct emm types, revealed that the protein shows more than 95% sequence identity 
within the analyzed Group A streptococcal strains [153].  
7.1.3 Specificity of Spy0416 towards IL-8 
In the next step we wanted to evaluate whether Spy0416 cleavage activity is also exerted 
towards the biological inactive IL-8F17K,F21K mutant. The observed reduced activity of 
Spy0416 towards IL-8F17K,F21K provided first evidence for the basis of the specificity of IL-8 
cleavage activity by Spy0416. Since the IL-8 mutant is deficient in neutrophil chemotaxis, 
Spy0416 seems to have evolved in a very efficient way to proteolytically inactivate the 
biological active chemokine, whereas inactivation of IL-8 by mutation coincided with 
abolished cleavage activity by Spy0416. As can be seen from the molecular structure of 
the wild type IL-8 molecule (see Figure 9A, page 67), the proximal loop containing the 
amino acids Phe17
 
and Phe21
 
is in close proximity to the C-terminal helix containing the 
Spy0416 cleavage site Gln21-Arg60. Introducing basic amino acids like lysine into the 
proximal loop of the chemokine induced a structural change – as detected in far-UV CD 
spectroscopy (data not shown) – which prohibited interaction with the protease by 
sterical and/or electrostatic hindrance.  
To evaluate the impact of Spy0416 on the biological activity of IL-8, neutrophils were 
tested for being activated by measuring the release of Ca2+. While Spy0416-cleaved IL-8 
  Discussion 
Andrea Fritzer  105 
was unable to promote neutrophil chemotaxis, our Ca2+-release data suggests that the 
cleavage of IL-8 did not affect its capability to activate neutrophils. This is in line with 
previous observations showing that the ELR motif of IL-8 is mainly responsible for 
receptor recognition. However, the C-terminal domain, cleaved off by Spy0416, is 
required for inducing neutrophil migration also because it is responsible for 
glycosaminoglycan (GAG) binding [174, 175]. Chemokine binding to cell-surface GAG 
molecules like heparan sulphate (HS) is a major prerequisite (1) for establishing the solid 
state chemotactic gradient along an inflamed endothelial tissue and (2) for inducing 
conformational changes and higher oligomerisation states of the chemokine in order to 
fully activate the protein. The impact of Spy0416 on IL-8 biological activity is apparently 
to impair the chemokine’s GAG binding activity, thereby interrupting the chemotactic 
response of neutrophils. 
7.1.4 Spy0416 Contribution to GAS Virulence In Vivo 
It was shown that Spy0416 represents an important virulence factor for GAS to avoid 
clearance by phagocytes at the infection sites. Therefore we wanted to evaluate the effect 
of spy0416 gene deletion on virulence of the mutant strain. An important role of Spy0416 
for GAS pathogenesis in vivo could be demonstrated although ΔSpy0416 showed 
deviation of M type from the parental M49591 strain. Nevertheless, we assume that our 
observations are the result of gene deletion and not of a change of emm-type. The delay 
of virulence observed for ΔSpy0416 over a period of two weeks in our intraperitoneal 
murine challenge models is in agreement with observations from other groups. Hidalgo-
Grass et al., demonstrated that in a murine model of GAS necrotizing fasciitis, a 
spy0416/scpA double mutant strain was significantly less virulent than either the scpA 
single mutant or the parental M14 wild type GAS strain [91]. Zinkernagel and colleagues 
showed by a murine necrotic skin infection model that a M1 mutant strain deficient in 
Spy0416 activity caused lesions ~50% reduced in size compared to those produced by 
the wild type strain [192]. Interestingly, contrasting observations were made by Sumby 
et al., where an isogenic spy0416 mutant strain generated significantly larger skin lesions 
than its parental strain in a mouse model of soft tissue infection [178]. In an experimental 
model of local severe soft tissue infection, Spy0416 augmented disease severity whereas 
in a systemic infection such as sepsis Spy0416 had a seemingly protective effect against 
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disease [193]. This indicates that Spy0416 might mediate different effects depending on 
the site of infection. 
7.1.5 Other Contributions of Spy0416 to GAS Pathogenesis 
The high level of sequence conservation of a large GAS protein gives reason to speculate 
that Spy0416 may exhibit additional functions besides its degradation of the CXC 
chemokines IL-8, GCP-2 and Gro-α.  
The successful confirmation of IL-8 degradation in our established in vitro Spy0416 assay 
led us to examine whether other CXC chemokines or even CC chemokines are also 
targeted by the Spy0416 enzymatic activity. Therefore I analyzed IP-10 (Interferon-
inducible protein 10) and I-TAC (IFN-inducible T-cell alpha-chemoattractant) belonging 
to the group of CXC-chemokines and MCP-1 (monocyte chemotactic protein 1), a CC 
chemokine. Interestingly, the analysis of IP-10 and I-TAC degradation, both involved in 
T-cell chemotaxis, revealed that they are not degraded by Spy0416 in vitro although they 
display very similar overall three-dimensional folds as seen in Gro-α [162]. The same 
was observed in case of MCP-1 involved in T-cell and monocyte recruitment from the 
group of CC chemokines. It was previously shown for the CC chemokine RANTES, also 
responsible for T cell and monocyte chemotaxis, that it could not be degraded by 
Spy0416 [91]. Maybe CC chemokines are not a target for Spy0416. On the other hand we 
could also show that the CXC chemokine NAP-2 (neutrophil activating peptide 2) was 
not degraded by Spy0416 in vitro which is involved in neutrophil activation [162]. We 
hypothesised in our previous work that the difference in degradability by Spy0416 is, in 
addition to sequence-specificity, dependent upon the different oligomerisation 
behaviour of the different chemokines, since both NAP-2 (neutrophil activating peptide 
2) and PF-4 (platelet factor 4) have been shown not to be degraded by Spy0416 in vitro 
although they contain similar isofunctional sequence deviations from IL-8 as Gro-α 
[162]. Such selectivity on chemokines that are targeted by Spy0416 could be the result 
from GAS facing situations in which the elimination of IL-8, GCP-2 and Gro-α is 
important. The specific chemokines that are produced and their deployment patterns 
may depend upon the location and stage of infection and therefore it is sufficient for 
GAS survival to target selected chemokines. This might also explain the observed 
different effects of Spy0416 depending on the infection site [193]. Similarly, it was 
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recently described that the related C5A peptidase from S. agalactiae, CspA, also exerts 
distinct specificity for individual CXC chemokines by degrading NAP-2 and Gro-α, but 
it displays no activity for IL-8 [194].  
The involvement of Spy0416 in other immune evasion mechanisms was not further 
investigated in this work. Other functions apart from its protease activity have not been 
reported but due to the high sequence conservation level it is possible that Spy0416 may 
contribute to GAS pathogenesis by multifunctional properties. The streptococcal serum 
opacity factor for example consists of two distinct functional domains. One domain 
exerts a fibronectin-binding activity while the N-terminal domain is responsible for the 
opacity reaction [56, 57]. In this regard it is of interest that the protease domain of Group 
B streptococcal C5a peptidase, ScpB, has been shown to contribute to adhesion of host 
cells by binding to immobilized fibronectin [195, 196] besides its ability to degrade C5a. 
Spy0416 may also act like ScpB as a bifunctional molecule serving as a protease and 
mediating binding to fibronectin since it shares ~30% sequence identity and ~50% 
sequence similarity with the GBS C5a peptidase. Binding of fibronectin has been 
implicated in attachment and invasion of eukaryotic cells by streptococci but 
Zinkernagel and colleagues showed that Spy0416 does not act as a GAS epithelial cell 
adhesion or invasion. An isogenic ΔcepA mutant was found to be ~3-fold more adherent 
and ~2-fold more invasive than the WT parental strain [192].  
Interestingly, CspA involved in group B streptococcal pathogenesis was beside its 
chemokine degradation activity found to be capable of degrading fibrinogen [197]. 
Harris et al., suggested that the cleavage of fibrinogen by CspA may be involved in 
protecting S. agalactiae from opsonophagocytic killing since they could show that a cspA- 
mutant was significantly more sensitive to opsonophagocytic killing by human 
neutrophils than the wild type in vitro. It might be possible that Spy0416, similar to 
CspA, allows GAS to avoid innate immune clearance in the non-immune host not only 
by IL-8 degradation but also by cleavage of fibrinogen. The resulting fibrin-like 
substances consequently would reduce access of opsonins or neutrophils to GAS. 
Although a fibrinogen cleaving activity for Spy0416 was not reported so far to my 
knowledge further work could be done on evaluating such an activity.  
A functional homolog of Spy0416 was found in S. iniae, an emerging zoonotic pathogen 
of humans [192]. The genomic position of cepl is consistent with spy0416 in GAS. A S. 
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iniae Δcepl strain lost the ability to degrade IL-8 and showed increased sensitivity to 
human neutrophil killing. This functional homolog of Spy0416 found in S. iniae 
contributes to chemokine degradation, neutrophil resistance and disease pathogenesis as 
it does for GAS. In case of Staphylococcus aureus, for example, similar bacterial factors 
that comprise the host immune response have been identified. A secreted beta-
hemolysin inhibits TNF-α induced IL-8 secretion in endothelial cells and hence 
neutrophil transmigration [198]. This interference with the ability of the host to induce 
an adequate inflammatory response in an S. aureus infection is similar as in S. pyogenes 
only targeting IL-8 on the transcriptional level. 
 
It would be interesting for future work to further evaluate the role of the ancillary C-
terminal domains of Spy0416 for enzymatic activity, concerning how they might interact 
with the catalytic domains or with IL-8. The identification of factors that determine 
substrate range, such as a common structural motif present on the chemokines which 
mediates binding or entry to the Spy0416 active site or possibly triggering of a 
conformational change within the protease, would be interesting, too. Furthermore, the 
examination whether it exerts a proteolytic activity towards fibrinogen and evaluate the 
susceptibility of a spy0416 gene deletion mutant to opsonophagocytosis might be 
interesting.  
To come to a conclusion, the generated data, the high sequence conservation together 
with our unpublished and the recently reported protection data [153, 154, 178, 192, 193] 
provide strong evidence that Spy0416 can contribute to a vaccine capable of preventing 
Group A streptococcal infections.  
7.2 Targeting of spy0895 and spy1536 for Gene Deletion 
Among the 9 vaccine candidates selected by the ANTIGENome technology, Spy0895 
with its putative histidine protein kinase function and Spy1536, annotated as conserved 
hypothetical protein, were selected for further characterization. Like the other 6 selected 
proteins from the ANTIGENome technology, these two proteins have not been 
previously characterized or shown to protect against GAS infections.  
  Discussion 
Andrea Fritzer  109 
In order to obtain information about their possible role in streptococcal virulence in 
terms of colonization, evasion strategies, establishment of infection and in turn to 
emphasize their value as vaccine candidates, strains, being devoid of functional Spy0895 
and Spy1536 expression, were generated and analyzed.  
The generation of gene deletion mutants was performed with pGhost5 which was 
described in the literature as an effective transformation system [166, 199-201]. The work 
with this shuttle vector turned out to be very difficult. It appeared to be very unstable, as 
during propagation in an E.coli culture larger than 5 ml (large scale), pGhost5 started to 
decrease in size by excising 1000 bp as assessed by digestion with restriction enzymes. 
Only in small scale growth (5 ml) it retained its original size. This was a problem for 
ligation with inserts and transformation into S. pyogenes since a higher amount of 
pGhost5 than obtained from small scale purification was needed for transformation. We 
could overcome these problems finally by pooling pGhost5 preparations from several 
purifications from E. coli which allowed us to generate a larger amount of pGhost5-0895 
and pGhost5-1536 for transformation into competent S. pyogenes cells. Transformation 
was not easy either. First of all, one reason might have been that S. pyogenes is not a 
naturally competent bacterium like for example, S. pneumoniae, and efficiencies in the 
generation of electrocompetent GAS cells for plasmid uptake may vary from strain to 
strain depending on capsule thickness. This might have been also the reason why we 
had to use strain M49591 kindly provided by Bernd Kreikemeyer (Rostock, Germany) 
instead of strain AP1. However, the problems with the transformation could also be 
attributed to the observed instability of pGhost5 as other vectors could be transformed 
into S. pyogenes. 
7.2.1 Efficiency of spy0895 and spy1536 Gene Deletion in Strain M49591 
Deletion of spy0895 was very efficient, as 50-60% of the analyzed erythromycin sensitive 
colonies showed the desired recombination event resulting in gene deletion. In contrast, 
deletion of spy1536 was only found in 1 of all analyzed clones. In order to lead to spy1536 
deletion, excision of pGhost5 occurred by recombination via the N-terminal and not the 
C-terminal fragment of spy1536. An explanation for the rare desired recombination event 
leading to spy1536 gene deletion might be the choice of knock out construct constituted 
by spy1536 N- and C-terminal regions. The C-terminal fragment for recombination was 
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296 bp larger than the N-terminal fragment which might have favored recombination 
resulting in the wild type. In contrast, the sizes of N- and C-terminal regions of spy0895 
for recombination differed only in 7 bp, and recombination to obtain the desired gene 
deletion occurred in 50-60% of the analyzed clones independent of the prior pGhost5 
integration scenario.  
7.3 Role of Spy0895 in Group A Streptococcal Pathogenesis 
In order to identify a role for Spy0895 in GAS pathogenesis a gene deletion mutant, 
ΔSpy0895, was generated. The analysis of ΔSpy0895 did not lead to the identification of 
a potential function or contribution of Spy0895 to GAS pathogenesis. The main reason 
for that might already have been explained by the observed lack of in vitro expression. It 
is evident that the lack of spy0895 expression represents a major obstacle for uncovering 
any effect of the respective gene deletion under in vitro conditions and consequently 
identifying a possible contribution to GAS pathogenesis. In vitro expression of such 
proteins is often very difficult because pathogenicity is a multifactorial property that is 
only fully manifested in vivo. It is necessary to simulate in vivo conditions in order to 
induce expression of certain proteins which is influenced by for example nutrient 
availability, pH, temperature, oxygen tension, osmolarity and growth phase [202] but an 
in vitro condition for Spy0895 expression could not be found to date for the strain 
M49591.  
Since all effects of spy0895 gene deletion can only be linked to Spy0895, the lack of 
Spy0895 in vitro expression in the wild type strain let us already expect the results for 
Spy0895 characterization. The spy0895 gene deletion mutant cells did not show a 
different behaviour compared to wild type cells in growth under different 
environmental conditions or in the intraperitoneal murine challenge model. 
Furthermore, they did not show an aberrant behaviour in their ability to bind human 
plasma- and extracellular matrix-proteins in vitro or a difference in surface protein 
localization in comparison to the wild type cells.  
The same was observed for the transcriptome analyses. It would have been especially 
interesting to know which genes are affected in terms of transcription by the lack of 
Spy0895. As putative histidine kinase it could be involved in a two-component system. 
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Lack of the sensor kinase would for sure reveal target genes regulated by the two 
component system in response to a certain environmental change. At least the genes that 
have been examined in this experiment due to the previous selection by microarray are 
not affected by spy0895 gene deletion. Under in vitro conditions, as already mentioned 
before, some virulence factors are expressed only in response to certain environmental 
changes. Under the applied conditions Spy0895 seems not to be needed to adapt to its 
environment. In their host the bacteria are subjected to mostly different environments 
that can rapidly change and therefore it might adapt to this milieu by the help of 
Spy0895 expression. The function of Spy0895 in streptococcal pathogenesis and whether 
it really acts as a virulence factor remains to date completely unknown.  
7.3.1 Attempts to Overcome Lack of spy0895 In Vitro Expression  
Since no in vitro expression for Spy0895 was observed in the wild type, overexpression 
of Spy0895 in the M49591 was attempted. The overexpression of Spy0895 unfortunately 
failed due to several reasons: 
First, Spy0895 is encoded by a gene that is part of a two-gene operon. The promoter 
region of the operon from which transcription is regulated is not directly located 
upstream of spy0895 but upstream of spy0894. Therefore, after having identified a 
potential promoter region upstream by bioinformatic analyses, the potential promoter 
sequence was fused to the spy0895 gene sequence and ligated into an expression vector 
lacking an inducible promoter. This means that the plasmid-driven expression of 
Spy0895 was dependent on this putative promoter region identified by bioinformatic 
analysis. Plasmid-driven expression of Spy0895 in M49591 analyzed by Western blot 
showed a signal which was twice the size as expected. Attempts to confirm specificity of 
the signal by blocking the Western blot signal with recombinant Spy0895 proteins failed. 
The fact that the promoter region was not directly located upstream of spy0895 besides 
the possibility of regulators acting additionally at more proximal sites reduces the 
guarantee of successful expression from a vector not containing an inducible promoter. 
The use of a constitutive promoter might have led to the overexpression of Spy0895, but 
there was no time left for this. 
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7.4 Role of Spy1536 in Group A Streptococcal Pathogenesis 
7.4.1 In Vitro Expression of Spy1536 
In contrast to Spy0895, characterization of Spy1536 was not hindered by the lack of 
expression under in vitro conditions. The analysis of transcription of spy1536 in wild 
type GAS cells by Northern blot verified first of all transcription of spy1536 in vitro. It 
further confirmed for ΔSpy1536 that spy1537 and spy1538 are not affected in 
transcription by the spy1536 deletion, since the polycistronic RNA was still detected. In 
view of this, under the applied in vitro conditions, Spy1536 is expected to be expressed 
in the wild type strain and thus some influence of spy1536 gene deletion on the mutant 
strain could be expected. 
7.4.2 In Vitro Growth, Bacterial Shape and In Vivo Virulence were Not Affected in 
ΔSpy1536 
Initially, the characterization of ΔSpy1536 was focused on the evaluation of growth 
under different environmental conditions, virulence in mice and bacterial shape by 
electron microscopy.  
Growth under different environmental conditions did not reveal a major growth defect. 
The only exception was the observation of growth in medium supplemented with 2% 
glucose. ΔSpy1536 doubled its optical density within one hour while the wild type strain 
already reached stationary phase. Bacteria coordinately control gene expression and 
virulence factor production by complex regulatory circuits in response to alterations in 
the host milieu [202, 203]. They encounter multiple microenvironments during the 
infectious process and must interact with numerous types of host cells and therefore S. 
pyogenes regulate virulence determinants in response. Transcription of the genes 
encoding M protein and C5a peptidase for example is stimulated by growth in elevated 
CO2 and slightly decreased in elevated O2 [204]. Other environmental factors such as 
temperature, osmolarity and iron limitations have also been shown to influence 
expression of the M protein [205]. For protein F, too, it could be shown that expression is 
influenced by alterations in atmosphere, and conditions that favour M protein 
expression tend to repress protein F expression [206]. The lack of certain virulence 
factors therefore may affect growth of the bacteria which might not be able to adapt to 
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the growth conditions applied. The reason for the observed rapid increase of optical 
density of ΔSpy1536 compared to wild type cells remains unclear. We can only speculate 
that the increased optical density is caused by aggregates of mutant cells resulting from 
changes of the bacterial surface. A decreased capsule expression may lead to increased 
clumping and aggregation or expression of pili that influence interaction between the 
cells. In regard to this it could be shown that expression of pili led to cellular aggregates 
of GAS cells in liquid culture, while GAS mutant cells characterized by mutation of 
genes encoding either the pilus backbone structural protein or the sortase C1 were much 
less efficient in forming such aggregates [182]. Another possibility might be the secretion 
of certain components similarly seen in biofilm formation. Nevertheless, this behaviour 
was not further investigated as it was only reproducible in a small scale 200 µl culture. 
In order to reveal a possible change on the surface of ΔSpy1536 cells or a change of their 
shape as a consequence of gene deletion, the mutant GAS cells were visualized with an 
analytical high-resolution scanning electron microscope. This analysis did not show any 
obvious alteration on the bacterial surface. It is known that scanning electron 
microscopy has not provided nearly as much information about cell walls as 
transmission electron microscopy, since it can only reveal the surface topography. The 
wall surface was “gold sputtered” to provide a thin conductive layer that prevents 
charging by the electron beam and this gold layer can reduce the resolution as well as 
compact polymeric filaments extending from the wall. Transmission electron 
microscopy was planned examining thin sections of the bacterial surface which might 
have given an idea of the thickness of the cell wall or capsule.  
 
To investigate the effect of gene deletion not only under in vitro but also under in vivo 
conditions, we analysed the virulence of ΔSpy1536 in an intraperitoneal murine 
challenge model. Our results did not show a reduction of virulence in ΔSpy1536. In this 
regard it should be mentioned that the mouse environment does not fulfil the 
requirements of human disease entirely although it has still been extensively used for 
studies in streptococcal pathogenesis [47, 179-181]. In addition, it was shown that 
bacterial virulence factors may trigger different disease symptoms and outcomes 
depending on the site of infection [193]. Therefore a different mouse model might have 
revealed an effect of spy1536 deletion on virulence. The use of a different mouse strain 
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might have differed markedly in its susceptibility to group A streptococcal infection. 
BALB/c mice, for example, have shown to be much more resistant than C3H/HeN mice 
[207], not only due to their impaired capacity of bacterial clearance but also due to a 
genetic predisposition to produce inflammatory mediators in response to streptococcal 
products [208]. The use of another infection model would have also been a possibility to 
test ΔSpy1536 virulence because M49591 wild type strain can cause both pharyngeal and 
skin infections. Subcutaneous or intranasal challenge might have given a better insight 
on virulence of ΔSpy1536.  
As we could not observe an obvious growth defect or reduction of virulence in mice for 
ΔSpy1536 as compared to wild type cells, we started with a more detailed analysis using 
functional assays. 
7.4.3 Spy1536 is Crucial for the Binding of Streptococci to Human Plasma and 
Extracellular Matrix Proteins 
The success of pathogens depends on their ability to colonize host tissue and persist by 
ensuring their long-term survival. Accordingly, bacterial pathogenesis is a complex 
process that can involve attachment, colonization as well as internalization by epithelial 
and endothelial cells, local tissue destruction and dissemination to distant anatomic 
sites. S. pyogenes expresses virulence factors that mediate one or more of these processes 
including cell surface adhesins that participate in attachment to host cells [209]. This is 
the reason why the interaction with and adherence to epithelial cells of S. pyogenes is 
generally accepted as a crucial mechanism to colonize and invade the human host and 
consequently cause diseases. Many different surface molecules (adhesins) mediate the 
attachment of GAS to human extracellular matrix components. Therefore, we wanted to 
evaluate whether deletion of spy1536 had an effect on the potential to bind selected 
human proteins in vitro in terms of adherence.  
Surprisingly, our data revealed that the deletion of the spy1536 gene in S. pyogenes 
M49591 showed an almost complete loss of binding to all of the assessed human plasma- 
and extracellular matrix proteins, fibrinogen, fibronectin, laminin, collagen type I and 
plasminogen, while the wild type adhered to these proteins in vitro.  
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It was previously shown that insertional inactivation of for example the gene prtF 
encoding protein F in S. pyogenes had resulted in the loss of fibronectin binding, and 
mutant cells had a much lower capacity to adhere to respiratory epithelial cells [50, 54].  
Due to the fact that we did not only observe lack of fibronectin-binding but observed a 
broad effect on binding to several human proteins (fibrinogen, fibronectin, collagen type 
I, laminin and plasminogen) led to the question whether the strongly reduced binding of 
spy1536 gene deletion mutant was the result of an unspecific change on the bacterial 
surface. For instance, it was shown that group A streptococci expressing M protein have 
a more hydrophobic and a more negatively charged surface than M-negative strains 
attaching better to pharyngeal epithelial cells [210]. Apart from the possibility that the 
spy1536 gene deletion affected the charge of the bacteria, Spy1536 could be involved in a 
more general process relevant for proper surface expression of streptococcal proteins or 
the consequence of a modulated gene expression of surface proteins.  
7.4.4 Spy1536 Influences the Surface Expression of Streptococcal Proteins  
The significantly reduced binding of spy1536 mutant cells to human plasma and 
extracellular matrix proteins indicated a change on the surface of ΔSpy1536. By 
immunostaining of selected surface proteins we wanted to evaluate whether there is 
indeed a change on the surface by reduced expression of adhesins such as the M protein. 
M protein specific surface staining showed on wild type cells a distribution to both the 
closing mother cell septum and the forming daughter cell septa, as it was also seen 
before [211, 212]. M protein is anchored concomitantly with peptidoglycan synthesis at 
the septum and is therefore distributed throughout the cell periphery [211]. One might 
expect an equal distribution of M protein over the wild type surface, but the observed 
pattern of M protein could be the result of taking a culture in late stationary phase of 
growth for immunofluorescence analysis. The use of M protein specific antibodies 
deriving from an M1 and not M49 serotype might also influence detection of M protein 
on the surface, meaning that the conserved M protein regions might only be limitedly 
accessible at these observed bacterial sites. It was shown previously that M protein is 
localized on the bacterial surface to sites of Lipid II export. There, newly anchored M 
protein was often detected at the closing primary division septum and the mature 
equatorial rings/daughter cell division sites [212]. 
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In contrast to the wild type cells, ΔSpy1536 did not show any M protein specific staining 
when visualized under the same conditions. This is in accordance with the assumption 
of a change on the bacterial surface as a result of spy1536 gene deletion.  
Apart from the fact that the M protein is the most prominent molecule on the surface of 
all pathogenic group A streptococci and an important mediator of streptococcal 
adherence [213], lack of M protein on the bacterial surface would make ΔSpy1536 cells 
more prone to phagocytic killing as compared to the wild type.  
In the virulence of GAS the M protein confers resistance to complement mediated killing 
by polymorphonuclear leukocytes and macrophages [46], thus protecting the bacteria 
from phagocytosis. By binding fibrinogen it interferes with complement deposition 
contributing to the known anti-opsonic property of M protein [214]. It could be 
previously shown that surface localization of M protein affected by the deletion of sagA 
increased the strains susceptibility to phagocytosis due to the lacking M protein on the 
bacterial surface [215]. In regard to this it might be very interesting to evaluate whether 
the spy1536 mutant cells would be more efficiently killed in an opsonophagocytosis 
assay than the parental wild type cells. 
Similar observations were made in case of Spy0269 specific staining, which also lacked 
on ΔSpy1536 cells. The Spy0269 protein was identified like Spy1536 using the 
ANTIGENome technology. It is annotated as a putative surface exclusion protein and 
possesses a short region showing similarity with the EzrA protein in B. subtilis that 
interacts with the cell-division protein FtsZ [170]. The observed lack of Spy0269 on the 
bacterial surface of ΔSpy1536 cells might indicate an effect of spy1536 gene deletion on 
selected surface proteins, since Spy1666 was still detectable on the surface. It is unknown 
how Spy0269 surface expression is affected. The Western blot analysis showed signals in 
cytoplasmic and cell wall fraction, also seen for the recombinant Spy0269 protein. It 
remains unclear why this protein is no longer detectable in immunofluorescent analysis. 
The probability that antibodies targeted to the recombinant Spy0269 protein do not bind 
surface exposed Spy0269 is excluded since the recombinant protein also provides 
protection against a lethal S. pyogenes challenge in mice [153].  
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7.4.5 Spy1536 is Involved in Regulation of Surface Protein Localization 
Independent of Transcription 
Since we could partly explain the reduced binding of ΔSpy1536 cells to human proteins 
caused by the lack of M protein on the mutant’s surface, we wanted to investigate 
whether this was the consequence of a transcriptional or translational modulation. The 
detection of M protein in the cytoplasm at similar levels in wild type and ΔSpy1536 cells, 
but not in the supernatant, suggests that Spy1536 does not influence the transcription of 
the emm gene. This was further supported by microarray analysis according to which the 
emm gene was not differentially expressed in ΔSpy1536 compared to the wild type 
strain.  
Since we could exclude a change on the transcriptional level, we hypothesized that 
Spy1536 might be involved in a process of protein surface localization or anchoring.  
In order to assess how Spy1536 could be involved in surface localization of M protein we 
tested whether recombinant Spy1536 added to ΔSpy1536 cells during overnight growth 
would be able to restore M protein surface localization. If it would be directly involved 
in the process of M protein anchoring, recombinant Spy1536 might be able to restore the 
wild type situation. However, the addition of recombinant Spy1536 did not affect 
surface expression of M protein.  
It is possible that Spy1536 not directly affects M protein localization. An indication for 
the involvement of Spy1536 might give its protein structure. Although Spy1536 is 
annotated in the SF370 genome as conserved hypothetical protein, it shows similarity to 
Lon-proteases, including a Lon protease PDZ domain, for which reason it was annotated 
in subsequently published GAS genomes as ATP-dependent endopeptidase Lon. Lon 
proteases are multi-domain enzymes [216-218] found in all living organisms and are 
involved in E. coli in the degradation of naturally unstable and misfolded proteins [218, 
219] as well as in targeting regulatory proteins for degradation. Spy1536 might act in 
similar ways as it was shown for the sagA gene product, which is involved in surface 
localization of M protein without directly affecting transcription of the M protein gene, 
but rather by indirectly affecting its proteolysis, thus preventing peptidoglycan 
anchoring [215]. Similarly, Spy1536 may affect the surface localization of other proteins 
such as Spy0269 using the same or yet another mechanism.  
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The obtained data, the lack of immunofluorescence staining of M protein and Spy0269 
on ΔSpy1536 cells in comparison to wild type M49591 cells, is consistent with the 
assumption that the reduced binding of ΔSpy1536 cells to human proteins is due to the 
diminished surface localization of several streptococcal proteins.  
7.4.6 Spy1536 Affects SpeB Activation in Culture Supernatant 
The immunofluorescence data confirmed the absence of at least two virulence factors on 
the bacterial surface. We could exclude repression of transcription of the corresponding 
genes by microarray and Western blot analysis. Still, it remained unclear whether this is 
caused by a defect in surface localization/ anchoring or yet another mechanism. 
Therefore, we wanted to address the possibility of an overproduction of proteases which 
degrade surface exposed M protein. Since it was reported that SpeB releases biologically 
active fragments from the bacterial surface including M protein [185, 220], we wanted to 
find out whether the lack of M protein on the bacterial surface is attributed to an 
increased expression of active SpeB. Surprisingly some kind of the opposite was 
observed in Western blot analysis. Our results revealed that the spy1536 gene deletion 
mutant showed only the inactive 40 kDa form of SpeB in culture supernatant. Despite 
the fact that this did not explain the lack of M protein on the ΔSpy1536 bacterial surface, 
inability of producing active SpeB in the culture supernatant attracted our attention. 
SpeB, which has been shown to cleave proteins including ECM components [221] and 
plasma proteins such as fibrinogen [222], is secreted as an inactive precursor of 40 kDa 
zymogen form and is auto-catalytically cleaved into an active enzyme of 28 kDa mainly 
in the beginning of stationary phase after 10 hours of growth [223]. Since reducing 
conditions accelerate cleavage of the pro-region which results in mature cysteine 
proteinase [224] we evaluated the effect of DTT to see whether SpeB could be activated 
in vitro. Upon addition of a reducing agent, DTT, SpeB could be activated in vitro. This 
might be an indication that SpeB maturation is not a matter of conformation. It is not 
known what could influence SpeB and prevents it from being activated. Interestingly, it 
was postulated that the generation of mature streptococcal cysteine proteinase is 
dependent on cell wall-anchored M1 protein [223]. Collin and colleagues suggested that 
M protein, when anchored to the cell wall is involved in the unfolding of the zymogen 
and generation of mature cysteine proteinase that can be activated under reducing 
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conditions. This would have been a logical explanation why in the spy1536 gene deletion 
mutant lacking cell wall anchored M protein, SpeB was only detected as inactive 
zymogen. On the contrary, according to Zimmerlein and his colleagues this hypothesis 
was not confirmed [225] when they showed that deletion of M49 and M-like proteins 
had no effect on protease maturation. This seems not to be a proper explanation for the 
inactive SpeB.  
A connection how Spy1536 might be involved in surface localization of both the M 
protein and SpeB cannot be established, since M protein surface localization is 
associated with peptidoglycan synthesis and Sortase A function [212]. In contrast, SpeB 
is exported at a distinct location of the bacteria - at the ExPortal [226] - and proper 
targeting and maturation of nascent SpeB was shown to require the ribosome-associated 
Trigger factor [227, 228] and the cell membrane associated chaperone HtrA [229, 230].  
Spy1536 might exert a similar function like Trigger factor or HtrA have, or influence 
their activity directly or indirectly. Interestingly, it was reported that HtrA is indirectly 
involved in the conversion of proSpeB into its active form [231]. In S. mutans, HtrA plays 
a role in the regulation of genetic competence, biofilm formation, and the biogenesis of 
cell wall-associated and secreted proteins [232, 233]. The involvement of HtrA in the 
degradation of unfolded or misfolded proteins destined for secretion across the 
cytoplasmic membrane [234] resembles an activity attributed to the Lon-protease in E. 
coli [218, 219]. Spy1536 containing a Lon-protease domain on its C-terminus might exert 
a similar function.  
A role for transcription, secretion and even more importantly processing of SpeB was 
also attributed to ropA, an rgg-like transcriptional regulator and homologue of Trigger 
factor which is essential for SpeB maturation exerting a PPIase activity. It was shown 
that RopA acts both to assist in targeting SpeB to the secretory pathway and to promote 
the ability of the pro-protein to establish an active conformation upon secretion [228]. 
Site specific mutagenesis in ropA, the gene encoding trigger factor in S. pyogenes, 
produced a mutant protein deficient in PPIase activity. As a result, although the 
protease was secreted efficiently it did not mature to an active form [227]. The model 
presented by Lyon and colleagues suggests two functions for RopA, one which 
participates in targeting the SpeB-polypeptide for secretion and a second one which 
participates in folding, both functions located at different domains. Spy1536 could 
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interact with the domain involved in SpeB folding. Therefore, in the spy1536 gene 
deletion mutant, lack of spy1536 could result in a misfolded SpeB protein that cannot be 
auto-catalytically activated.  
According to this, there is an indication that Spy1536 is involved in proper surface 
protein localization of M protein and Spy0269 independent of transcription. 
Furthermore, deletion of functional Spy1536 results in the inability of the mutant for 
proper SpeB activation in culture supernatant. SpeB makes important contributions to 
the pathogenesis of streptococcal infections. It could be shown that insertional 
inactivation of speB can reduce virulence of S. pyogenes following intraperitoneal 
challenge of mice [235, 236]. This supports the notion that Spy1536 is directly involved in 
S. pyogenes pathogenesis which even reflects the value of selecting this protein as vaccine 
candidate. 
7.4.6.1 Complementation of spy1536 Gene Deletion 
Attempts to complement the gene deletion in order to attribute the observed phenotype 
to the lack of Spy1536 expression, failed due to several reasons. Like it was already 
explained for spy0895, the Spy1536 encoding gene is part of an operon which 
complicates complementation. For spy1536, too, a potential promoter region had to be 
identified by bioinformatic analysis since it is not directly located upstream of the gene 
but upstream of spy1538. Although the expression vector harboring spy1536 with its 
potential promoter was successfully transformed into S. pyogenes, expression of Spy1536 
could not be observed in Western blot. Unfortunately, time elapsed to complement 
ΔSpy1536 by expressing spy1536 from an expression vector with a constitutive promoter. 
This would be necessary for the verification that the observed phenotype could indeed 
be attributed to spy1536 deletion. 
7.4.6.2 Spy1536 is Involved in Transcriptional Regulation of Adhesin Encoding 
Genes 
I got the opportunity to perform microarray analysis in Rostock in Bernd Kreikemeyer’s 
laboratory to evaluate the effect of gene deletion directly on the transcriptional level. 
Such quantitative whole genome transcript measurements, to name only a few, have 
repeatedly been used to compare regulatory gene mutant bacteria to their corresponding 
wild type strains [237, 238], or specifically stressed bacteria have been compared to their 
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non-stressed isogenic ones [239]. Biofilm associated bacteria, too, could be compared to 
their planktonic counterparts using microarray analysis [240]. In GAS serotypes M1 and 
M49 strains defined mutants have been employed to examine the impact of the CsrRS 
and Rgg regulators based on the whole genome gene expression levels [241, 242].  
Microarray analysis of ΔSpy1536 has resulted in the selection of 10 genes showing 
differential expression compared to the wild type cells at least 2 fold. Among those 
candidates tested in Real Time RT-PCR this observation was confirmed for 5 genes. 
Previous experiments indicated an important role for Spy1536 in streptococcal virulence 
concerning its adhesion to human plasma- and extracellular matrix proteins and in the 
surface localization of M protein and Spy0269. Interestingly, among the genes that have 
been selected based on microarray analysis and furthermore confirmed to be 
differentially expressed by Real Time RT-PCR, some of them encode virulence factors 
involved in adherence and invasion of S. pyogenes. The results substantiate the reduced 
binding to human plasma and extracellular matrix proteins observed for the ΔSpy1536 
strain.  
The spy1536 gene deletion mutant was characterized by a ~100 fold decreased 
transcription of spym49s0079, which encodes the fibronectin binding protein SfbX49. The 
observation of a decrease in sfbX49 transcription is in agreement with the reduced 
binding of ΔSpy1536 to human fibronectin in vitro. SfbX49 has been identified by Jeng 
and his colleagues in 2003 [187] where the respective gene, sfbX49, was shown to encode 
a fibronectin-binding function. A sfbX mutant was characterized by a marked decrease 
in fibronectin binding which could be restored by complementation. Additionally it was 
demonstrated that sfbX49 is located together with serum opacity factor (sof49) within a 
two-gene operon, under positive control of the GAS multiple gene regulator Mga [243]. 
According to the microarray data analysis, serum opacity factor expression was also 
affected by the spy1536 gene deletion but this could not be confirmed by Real Time RT-
PCR according to which the gene spym49s0078 showed no significant change in 
transcription. However, studies on sof and sfbX49 have shown that each gene contributes 
strongly and independently to the ability of log-phase GAS to bind to immobilized 
fibronectin [187].  
The spy1536 gene deletion mutant showed also reduced binding to collagen type I in 
vitro. This is again in accordance with the Microarray analyses and Real Time RT-PCR 
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which revealed ~5-10 fold downregulation of spym49b1739 (scIB) and spym49c1149 (scIA), 
both encoding putative collagen-like proteins, SclA and SclB, being structurally related 
to one another [244]. Isogenic strains in which the scl gene was inactivated were 
significantly reduced in their ability to adhere to human epithelial cells grown in culture 
and were significantly less pathogenic in a mouse model of soft tissue infection [49]. The 
downregulation of these two collagen-binding proteins may not have only an effect in 
terms of adherence but also in evasion of host immune mechanisms. For instance, it 
could be shown that S. pyogenes counteracts host attacks by recruiting host proteinases to 
its surface. SclA and SclB might be involved in modulating inflammatory reactions in 
the host. By binding TAFI, a Thrombin-activable Fibrinolysis Inhibitor [245] which has 
been shown to inactivate anaphylatoxins C3a and C5a [246], SclA and SclB could 
contribute to the inhibition of phagocyte recruitment to the infection site. Similar 
mechanisms for adhesins binding human proteinases have been described. The best 
studied human proteinase in this respect is plasminogen, which apart from S. pyogenes 
also interacts with many other species, including Borrelia burgdorferi, E. coli, Salmonella 
enteritidis, Yersinia pestis and the Neisseria species gonorrhoeae and meningitides [247]. Once 
plasminogen is bound to the bacterial surface, the zymogen can be activated and 
enhance bacterial dissemination. Plasminogen binding to the streptococcal surface is 
mediated by M and M-like proteins [61, 248] as well as α-enolase [63]. Some M proteins 
bind plasminogen indirectly via fibrinogen [248], and other strains that express PAM 
(Plasminogen-binding group A streptococcal M-like protein) bind plasminogen directly 
with high affinity [61].  
Furthermore, SclA from an M6-type group A streptococcus has recently been shown to 
be involved in inhibiting the alternative pathway of complement by binding factor H 
[249], an important mechanism that has also been described for M and M-like proteins. 
This indicates that apart from the observed lack of M protein, ΔSpy1536 might be more 
prone to phagocytosis in its host. 
The approximately 100-fold downregulation of fcrA (spym49s0005) in ΔSpy1536, too, 
speaks for the hypothesis of an increased susceptibility to phagocytosis. FcrA, encoding 
an M-related Ig-binding protein (precursor), has been identified in serotype M49 to be 
expressed under the control of the vir49 regulon clustered on the streptococcal 
chromosome with emm49, enn49 as well as scpA49 [188-190]. A mutant devoid of vir49 
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function did not express Ig-binding proteins and became sensitive to phagocytosis by 
human leukocytes [250].  
The only slightly upregulated gene identified in ΔSpy1536 was hasA (spy2200), encoding 
the membrane associated hyaluronate synthase, which is part of the hasABC operon. 
This effect of gene deletion is quite interesting because the question is whether this 
contributes to a reduced virulence or even supports adherence/ invasion of the 
streptococci apart from the fact of other adhesins not being expressed on the surface. 
There are contrasting reports regarding the role of hyaluronic acid capsule in GAS 
internalization. In one study the presence of capsule did not affect internalization [251], 
while other studies reported both augmentation [9] and inhibition of bacterial entry [252, 
253]. The inhibitory effect of hyaluronic acid capsule concerning invasion was attributed 
to masking the bacterial surface molecules required for interactions of the host cells [254, 
255].  
7.4.7 Regulation of Transcription: Is Spy1536 Involved in a Regulatory Network of 
S. pyogenes? 
In order to colonize and cause disease at distinct anatomical sites, bacterial pathogens 
must tailor gene expression in a microenvironment-specific manner. Interactions 
between regulatory systems contribute to the control of tissue tropism and infection. The 
main question that remains unanswered here is the role Spy1536 might play in all the 
observations described. An influence of the spy1536 gene deletion was not only seen on 
the transcriptional level (upregulation of hasA and downregulation of fcrA, sclA, sclB, 
and fsbX49), also a defect in surface localization of the major virulence factor, the M 
protein, and Spy0269 could be observed. Besides that, an inability of producing an active 
form of SpeB, that is usually secreted as inactive zymogen and is mainly activated by its 
autocatalytic activity, was found for ΔSpy1536. Many regulatory networks have been 
described in Group A streptococci involving several transcriptional regulators that 
influence the expression of secreted and surface proteins. Mga for instance, coordinates 
expression of genes encoding proteins involved in adherence and proteins that confer 
ability to resist phagocytosis. Besides C5a peptidase (scpA) and serum opacity factor 
(sof), M (emm) and M related proteins (e.g. fcrA), SclA (sclA) as well as SclB (sclB) have 
been reported to be positively regulated by Mga [49, 79, 243, 256]. One could say that 
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activation of Mga might be mediated by Spy1536 which leads in ΔSpy1536 to lack of 
sfbX49, sclA and sclB transcription, but the M protein in contrast is not affected on the 
transcriptional level but merely not targeted to the cell surface. Similar it is seen for speB 
and hasA. SpeB expression and hyaluronic acid capsule synthesis are under the negative 
control of the covR/covS (control of virulence factors) two-component system [257]. Here, 
too, one could say Spy1536 might inhibit CovR activity to increase capsule expression, 
but this would at the same time also affect speB transcription. Whereas in ΔSpy1536 
SpeB expression is not increased, the protease is just not detectable in its active form.  
It is difficult to determine a common pattern of regulation maybe due to the fact that 
regulation of virulence in group A streptococcus is extremely complex. An example that 
virulence factor regulation is exerted from many different regulatory systems and not 
enough is also strain dependent was shown for Spy0416. The spy0416 gene is one of the 
most highly differentially expressed upon comparison of the transcriptional profile of 
invasive M1T1 GAS isolates versus similar clonal strains isolated from the pharyngeal 
mucosa [178]. In simple colonization, results generated by Zinkernagel and colleagues 
indicate that Spy0416 may decrease epithelial cell adherence and therefore, its 
expression would not be favoured. Furthermore, it was found that its transcription is 
negatively regulated by CovRS where mutations in CovS in emm 49 clinical isolates led 
to a significant change of virulence factor transcription, increasing Spy0416 (ScpC), 
hyaluronic acid capsule, C5a-peptidase expression while SpeB was downregulated [258]. 
On the other hand it was reported by Hidalgo-Grass and colleagues that in an M14 
strain SilCR pheromone downregulates transcription of scpC via the two component 
system SilA/B [91]. This again points out that an effective vaccine should target more 
than just one or two protective candidates. 
The gene deletion studies have furthermore provided evidence for an important role of 
Spy1536. To my knowledge, all these observations in the spy1536 gene deletion mutant 
have not been previously described for Spy1536. The significantly reduced binding to 
human plasma and extracellular matrix proteins is further substantiated by the reduced 
surface localization of M protein and Spy0269 and the reduced transcription of adhesin 
encoding genes. The data strongly indicates an important role for Spy1536 in regulation 
of virulence factors and hence streptococcal pathogenicity.  
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7.5 Conclusion 
The presented data further strengthens the selection of Spy0416 and Spy1536 as 
potential vaccine candidates. Spy0416 was one of the most frequently selected protective 
antigens by the ANTIGENome Technology. Its ability to protect against lethal infection 
in mice was shown in three different mouse models that try to mimic human disease. In 
addition, Spy0416 (ScpC) was shown to mediate cleavage of IL-8, thereby impairing 
clearance from infected tissues and promoting resistance to neutrophil killing [91, 192]. 
We provided further evidence that this activity can be exerted by the recombinant 
Spy0416 protein and that it relied on the concerted activity of the enzymatic as well as 
ancillary domains of the large ScpC protein [162]. These studies strengthen the selection 
of Spy0416 as candidate for a GAS vaccine.  
Furthermore, the results from the gene deletion mutant experiments indicated an 
important function for Spy1536 adherence to human plasma- and extracellular matrix 
proteins. This is a very interesting finding as Spy1536 was previously not characterized 
and a contribution to virulence has to my knowledge not been shown before. Adherence 
and invasion are the important disease-causing mechanisms of gram-positive 
organisms. Since interaction of these pathogens with the components of host ECM is 
involved in adherence and invasion, the underlying mechanism of this interaction are of 
utmost importance for designing novel therapeutic strategies. The exact mechanism how 
Spy1536 acts on gene transcription encoding adhesins (sfbX49, hasA, sclA, sclB and fcrA) 
still remains unanswered. Lon proteases have the ability to target regulatory proteins for 
degradation, so it might be possible that Spy1536 degrades general regulators such as 
Mga or CovR/S to control virulence factor expression according to the environmental 
conditions it is subjected to. Furthermore, Spy1536 seems to be directly or indirectly 
involved in the surface localization of M protein, Spy0269 and potentially other selected 
surface proteins as well as in the maturation of SpeB. A detailed understanding of these 
mechanisms is crucial, since interference with microbial surface components recognizing 
adhesive matrix molecules functioning alone or in conjunction with specific 
manipulations of regulators is an attractive goal for novel anti-infective strategies. So far 
we could not detect any proteolytic activity for Spy1536. Although the exact 
contribution and mechanism of how Spy1536 is involved in the transcriptional 
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regulation of adhesins and surface localization of proteins is unknown the data clearly 
emphasizes its important role for GAS pathogenesis. 
In summary, the described GAS vaccine candidates are highly conserved not only in the 
published 13 S. pyogenes genomes, but also in up to 51 further analyzed clinical isolates. 
Thus it can be assumed that an immune response against any of these candidates will be 
able to recognize the pathogen if the respective protein is surface accessible during the 
infection. The observed high level of sequence conservation and their ability to 
individually induce protection in mice [153] argues that these proteins provide an 
important function to the pathogen. As S. pyogenes has evolved many mechanisms to 
evade the immune system of its human host, targeting not only a single protein but 
several surface proteins or virulence factors in a vaccine will decrease the likelihood that 
the pathogen will be capable of evading the host immune response and cause disease in 
an immunized individual. Studies are therefore currently ongoing to evaluate whether a 
combination of several proteins will be able to achieve a high level of protection against 
various serotypes of group A streptococcus. The described work will thus strongly 
support the endeavour to develop vaccines to lower the large burden of disease caused 
by group A streptococcus throughout the developed and developing world. 
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9 ABBREVIATIONS 
 
ABTS    2,2'-Azinobis-(3-ethylbenzthiazolin-6-sulfonsäure) 
AEBSF    4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride 
Ala    Alanine 
Asp    Aspartate 
BCA    Bicinchoninic Acid 
BSA  Bovine Serum Albumin 
EDTA  Ethylenediaminetetracetic Acid 
CFA  Complete Freund’s Adjuvant 
CFU  Colony Forming Unit 
DEPC  Diethylpyrocarbonate 
DNA  Desoxyribonucleic Acid 
DMEM  Dulbecco´s Modified Eagle Medium 
ELISA  Enzyme-linked Immunosorbant Assay 
FBS  Fetal Bovine Serum 
FCS  Fetal Calf Serum 
FITC  Fluoresceinisothiocyanat 
GAS  Group A streptococcus 
GBS  Group B streptococcus 
Gln  Glutamine 
GRO-α  Growth-Related-Oncogene α 
HBSS  Hanks’ Balanced Salt Solution 
HEPES  N-2-Hydroxyethylpiperazine-N'-2-Ethanesulfonic Acid 
His  Histidine 
His-tag  Histidine-tag 
IFN  Interferon 
IFA  Incomplete Freund’s Adjuvant 
IL-8  Interleukin 8 
IP-10   Interferon-inducible protein 10  
I-TAC   IFN-inducible T-cell alpha-chemoattractant 
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IPTG  Isopropyl β-D-Thiogalacto-Pyranoside 
KC   Keratinocyte-derived Chemokine 
Leu  Leucine 
LB  Luria Bertani 
MACS   Magnetic Cell Sorting 
mid-log  mid-logarithmic 
MIP-2   Macrophage Inflammatory Protein 2 
MHB  Mueller-Hinton Broth 
Mw  Molecular weight 
MWM  Molecular Weight Marker 
OD  Optical Density 
PBS  Phosphate Buffered Saline 
PBS-T  Phosphate Buffered Saline with 0.1% Tween-20 
Phe  Phenylalanine 
PMSF  Phenylmethylsulfonyl fluoride 
PEG  Polyethylen-glycol 
RHD  Rheumatic Heart Disease 
SDS  Sodium Dodecyl Sulfate 
SDS-PAGE  Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis 
Ser  Serine 
SLO  Streptolysin O 
SLS  Streptolysin S 
SPR  Surface Plasmon Resonance  
STSS  Streptococcal Toxic Shock Syndrome 
TCA  Trichloric acid 
TEMED  N,N,N',N'-Tetramethylethylenediamine 
THB  Todd Hewitt Broth 
Thr  Threonine 
Tris  TRIZMA®base 
Tx100  Triton 
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10 APPENDIX 
10.1 Appendix I - Primers 
Table 3: Primers for generation of gene specific probes used in Southern and Northern blot analysis 
Primer names and respective sequences (forward and reverse, 5’-3’). Specificities indicate gene regions to 
which primers bind. 
 
Name Primer sequence (forward, reverse) Specificity 
 
6074 
6075 
 
Fw:   5’-GAATTGAACCTTGCCTTTCTAGCG-3’ 
Rev:  5’-CCTCGTGATCAGATTCCAACATG-3’ 
 
spy0895 
6076 
6077 
Fw:   5’-GCATCGCTGTATCCGCCTGT-3’ 
Rev:  5’-CCAGTTTGTTGCAGTGGGCATT-3’ 
spy1536 
6333 
6334 
Fw:   5’-CCTCTTTAATTTGGTTATATGAATTTTGC-3’ 
Rev:  5’-CTTGCTCTTTTGTCAGAGAAATCATAAC-3’ 
pGhost5 
7268 
7269 
Fw:   5’-TGCCTTCGATCTCTATCTATGCTCG-3’ 
Rev:  5’-GTTATCTGAGATCGTCATGATTCCAAG-3’ 
spy0894 
7270 
7271 
Fw:   5’-CAGAGCTTGAGTAAGCATTGCTTTAC-3’ 
Rev:  5’-GGTCATTTGATCCTGTTACAAACG-3’ 
spy1537 
7272 
7273 
Fw:   5’-CCAGTCAAGCAATCAATAGCTCG-3’ 
Rev:  5’-GACGCTCGATGGAAAGATAACAC-3’ 
spy1538 
 
 
 
Table 4: Primers used for generation of Spy0416 subconstructs 
Open reading frames (ORF) with primer names and respective sequences (forward and reverse, 5’-3’) are 
presented. Amplification of PCR products (bp) carried out under standard conditions. Restriction enzyme 
recognition sites (underlined) for cloning are NcoI and XhoI except for Spy0416A and Spy0416B cloning 
where EcoRI and XhoI as well as Spy0416ΔFn1 where AflII and XhoI were utilized.  
 
ORF Name Primer (forward, reverse) Product  
 
Spy0416A 
 
2246 
2247 
 
FW:     5'-TAGTAGGAATTCGGCAGATGAGCTAAGCACAATG-3 
REV:   5'-TAGTAGCTCGAGCTCTGAACCAAGAGTGACAAG-3' 
 
2502 
Spy0416B 2248 
2249 
FW:     5'-TAGTAGGAATTCGCATGTAGACCCACAAAAGGGC-3 
REV:   5'-TAGTAGCTCGAGCGTTGATGGTAGGGCTTTTGC-3' 
2646 
Spy0416A 
ΔFn2 
6408 
6409 
FW:     5’-TAGTAGACATGTGCAGATGAGCTAAGCACAATGAG-3’ 
REV:   5’-GTGGTGCTCGAGTTGCCCTTTAAAACCAACAAAAG-3’ 
2382  
Spy0416B 
Fn2Fn3 
6410 
6411 
FW:     5’-GATATACCATGGCCTTTGAAAACTTAGCAGTTGCAGAAG-3’ 
REV:   5’-GTGGTGCTCGAGTGTTTGTGGTAAGTGATCTCCTAAC-3’ 
950 
Spy0416B 
Fn2´Fn3´ 
6412 
6413 
FW:     5’-GATATACCATGGCCTTAGGTAAAACACCAATTAAACTTAAGC-3’ 
REV:   5’-GTGGTGCTCGAGGTCACGCAAGGTAGCAAAAGAC-3’ 
789 
Spy0416B 
Y 
6414 
6415 
FW:     5’-GATATACCATGGCCCTAAAAGCGGTCGGAAAAGAC-3’ 
REV:   5’-GTGGTGCTCGAGGGCAGAGGCTGTCAAAGCC-3’ 
630 
Spy0416B 
Fn2´Fn3´Y 
6412 
6415 
FW:     5’-GATATACCATGGCCTTAGGTAAAACACCAATTAAACTTAAGC-3’ 
REV:   5’-GTGGTGCTCGAGGGCAGAGGCTGTCAAAGCC-3’ 
1419 
Spy0416B 
∆Fn1 
6410 
6415 
FW:     5’-GATATACCATGGCCTTTGAAAACTTAGCAGTTGCAGAAG-3’ 
REV:   5’-GTGGTGCTCGAGGGCAGAGGCTGTCAAAGCC-3’ 
2343 
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Table 5: Primers used for the generation of spy0895 and spy1536 knock out constructs and for confirmation of 
pGhost5 integration  
Primer names and respective forward and reverse (5’-3’) sequences are listed. Restriction enzyme 
recognition sites KpnI and BamHI are underlined. Primer specificities indicate genome regions to which 
primers anneal. Standard PCR conditions were used for all primer pairs listed. Ligation of spy0895 N- and 
C-terminal fragments required the following optimized conditions: 2.25 mM MgCl2, 5 cycles with an 
annealing temperature of 47°C followed by 35 cycles with an increased annealing temperature of 50°C. 
Ligation of spy1536 N- and C-terminal fragments required 2.25 mM MgCl2, 5 cycles with an annealing 
temperature of 53°C followed by 35 cycles with an increased annealing temperature of 55°C 
 
Name Primer (forward, reverse) Specificity 
 
5412 
5413 
 
Fw:  5’-ATATAGGTACCTGCCTTCGATCTCTATCTATGCTCG-3’ 
Rev: 5’-TGGCATTCATGTCATCAAAGTTAACATCTCTAGTAAATAGAGGGCAG-3’ 
 
spy0895, N-term 
spy0895, N-term 
 
5414 
5415 
 
Fw:  5’-CTGCCCTCTATTTACTAGAGATGTTAACTTTGATGACATGAATGCCA-3’ 
Rev: 5’-TATATGGATCCTCTCTTTATCAACGACTATAACCGAGAT-3’ 
 
spy0895, C-term 
spy0895, C-term 
 
5416 
5417 
 
Fw:  5’-ATATAGGTACCCGCTGTCAAGTTAGATATGTTTTATGTA-3’ 
Rev: 5’-AAATGCCTGGAGGCGCTTACTGGGATTGGCATTGCCTTGAC-3’ 
 
Spy1536, N-term 
Spy1536, N-term 
 
5418 
5419 
 
Fw:  5’-GTCAAGGCAATGCCAATCCCAGTAAGCGCCTCCAGGCATTT-3’ 
Rev: 5’-TATATGGATCCTTGAAACCGTCTATTTGATATCAAG-3’ 
 
Spy1536, C-term 
Spy1536, C-term 
 
6005 
6006 
 
Fw:  5’-ACATGGCGTTAGTTCCCTAAATTTCAGTC-3’ 
Fw:  5’-AGGGTTTTCCCAGTCACGACGTT-3’ 
 
spy0894, upstream 
pGhost5 
 
6007 
6008 
 
Rev: 5’-GAGCGGATAACAATTTCACACAGG-3’ 
Rev: 5’-TGTACTTATGAGAATTCAACAACTGCATTA-3’ 
 
pGhost5 
spy0895downstream 
 
6009 
6010 
 
Fw:  5’-TCCTTTTTGAGAAATATACCTGGAGACTGTT-3’ 
Rev: 5’-CAAACGGTCATCTCGATATTGTTAAAC-3’ 
 
spy1536, upstream 
spy1536,downstream 
 
Table 6: Sequences of primers used for Real Time RT-PCR determinations 
Genes that have been identified by microarray analysis as differentially expressed genes are listed with 
sense and antisense primers for the amplification of 100-150 bp gene specific sequences in Real Time RT-
PCR. 
 
∆Spy0895 
Gene Sense (5’-3’) Antisense (5’-3’) 
spy0441 GTGCTTGGAGCAACAAATACCC AAAGTCTCTTTGGTCAATCATGTCC 
spy0570 CCACAGCTATTCGAGAATTGCC GACACCGCTTGTGAATTCTGG 
spy1031 GTGCTTTTGGCACTTCAAGTCC AAGTTATCGGCTACATCGGTGC 
spy1691 TGTCCTCCTTGGGCTAATATGG AAAATAAGGAGCCGTATTGTGACC 
spy1718 CTAAACAAGATGACCCAAGCTTCC TCCAAGAGTAAACCTGCATGCC 
spym180822 TTTCATAATTGCTGCCTTGGC AATATGCCATGGACTCTGGCC 
spym49b0400 CTTGAAAGAAGATGCCCTGTGC AACAAATCCTGTCCTGTATAAATCCC 
spym49b0627 TGACAGCTCCATCTGTACAATTCG CTTCGTTAGCTTTAGCGATTTTACG 
spym180822 CCGAGATATCACGAATGGAAGC TTGTAAGTCGCACGACTTGGC 
spym49b0627 TTGAAAGTCCTTTAGTCGGTGTAGC ATGGCTTCGATAATCACAAGGG 
   
∆Spy1536 
Gene Sense (5’-3’) Antisense (5’-3’) 
spy0611 TATCCAAGGTTCAGCTCTTAAAGCTC AGAATACATCTTCGACTGGAAGAAGC 
spy0738 GCGTATAACTTCCGCTACCACC AGTGTAGCTGAAACAACTCAAGTTGC 
spy1642 AGGAACATCTTCCCAAGTAATCCC ATGGGATGATTGATTGCTGTCC 
spy2200 TTAGGAGTTCTTCTAAGGCATTTGG AAACGTTATCGTTCACCGTTCC 
spym49b0963 TTAACATCACTTGTCAATACAGAAATCG CTCACTGATGATTATTGCACTCGG 
spym49b1739 AACACAAGGTGGTAATCAGCTCG CGTTTCGCAACAGCTACAACC 
spym49c1149 CCTTTGGTATCATGCTCACGC GGCAGAATGTGCTAAGAAAGCG 
spym49s0005 TCCAATCTCTTGTTTATACTTGTCGC TGTAAAAGCTGCTTTGGCAGG 
spym49s0078 AACTTGCCGTTATCCACTTTAAGC GCTTGAGCTGGTTTTCATCAGC 
spym49s0079 TAAGCATGAGGAAATAGGTCTGGG TAACGCTAGAACAGATCGCAACC 
 
 
 
Housekeeping genes 
Gene Sense (5’-3’) Antisense (5’-3’) 
gki TTTGCCATTGACAATGATGCC TTACCATCAGCAATAATGCCTCC 
mutS AGTGATGACAATTGCAGTTAAATCG AAGATTTCTAATGACAGCACGTTAGC 
recP CAGACGGTGTCGAAGCAACC CAAAGCAAATGTGTAGTGATCAACG 
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10.2 Appendix II -Vectors 
 
pET28b(+)
Kan
lacI
His-Tag
His-Tag
ICC 102
ICC 103
T7 promoter
T7 terminator
5368 bp
 
Figure: Expression vector pET28b(+)  
 
 
 
 
 
 
Figure: Cloning/Expression region of pET28b(+)  
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pET28bn-His
5311 bp
Kan
lacI
T7 promoter
T7 terminator
new linker
 
 
Figure: Expression vector pET28bn-His 
 
 
S ac I
A f l II I
( Ac cI )pGhost5
5249 bp
ori 
pBR 322
erm
ori Ts
MCS
Kpn I
Apa I
Xho I
Sal I
(Acc I)
Cla I
Hind III
Eco RV
Eco RI
Pst I
Sma I
Bam HI
Spe I
Xba I
Xma III
Not I
Sac II
Bst XI
(Sac I)
 
 
Figure 1: Shuttle vector pGhost5 
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10.3 Appendix III - Sequences 
Spy0416A: 
Protein sequence 
ADELSTMSEPTITNHAQQQAQHLTNTELSSAESKSQDTSQITLKTNREKEQSQDLVSEPTTTELADTDAASMANTGSDA
TQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGSW
INDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQT
DDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDIMGSAESLFIKAIEDAVALGADVINLSLGT
ANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLMT
VKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKESTDAGYNAQDVKGKIALIERDPNKTYDEMIALAKKH
GALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLTS
DGYLKPDITAPGGDIYSTYNDNHYGSQTGTSMASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNPE
TKTTTSPRQQGAGLLNIDGAVTSGLYVTGKDNYGSISLGNITDTMTFDVTVHNLSNKDKTLRYDTELLTDHVDPQKGRF
TLTSHSLKTYQGGEVTVPANGKVTVRVTMDVSQFTKELTKQMPNGYYLEGFVRFRDSQDDQLNRVNIPFVGFKGQFENL
AVAEESIYRLKSQGKTGFYFDESGPKDDIYVGKHFTGLVTLGSELEHHHHHH* 
 
The protein has the HIS tag at both N & C termini and was purified from the soluble fraction 
over Ni-Agarose column. The theoretical molecular weight of SPy0416A is 94.52 kDa. 
 
SPy0416B 
Protein sequence 
HVDPQKGRFTLTSHSLKTYQGGEVTVPANGKVTVRVTMDVSQFTKELTKQMPNGYYLEGFVRFRDSQDDQLNRVNIPFV
GFKGQFENLAVAEESIYRLKSQGKTGFYFDESGPKDDIYVGKHFTGLVTLGSETNVSTKTISDNGLHTLGTFKNADGKF
ILEKNAQGNPVLAISPNGDNNQDFAAFKGVFLRKYQGLKASVYHASDKEHKNPLWVSPESFKGDKNFNSDIRFAKSTTL
LGTAFSGKSLTGAELPDGHYHYVVSYYPDVVGAKRQEMTFDMILDRQKPVLSQATFDPETNRFKPEPLKDRGLAGVRKD
SVFYLERKDNKPYTVTINDSYKYVSVEDNKTFVERQADGSFILPLDKAKLGDFYYMVEDFAGNVAIAKLGDHLPQTLGK
TPIKLKLTDGNYQTKETLKDNLEMTQSDTGLVTNQAQLAVVHRNQPQSQLTKMNQDFFISPNEDGNKDFVAFKGLKNNV
YNDLTVNVYAKDDHQKQTPIWSSQAGASVSAIESTAWYGITARGSKVMPGDYQYVVTYRDEHGKEHQKQYTISVNDKKP
MITQGRFDTINGVDHFTPDKTKALDSSGIVREEVFYLAKKNGRKFDVTEGKDGITVSDNKVYIPKNPDGSYTISKRDGV
TLSDYYYLVEDRAGNVSFATLRDLKAVGKDKAVVNFGLDLPVPEDKQIVNFTYLVRDADGKPIENLEYYNNSGNSLILP
YGKYTVELLTYDTNAAKLESDKIVSFTLSADNNFQQVTFKITMLATSQITAHFDHLLPEGSRVSLKTAQDQLIPLEQSL
YVPKAYGKTVQEGTYEVVVSLPKGYRIEGNTKVNTLPNEVHELSLRLVKVGDASDP(S)TGDHKVMSKNNSQALTASAT
PTKSTTSATAKALPSTLEHHHHHH* 
 
The protein has the HIS tag at both N & C termini. The theoretical molecular weight of SPy0416B 
is 103.11  kDa. 
 
Spy0416BFn2Fn3 
 
Protein sequence 
 
MAFENLAVAEESIYRLKSQGKTGFYFDESGPKDDIYVGKHFTGLVTLGSETNVSTKTISDNGLHTLGTFKNADGKFILE
KNAQGNPVLAISPNGDNNQDFAAFKGVFLRKYQGLKASVYHASDKEHKNPLWVSPESFKGDKNFNSDIRFAKSTTLLGT
AFSGKSLTGAELPDGHYHYVVSYYPDVVGAKRQEMTFDMILDRQKPVLSQATFDPETNRFKPEPLKDRGLAGVRKDSVF
YLERKDNKPYTVTINDSYKYVSVEDNKTFVERQADGSFILPLDKAKLGDFYYMVEDFAGNVAIAKLGDHLPQTLEHHHH
HH* 
 
The protein has the HIS tag at its N-terminus. The theoretical molecular weight of Spy0416BFn2Fn3 
is 34.8 kDa 
 
 
  Appendix III 
Andrea Fritzer  161 
Spy0416BFn2’Fn3’ 
 
Protein sequence 
 
MALGKTPIKLKLTDGNYQTKETLKDNLEMTQSDTGLVTNQAQLAVVHRNQPQSQLTKMNQDFFISPNEDGNKDFVAFKG
LKNNVYNDLTVNVYAKDDHQKQTPIWSSQAGASVSAIESTAWYGITARGSKVMPGDYQYVVTYRDEHGKEHQKQYTISV
NDKKPMITQGRFDTINGVDHFTPDKTKALDSSGIVREEVFYLAKKNGRKFDVTEGKDGITVSDNKVYIPKNPDGSYTIS
KRDGVTLSDYYYLVEDRAGNVSFATLRDLEHHHHHH* 
 
The protein has the HIS Tag at its N-terminus. The theoretical molecular weight  of  
Spy0416BFn2’Fn3’ is 28.9 kDa 
 
Spy0416BFn2’Fn3’Y 
 
Protein sequence 
 
MALGKTPIKLKLTDGNYQTKETLKDNLEMTQSDTGLVTNQAQLAVVHRNQPQSQLTKMNQDFFISPNEDGNKDFVAFKG
LKNNVYNDLTVNVYAKDDHQKQTPIWSSQAGASVSAIESTAWYGITARGSKVMPGDYQYVVTYRDEHGKEHQKQYTISV
NDKKPMITQGRFDTINGVDHFTPDKTKALDSSGIVREEVFYLAKKNGRKFDVTEGKDGITVSDNKVYIPKNPDGSYTIS
KRDGVTLSDYYYLVEDRAGNVSFATLRDLKAVGKDKAVVNFGLDLPVPEDKQIVNFTYLVRDADGKPIENLEYYNNSGN
SLILPYGKYTVELLTYDTNAAKLESDKIVSFTLSADNNFQQVTFKITMLATSQITAHFDHLLPEGSRVSLKTAQDQLIP
LEQSLYVPKAYGKTVQEGTYEVVVSLPKGYRIEGNTKVNTLPNEVHELSLRLVKVGDASDSTGDHKVMSKNNSQALTAS
ALEHHHHHH* 
 
The protein has the HIS tag at its N-terminus. The theoretical molecular weight of 
Spy0416BFn2’Fn3’Y is 52 kDa. 
 
Spy0416BY  
 
Protein sequence 
 
MALKAVGKDKAVVNFGLDLPVPEDKQIVNFTYLVRDADGKPIENLEYYNNSGNSLILPYGKYTVELLTYDT
NAAKLESDKIVSFTLSADNNFQQVTFKITMLATSQITAHFDHLLPEGSRVSLKTAQDQLIPLEQSLYVPKA
YGKTVQEGTYEVVVSLPKGYRIEGNTKVNTLPNEVHELSLRLVKVGDASDSTGDHKVMSKNNSQALTASAL
EHHHHHH* 
 
The protein has the HIS tag at its N-terminus. The theoretical molecular weight of Spy0416BY is 
32.1 kDa. 
 
Spy0416BΔFn1 
 
Protein sequence 
 
HHHHHHSMAFENLAVAEESIYRLKSQGKTGFYFDESGPKDDIYVGKHFTGLVTLGSETNVSTKTISDNGLHTLGTFKNA
DGKFILEKNAQGNPVLAISPNGDNNQDFAAFKGVFLRKYQGLKASVYHASDKEHKNPLWVSPESFKGDKNFNSDIRFAK
STTLLGTAFSGKSLTGAELPDGHYHYVVSYYPDVVGAKRQEMTFDMILDRQKPVLSQATFDPETNRFKPEPLKDRGLAG
VRKDSVFYLERKDNKPYTVTINDSYKYVSVEDNKTFVERQADGSFILPLDKAKLGDFYYMVEDFAGNVAIAKLGDHLPQ
TLGKTPIKLKLTDGNYQTKETLKDNLEMTQSDTGLVTNQAQLAVVHRNQPQSQLTKMNQDFFISPNEDGNKDFVAFKGL
KNNVYNDLTVNVYAKDDHQKQTPIWSSQAGASVSAIESTAWYGITARGSKVMPGDYQYVVTYRDEHGKEHQKQYTISVN
DKKPMITQGRFDTINGVDHFTPDKTKALDSSGIVREEVFYLAKKNGRKFDVTEGKDGITVSDNKVYIPKNPDGSYTISK
RDGVTLSDYYYLVEDRAGNVSFATLRDLKAVGKDKAVVNFGLDLPVPEDKQIVNFTYLVRDADGKPIENLEYYNNSGNS
LILPYGKYTVELLTYDTNAAKLESDKIVSFTLSADNNFQQVTFKITMLATSQITAHFDHLLPEGSRVSLKTAQDQLIPL
EQSLYVPKAYGKTVQEGTYEVVVSLPKGYRIEGNTKVNTLPNEVHELSLRLVKVGDASDSTGDHKVMSKNNSQALTASA
LE 
 
The protein has the HIS tag at its N-terminus. The theoretical molecular weight of Spy0416BΔFn1  is 
85.9 kDa. 
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Spy0416AΔFn2 
Protein sequence 
 
MADELSTMSEPTITNHAQQQAQHLTNTELSSAESKSQDTSQITLKTNREKEQSQDLVSEPTTTELADTDAASMANTGSD
ATQKSASLPPVNTDVHDWVKTKGAWDKGYKGQGKVVAVIDTGIDPAHQSMRISDVSTAKVKSKEDMLARQKAAGINYGS
WINDKVVFAHNYVENSDNIKENQFEDFDEDWENFEFDAEAEPKAIKKHKIYRPQSTQAPKETVIKTEETDGSHDIDWTQ
TDDDTKYESHGMHVTGIVAGNSKEAAATGERFLGIAPEAQVMFMRVFANDIMGSAESLFIKAIEDAVALGADVINLSLG
TANGAQLSGSKPLMEAIEKAKKAGVSVVVAAGNERVYGSDHDDPLATNPDYGLVGSPSTGRTPTSVAAINSKWVIQRLM
TVKELENRADLNHGKAIYSESVDFKDIKDSLGYDKSHQFAYVKESTDAGYNAQDVKGKIALIERDPNKTYDEMIALAKK
HGALGVLIFNNKPGQSNRSMRLTANGMGIPSAFISHEFGKAMSQLNGNGTGSLEFDSVVSKAPSQKGNEMNHFSNWGLT
SDGYLKPDITAPGGDIYSTYNDNHYGSQTGTSMASPQIAGASLLVKQYLEKTQPNLPKEKIADIVKNLLMSNAQIHVNP
ETKTTTSPRQQGAGLLNIDGAVTSGLYVTGKDNYGSISLGNITDTMTFDVTVHNLSNKDKTLRYDTELLTDHVDPQKGR
FTLTSHSLKTYQGGEVTVPANGKVTVRVTMDVSQFTKELTKQMPNGYYLEGFVRFRDSQDDQLNRVNIPFVGFKGQLEH
HHHHH* 
 
The protein has the HIS tag at its N-terminus. The theoretical molecular weight of Spy0416AΔFn2 is 
87.3 kDa. 
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spy0895 Knock Out Construct 
 
Nucleotide sequence 
 
ATATAGGTACCTGCCTTCGATCTCTATCTATGCTCGTGAATTAATCGTTGATTACGGTGTCAAAACATTGATCCGTGTT
GGTACTGCGGGTGCGATTGACCCAGAAGTTCATGTGCGTGAATTGGTGCTTGCCCAAGCAGCAGCAACCAACTCAAATA
TTATCCGTAATGACTTCCCAGAATTTGATTTCCCACAAATTGCTGATTTTGGTTTACTTGACAAGGCTTACCATATCGC
CAGAGAAATGGGAGTAACAACTCACGTTGGGAATGTGCTTTCTTCTGATGTCTTTTACACTAACATGCCTGAGCGTAAT
ATGGCTCTTGGTAAATTGGGTGTTAAAGCCATCGAAATGGAAGCAGCAGCTCTTTACTATTTAGCTGCTCAGCACCATG
TCAAAGCCCTTGGAATCATGACGATCTCAGATAACTTGAATGATCCAACCGAAGATACTACAGCTGAAGAGCGCCAAAC
AACTTTCACTGATATGATGAAGGTCGGCTTGGAAACCTTAATTGCCAATGACTAATAATCAAACACTAGACATCCTTTT
GGATGTCTATGCTTATAATCACGCCTTTAGAATTGCTAAAGCCTTGCCAAATATCCCTAAAACTGCCCTCTATTTACTA
GAGATGTTAACTTTGATGACATGAATGCCATTATTAAAAAGGAGTTGAGCCTTTGGAGACAATCTATTGTCTGATATTT
ATCAAAAAACACGATAACTTGACCGATACAGGTCTTACTACCGTGTTTTTTAGTATGACGATTGAAAAAGACATTAATC
AAAGGTTACTTCTTCGAGAAGGTATTCGATAAAACGTTCCCCCATTTTGGACAAGTTGGCTTTTTCATGCTTGATAAAA
ACAATGTCAATTTCGTCAGGGACATCTAGCGGGATAGCCACAATCTGGTCACCATTTAGATTGCTATTTAGAATACCAC
TGGCAACGGTGTAGCCATCTAAACCAATCATTAAGTTAAAGAGGGTGGCACGGTCACTGACCACAATTGATTTGTTGTG
GGGCATCTGGGACATCATCTCTTCTGAAAAATAAAAGGAGTTGTGAATCCCTTGGTCATAGCTCAGGTAAGGAAAATCT
CTCAAGTCGTCCATGCTTAATAGGCTTTTAGTTGCTAGAGGATTTGATTTGCTGACAAAAATATGAGGCTGTGCCTTAA
ATAATGGAGAGGCGGTCAAATGATTGTCATCAAATAATTTGGTCAAGACATCTCGGTTATAGTCGTTGATAAAGAGAGG
ATCCATATA 
 
The underlined nucleotides show restriction enzyme recognition sites KpnI and BamHI, respectively. 
Sequence highlighted in grey represents the sequence of the N-terminal region of spy0895. The C-terminal 
spy0895 region is the non-highlighted sequence. 
 
spy1536 Knock Out Construct 
 
Nucleotide sequence 
 
ATATAGGTACCCGCTGTCAAGTTAGATATGTTTTATGTAAAAAATGATTGAACCCAAAAGACTGGTCAAGGATCTGTCT
ATCTGGTTCAACCGTTTTTTATGAGTTAATAGCGTGAATATAATTGAATATAATACATTCATAGTTATTTTATTTGCGA
AGATAAACCAGTGCCTCTTGAACAGTCGTAACAGGAACAATCTTCATTTTGGTCTTTAGTCGTTTGGCTGCCCGTTTGG
CTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATAT
ATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATA
GTTCCTGTACCTGCAATTGTACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTA
GACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATCACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAA
GGCAATGCCAATCCCAGTAAGCGCCTCCAGGCATTTCAATATAATAAGGTAGCGGAAAAAATAACGCTAGCAACAAAGA
GATTAAAGCTAGCAGACCCACTAACCACCATTTGATTTTTTTAAGTCTTTTCATTCATTTTCTCCACTTGAGCAATAAC
CGACTGAGGAACCAAACCTTCTAAGGAAGACTGAAAATGAATTAGCTCTCTCACACGACTAGAGCTAAGGGCCTGCCAT
TTATTTCTTGATATCAAATAGACGGTTTCAAGGATCCATATA 
 
The underlined nucleotides show restriction enzyme recognition sites KpnI and BamHI, respectively. 
Sequence highlighted in grey represents the sequence of the N-terminal region of spy1536.  The C-terminal 
spy1536 region is the non-highlighted sequence. 
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Sequence alignments of spy0895 gene deletion in strain ΔSpy0895 
C
0894
N
6005 6008
∆
M49591 - WT Spy08950894
N C
ΔSpy0895
6005 6008
N-, C-terminal regions
N-, C-terminal regions
5412
5412 5415
5415
5413 5414
 
Figure: Region view of spy0895 operon in wildtype and spy0895 gene deletion mutant with a schematic 
representation of primer localization used for sequencing 
 
 
Sequence alignment spy0895 gene deletion mutant (deletion highlighted in yellow) 
 
                         1673                                                                                            1772 
    Spy0895 K.O.  (1673) GTGGAAAGCTCGGAAACTAGATAAACTAACTTTTGAGCTCACACATGGCGTTAGTTCCCTAAATTTCAGTCGCTTTCTGTCCGCCCTCTGACCTTCTACA 
   0895K.O.-5412     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005     (1) ---------------------------------------------------------------------------------------------------- 
         WT-0895    (73) GTGGAAAGCTCGGAAACTAGATAAACTAACTTTTGAGCTCACACATGGCGTTAGTTCCCTAAATTTCAGTCGCTTTCTGTCCGCCCTCTGACCTTCTACA 
         WT-5412     (1) ---------------------------------------------------------------------------------------------------- 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (1673)                                                                                                      
                         1773                                                                                            1872 
    Spy0895 K.O.  (1773) AAATAAAAGGAAAGGTAGGGCTAACTGTATTCATTGAATTGAATACGGGCGGAGAACTGTTTTTCTTCCTTATAAAAAATAAAAAAATAAGAAAGGTGAG 
   0895K.O.-5412     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005     (1) --------------------------------------------------------------------------------------------------CT 
         WT-0895   (173) AAATAAAAGGAAAGGTAGGGCTAACTGTATTCATTGAATTGAATACGGGCGGAGAACTGTTTTTCTTCCTTATAAAAAATAAAAAAATAAGAAAGGTGAG 
         WT-5412     (1) ---------------------------------------------------------------------------------------------------- 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (1773)                                                                                                      
                         1873                                                                                            1972 
    Spy0895 K.O.  (1873) GGCTGAGTTCATTAATTTGAATTCGGGCTAAGGACTTGGTCAAAAAGATAAGTTGTCTAGAAAATCAGGATTTTCTGCCAACTTCCTATTTTGCCATCGT 
   0895K.O.-5412     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005     (3) AACTGTATTCATTGAATTGAATACGGGCGGAGAACTGTGTAAAAAAGATAAACTGTCTAGCATCTG-GGATGCGTCGTCAGTTTCCTATTTTTACTTTGT 
         WT-0895   (273) GGCTGAGTTCATTAATTTGAATTCGGGCTAAGGACTTGGTCAAAAAGATAAGTTGTCTAGAAAATCAGGATTTTCTGCCAACTTCCTATTTTGCCATCGT 
         WT-5412     (1) ---------------------------------------------------------------------------------------------------- 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005     (1) AACTGTATTCATTGAATTGAATACGGGCGGAGAACTGTGTAAAAAAGATAAACTGTCTAGCATCTG-GGATGCGTCGTCAGTTTCCTATTTTTACTTTGT 
      WT-5413rev     (1) -----------------------------------------AAAAAGATAAACTGTCTAGCATCTG-GGATGCGTCGTCAGTTTCCTATTTTTACTTTGT 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (1873)                                                                                                      
                         1973                                                                                            2072 
    Spy0895 K.O.  (1973) TCTTTTAACGCCCTCAGTATCATAATTTATGTCTATCCATATTTCTGCCAAAAAAGGCGATATTGCTGATAAAATTCTTCTACCTGGAGATCCTTTGCGC 
   0895K.O.-5412     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (102) TCTTTGT-CGCCTTTAATATCTTAATA-ATGTCTATCCATATTTCTGCCAAAAAAGGTGATATTGCTGATAAAATTCTTCTACCTGGAGACCCTTTGCGC 
         WT-0895   (373) TCTTTTAACGCCCTCAGTATCATAATTTATGTCTATCCATATTTCTGCCAAAAAAGGCGATATTGCTGATAAAATTCTTCTACCTGGAGATCCTTTGCGC 
         WT-5412     (1) ---------------------------------------------------------------------------------------------------- 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (100) TCTTTGT-CGCCTTTAATATCTTAATA-ATGTCTATCCATATTTCTGCCAAAAAAGGTGATATTGCTGATAAAATTCTTCTACCTGGAGACCCTTTGCGC 
      WT-5413rev    (59) TCTTTGT-CGCCTTTAATATCTTAATA-ATGTCTATCCATATTTCTGCCAAAAAAGGTGATATTGCTGATAAAATTCTTCTACCTGGAGACCCTTTGCGC 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (1973)                                                                                                      
                         2073                                                                                            2172 
    Spy0895 K.O.  (2073) GCGAAATTTATCGCTGAAAATTTCCTAGAAGATGCAGTGTGTTTTAACGAAGTGCGTAACATGTTTGGCTACACAGGAACTTACAAAGGGCACCGCGTTT 
   0895K.O.-5412     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (200) GCGAAATTTATCGCTGAAAATTTCCTAGAAGATGCAGTGTGTTTTAACGAAGTGCGTAACATGTTTGGCTACACAGGAACTTACAAAGGGCACCGCGTTT 
         WT-0895   (473) GCGAAATTTATCGCTGAAAATTTCCTAGAAGATGCAGTGTGTTTTAACGAAGTGCGTAACATGTTTGGCTACACAGGAACTTACAAAGGGCACCGCGTTT 
         WT-5412     (1) ---------------------------------------------------------------------------------------------------- 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (198) GCGAAATTTATCGCTGAAAATTTCCTAGAAGATGCAGTGTGTTTTAACGAAGTGCGTAACATGTTTGGCTACACAGGAACTTACAAAGGGCACCGCGTTT 
      WT-5413rev   (157) GCGAAATTTATCGCTGAAAATTTCCTAGAAGATGCAGTGTGTTTTAACGAAGTGCGTAACATGTTTGGCTACACAGGAACTTACAAAGGGCACCGCGTTT 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (2073)                                                                                                      
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                         2173                                                                                            2272 
    Spy0895 K.O.  (2173) CTGTCATGGGAACTGGTATGGGGATGCCTTCGATCTCTATCTATGCTCGTGAATTAATCGTTGATTACGGTGTCAAAACATTGATCCGTGTTGGTACTGC 
   0895K.O.-5412     (1) -----------------------------------------------------------------------GTCAAAACATTGATCCGAGTTGGTACTGC 
0895K.O.-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (300) CTGTCATGGGAACTGGTATGGGGATGCCTTCGATCTCTATCTATGCTCGTGAATTAATCGTTGATTACGGTGTCAAAACATTGATCCGTGTTGGTACTGC 
         WT-0895   (573) CTGTCATGGGAACTGGTATGGGGATGCCTTCGATCTCTATCTATGCTCGTGAATTAATCGTTGATTACGGTGTCAAAACATTGATCCGTGTTGGTACTGC 
         WT-5412     (1) ------------------------------------------------------------------------------CATTGATCCGTGTTGGTACTGC 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (298) CTGTCATGGGAACTGGTATGGGGATGCCTTCGATCTCTATCTATGCTCGTGAATTAATCGTTGATTACGGTGTCAAAACATTGATCCGTGTTGGTACTGC 
      WT-5413rev   (257) CTGTCATGGGAACTGGTATGGGGATGCCTTCGATCTCTATCTATGCTCGTGAATTAATCGTTGATTACGGTGTCAAAACATTGATCCGTGTTGGTACTGC 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (2173)                                                                        GTCAAAACATTGATCCGTGTTGGTACTGC 
                         2273                                                                                            2372 
    Spy0895 K.O.  (2273) GGGTGCGATTGACCCAGAAGTTCATGTGCGTGAATTGGTGCTTGCCCAAGCAGCAGCAACCAACTCAAATATTATCCGTAATGACTTCCCAGAATTTGAT 
   0895K.O.-5412    (30) GGGTGCGATTGACCCAGAAGTTCATGTGCGTGAATTGGTGCTTGCCCAAGCAGCAGCAACCAACTCAAATATTATCCGTAATGACTTCCCAGAATTTGAT 
0895K.O.-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (400) GGGTGCGATTGACCCAGAAGTTCATGTGCGTGAATTGGTGCTTGCCCAAGCAGCAGCAACCAACTCAAATATTATCCGTAATGACTTCCCAGAATTTGAT 
         WT-0895   (673) GGGTGCGATTGACCCAGAAGTTCATGTGCGTGAATTGGTGCTTGCCCAAGCAGCAGCAACCAACTCAAATATTATCCGTAATGACTTCCCAGAATTTGAT 
         WT-5412    (23) GGGTGCGATTGACCCAGAAGTTCATGTGCGTGAATTGGTGCTTGCCCAAGCAGCAGCAACCAACTCAAATATTATCCGTAATGACTTCCCAGAATTTGAT 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (398) GGGTGCGATTGACCCAGAAGTTCATGTGCGTGAATTGGTGCTTGCCCAAGCAGCAGCAACCAACTCAAATATTATCCGTAATGACTTCCCAGAATTTGAT 
      WT-5413rev   (357) GGGTGCGATTGACCCAGAAGTTCATGTGCGTGAATTGGTGCTTGCCCAAGCAGCAGCAACCAACTCAAATATTATCCGTAATGACTTCCCAGAATTTGAT 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (2273) GGGTGCGATTGACCCAGAAGTTCATGTGCGTGAATTGGTGCTTGCCCAAGCAGCAGCAACCAACTCAAATATTATCCGTAATGACTTCCCAGAATTTGAT 
                         2373                                                                                            2472 
    Spy0895 K.O.  (2373) TTCCCACAAATTGCTGATTTTGGTTTACTTGACAAGGCTTACCATATCGCCAGAGAAATGGGAGTAACAACTCACGTTGGGAATGTGCTTTCTTCTGATG 
   0895K.O.-5412   (130) TTCCCACAAATTGCTGATTTTGGTTTACTTGACAAGGCTTACCATATCGCCAGAGAAATGGGAGTAACAACTCACGTTGGGAATGTGCTTTCTTCTGATG 
0895K.O.-5415rev     (1) -----------------------------------------------------------------------------------------TTCTTCTGA-G 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (500) TTCCCAC--------------------------------------------------------------------------------------------- 
         WT-0895   (773) TTCCCACAAATTGCTGATTTTGGTTTACTTGACAAGGCTTACCATATCGCCAGAGAAATGGGAGTAACAACTCACGTTGGGAATGTGCTTTCTTCTGATG 
         WT-5412   (123) TTCCCACAAATTGCTGATTTTGGTTTACTTGACAAGGCTTACCATATCGCAAGAGAAATGGGAGTAACAACTCACGTTGGGAATGTGCTTTCTTCTGATG 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (498) TTCCCACAAATTGCTGATTTTGGTTTACTTGACAAGGCTTACCATATCGCAAGAGAAATGGGAGTAACAACTCACGTTGGGAATGTGCTTTCTTCTGATG 
      WT-5413rev   (457) TTCCCACAAATTGCTGATTTTGGTTTACTTGACAAGGCTTACCATATCGCAAGAGAAATGGGAGTAACAACTCACGTTGGGAATGTGCTTTCTTCTGATG 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (2373) TTCCCACAAATTGCTGATTTTGGTTTACTTGACAAGGCTTACCATATCGC AGAGAAATGGGAGTAACAACTCACGTTGGGAATGTGCTTTCTTCTGATG 
                         2473                                                                                            2572 
    Spy0895 K.O.  (2473) TCTTTTACACTAACATGCCTGAGCGTAATATGGCTCTTGGTAAATTGGGTGTTAAAGCCATCGAAATGGAAGCAGCAGCTCTTTACTATTTAGCTGCTCA 
   0895K.O.-5412   (230) TCTTTTACACTAACATGCCTGAGCGTAATATGGCTCTTGGTAAATTGGGTGTTAAAGCCATCGAAATGGAAGCAGCAGCTCTTTACTATTTAGCTGCTCA 
0895K.O.-5415rev    (11) TCTTTTACACTAACATGCCTGAGCGTAATATGGCTCTTGGTAAATTGGGTGTTAAAGCCATCGAAATGGAAGCAGCAGCTCTTTACTATTTAGCTGCTCA 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895   (873) TCTTTTACACTAACATGCCTGAGCGTAATATGGCTCTTGGTAAATTGGGTGTTAAAGCCATCGAAATGGAAGCAGCAGCTCTTTACTATTTAGCTGCTCA 
         WT-5412   (223) TCTTTTACACTAACATGCCTGAGCGTAATATGGCTCTTGGTAAATTGGGTGTTAAAGCCATCGAAATGGAAGCAGCAGCTCTTTACTATTTAGCTGCTCA 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (598) TCTTTTACACTAACATGCCTGAGCGTAATATGGCTCTTGGTAAATTGGGTGTTAAAGCCATCGAAATGGAAGCAGCAGCTCTTTACTATTTAGCTGCTCA 
      WT-5413rev   (557) TCTTTTACACTAACATGCCTGAGCGTAATATGGCTCTTGGTAAATTGGGTGTTAAAGCCATCGAAATGGAAGCAGCAGCTCTTTACTATTTAGCTGCTCA 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (2473) TCTTTTACACTAACATGCCTGAGCGTAATATGGCTCTTGGTAAATTGGGTGTTAAAGCCATCGAAATGGAAGCAGCAGCTCTTTACTATTTAGCTGCTCA 
                         2573                                                                                            2672 
    Spy0895 K.O.  (2573) GCACCATGTCAAAGCCCTTGGAATCATGACGATCTCAGATAACTTGAATGATCCAACCGAAGATACTACAGCTGAAGAGCGCCAAACAACTTTCACTGAT 
   0895K.O.-5412   (330) GCACCATGTCAAAGCCCTTGGAATCATGACGATCTCAGATAACTTGAATGATCCAACCGAAGATACTACAGCTGAAGAGCGCCAAACAACTTTCACTGAT 
0895K.O.-5415rev   (111) GCACCATGTCAAAGCCCTTGGAATCATGACGATCTCAGATAACTTGAATGATCCAACCGAAGATACTACAGCTGAAGAGCGCCAAACAACTTTCACTGAT 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895   (973) GCACCATGTCAAAGCCCTTGGAATCATGACGATCTCAGATAACTTGAATGATCCAACCGAAGATACTACAGCTGAAGAGCGCCAAACAACTTTCACTGAT 
         WT-5412   (323) GCACCATGTCAAAGCCCTTGGAATCATGACGATCTCAGATAACTTGAATGATCCAACCGAAGATACTACAGCTGAAGAGCGTCAAACCACTTTCACTGAT 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (698) GCACCATGTCAAAGCCCTTGGAATCATGACGATCTCAGATAACTTGAATGATCCAACCGAAGATACTACAGCTGAAGAGCGTCAAACCACTTTCACTGAT 
      WT-5413rev   (657) GCACCATGTCAAAGCCCTTGGAATCATGACGATCTCAGATAACTTGAATGATCCAACCGAAGATACTACAGCTGAAGAGCGTCAAACCACTTTCACTGAT 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (2573) GCACCATGTCAAAGCCCTTGGAATCATGACGATCTCAGATAACTTGAATGATCCAACCGAAGATACTACAGCTGAAGAGCG CAAAC ACTTTCACTGAT 
                         2673                                                                                            2772 
    Spy0895 K.O.  (2673) ATGATGAAGGTCGGCTTGGAAACCTTAATTGCCAATGACTAATAATCAAACACTAGACATCCTTTTGGATGTCTATGCTTATAATCACGCCTTTAGAATT 
   0895K.O.-5412   (430) ATGATGAAGGTCGGCTTGGAAACCTTAATTGCCAATGACTAATAATCAAACACTAGACATCCTTTTGGATGTCTATGCTTATAATCACGCCTTTAGAATT 
0895K.O.-5415rev   (211) ATGATGAAGGTCGGCTTGGAAACCTTAATTGCCAATGACTAATAATCAAACACTAGACATCCTTTTGGATGTCTATGCTTATAATCACGCCTTTAGAATT 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (1073) ATGATGAAGGTCGGCTTGGAAACCTTAATTGCCAATGACTAATAATCAAACACTAGACATCCTTTTGGATGTCTATGCTTATAATCACGCCTTTAGAATT 
         WT-5412   (423) ATGATGAAGGTCGGCTTGGAAACCTTAATTGCCAATGACTAATAATCAAACGCTAGACATCCTTTTGGATGTCTATGCTTATAATCACGCCTTTAGAATT 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (798) ATGA------------------------------------------------------------------------------------------------ 
      WT-5413rev   (757) ATGATGAAGGTCGGCTTGGAAACCTTAATTGCCAATGACTAATAATCAAACGCTAGACATCCTTTTGGATGTCTATGCTTATAATCACGCCTTTAGAATT 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (2673) ATGATGAAGGTCGGCTTGGAAACCTTAATTGCCAATGACTAATAATCAAAC CTAGACATCCTTTTGGATGTCTATGCTTATAATCACGCCTTTAGAATT 
                         2773                                                                                            2872 
    Spy0895 K.O.  (2773) GCTAAAGCCTTGCCAAATATCCCTAAAACTGCCCTCTATTTACTAGAGATGTTAA--------------------------------------------- 
   0895K.O.-5412   (530) GCTAAAGCCTTGCCAAATATCCCTAAAACTGCCCTCTATTTACTAGAGATGTTAA--------------------------------------------- 
0895K.O.-5415rev   (311) GCTAAAGCCTTGCCAAATATCCCTAAAACTGCCCTCTATTTACTAGAGATGTTAA--------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (1173) GCTAAAGCCTTGCCAAATATCCCTAAAACTGCCCTCTATTTACTAGAGATGTTAAAAGAGCGCAGAGAATTGAACCTTGCCTTTCTAGCGGAACATGCAG 
         WT-5412   (523) GCTAAAGCCTTGCCAAATATCCCTAAAACTGCTCTCTATTTACTAGAGATGTTAAAAGAGCGCAGAGAATTGAACCTTGCCTTTCTGGCGGAACATGCAG 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (857) GCTAAAGC-------------------------------------------------------------------------------------------- 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (2773) GCTAAAGC                                                                                             
                         2873                                                                                            2972 
    Spy0895 K.O.  (2828) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-5412   (585) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (366) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (1273) CAGAGAATCGGACCATTGAAGACCAGTATCACTGTTCATTATGGCTTAACCAATCGCTTGAAGATGAGCAGATTGCCAATTACATTTTGGATTTAGAAGT 
         WT-5412   (623) CAGAGAATCGGACCATTGAAGACCAGTACCACTGTTCATTATGGCTTAACCAATCGCTTGAAGATGAGCAGATTGCCAATTACATTTTGGATTTAGAAGT 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (2873)                                                                                                      
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                         2973                                                                                            3072 
    Spy0895 K.O.  (2828) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-5412   (585) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (366) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (1373) TAAAGTAAAAAACGGTGCTATTATTGATTTCGTCAGGTCAGTGTCGCCTATTCTTTACCGACTTTTTCTCAGACTAATCACGTCAGAAATTCCAAACTTC 
         WT-5412   (723) TAAAGTAAAAAACGGTGCTATTATTGATTTCGTCAGGTCAGTGTCGCCTATTCTTTACCGACTTTTTCTCAGACTAATCACGTCAGAAATTCCAAACTTC 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev     (1) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (2973)                                                                                                      
                         3073                                                                                            3172 
    Spy0895 K.O.  (2828) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-5412   (585) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (366) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (1473) AAGGCTTATATTTTTGATACAAAGAATGACCAATATGATACCTGGCATTTTCAGGCCATGTTGGAATCTGATCACGAGGTTTTCAAGGCTTACCTGTCTC 
         WT-5412   (823) AAGGCTTATATTTTTGATACAAAGAATGACCAATATGATACCTGGCATTT-------------------------------------------------- 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev     (1) ---------------------------------------------------------------------------GAGGTTTTCAAGGCTTACCTGTCTC 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (3073)                                                                                                      
                         3173                                                                                            3272 
    Spy0895 K.O.  (2828) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-5412   (585) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (366) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (1573) AAAAGCAGTCTCGCAATGTGACGACCAAAAGCTTAGCAGACATGTTGACGTTGACCTCCTTACCTCAGGAAATCAAGGACTTGGTTTTTTTGTTACGACA 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev    (26) AAAAGCAGTCTCGCAATGTGACGACCAAAAGCTTAGCAGACATGTTGACGTTGACCTCCTTACCTCAGGAAATCAAGGACTTGGTTTTTTTGTTACGACA 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (3173)                                                                                                      
                         3273                                                                                            3372 
    Spy0895 K.O.  (2828) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-5412   (585) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (366) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (1673) TTTTGAAAAGGCTGTCCGTAATCCTCTGGCTCATTTGATTAAGCCTTTTGATGAAGAGGAACTGCATCGCACCACTCATTTTTCTTCTCAGGCTTTTTTG 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (126) TTTTGAAAAGGCTGTCCGTAATCCTCTGACTCATTTGATTAAGCCTTTTGATGAAGAGGAACTGCATCGCACCACTCATTTTTCTTCTCAGGCTTTTTTG 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (3273)                                                                                                      
                         3373                                                                                            3472 
    Spy0895 K.O.  (2828) -----------------------------------------------------------CTTTGATGACATGAATGCCATTATTAAAAAGGAGTTGAGCC 
   0895K.O.-5412   (585) -----------------------------------------------------------CTTTGATGACATGAATGCCATTATTAAAAAGGAGTTGAGCC 
0895K.O.-5415rev   (366) -----------------------------------------------------------CTTTGATGACATGAATGCCATTATTAAAAAGGAGTTGAGCC 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (1773) GAAAACATTATCACCTTGGCGACTTTTTCTGGTGTAATCTACCGACGTGAGCCTTTTTACTTTGATGACATGAATGCCATTATTAAAAAGGAGTTGAGCC 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414     (1) ---------------------------------------------------------------------------------------------TTGAGCC 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (226) GAAAACATTATCACCTTGGCGACTTTTTCTGGTGTAATCTACCGACGTAAGCCTTTTTACTTTGATGACATGAATGCCATTATTAAAAAGGAGTTGAGCC 
      WT-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (3373)                                                                                              TTGAGCC 
                         3473                                                                                            3572 
    Spy0895 K.O.  (2869) TTTGGAGACAATCTATTGTCTGATATTTATCAAAAAACACGATAACTTGACCGATACAGGTCTTACTACCGTGTTTTTT-AGTATGACGATTGAAAAAGA 
   0895K.O.-5412   (626) TTTGGAGACAATCTATTGTCTGATATTTATCAAAAAACACGATAACTTGACCGATACAGGTCTTACTACCGTGTTTTTT-AGTATGACGATTGAAAAAGA 
0895K.O.-5415rev   (407) TTTGGAGACAATCTATTGTCTGATATTTATCAAAAAACACGATAACTTGACCGATACAGGTCTTACTACCGTGTTTTTT-AGTATGACGATTGAAAAAGA 
0895K.O.-6008rev     (1) ---------------------------------------------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (1873) TTTGGAGACAATCTATTGTCTGATATTTATCAAAAAACACGATAACTTGACCGATACAGGTCTTACTACCGTGTTTTTT-AGTATGACGATTGAAAAAGA 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414     (8) TTTGGAGACAATCTATTGTCTGATATTTATCAAAAAACACGATAACTTGACCGATACAGGTCTTACTACCGTGTTTTTTTAGTATGACGATTGAAAAAGA 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (326) TTTGGAGACAATCTATTGTCTGATATTTATCAAAAAACACGATAACTTGACCGATACAGGTCTTACTACCGTGTTTTTTTAGTATGACGATTGAAAAAGA 
      WT-6008rev     (1) --------------------------TTATCAAAAA-CACGATACCTTGACCGATACAGGTCTTACTACCCGTGTTTTTTAGTATGACGATTGAAAAAGA 
       Consensus  (3473) TTTGGAGACAATCTATTGTCTGATATTTATCAAAAAACACGATAACTTGACCGATACAGGTCTTACTACCGTGTTTTTT AGTATGACGATTGAAAAAGA 
                         3573                                                                                            3672 
    Spy0895 K.O.  (2968) CATTAATCAAAGGTTACTTCTTCGAGAAGGTATTCGATAAAACGTTCCCCCATTTTGGACAAGTTGGCTTTTTCATGCTTGATAAAAACAATGTCAATTT 
   0895K.O.-5412   (725) CATTAATCAAAGGTTACTTCTTCGAGAAGGTATTCGATAAAACGTTCCCCCATTTTGGACAAGTTGGCTTTTTCATGCTTGATAAAAACAATGTCAATTT 
0895K.O.-5415rev   (506) CATTAATCAAAGGTTACTTCTTCGAGAAGGTATTCGATAAAACGTTCCCCCATTTTGGACAAGTTGGCTTTTTCATGCTTGATAAAAACAATGTCAATTT 
0895K.O.-6008rev     (1) ----------------------------------------------------------------TGGCTTTTTCATGCTTGATAAAAACAATGTCAATTT 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (1972) CATTAATCAAAGGTTACTTCTTCGAGAAGGTATTCGATAAAACGTTCCCCCATTTTGGACAAGTTGGCTTTTTCATGCTTGATAAAAACAATGTCAATTT 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414   (108) CATTAATCAAAGGTTACTTCTTCGAGAAGGTATTCGATAAAACGTTCCCCCATTTTGGACAAGTTGGCTTTTTCATGCTTGATAAAAACAATGTCAATTT 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (426) CATTAATCAAAGGTTACTTCTTCGAGAAGGTATTCGATAAAACGTTCCCCCATTTTGGACAAGTTGGCTTTTTCATGCTTGATAAAAACAATGTCAATTT 
      WT-6008rev    (74) CATTAATCAAAGGTTACTTCTTCGAGAAGGTATTCGATAAAACGTTCCCCCATTTTGGACAAGTTGGCTTTTTCATGCTTGATAAAAACAATGTCAATTT 
       Consensus  (3573) CATTAATCAAAGGTTACTTCTTCGAGAAGGTATTCGATAAAACGTTCCCCCATTTTGGACAAGTTGGCTTTTTCATGCTTGATAAAAACAATGTCAATTT 
                         3673                                                                                            3772 
    Spy0895 K.O.  (3068) CGTCAGGGACATCTAGCGGGATAGCCACAATCTGGTCACCATTTAGATTGCTATTTAGAATACCACTGGCAACGGTGTAGCCATCTAAACCAATCATTAA 
   0895K.O.-5412   (825) CGTCAGGGACATCTAGCGGGATAGCCACAATCTGGTCACCATTTAGATTGCTATTTA------------------------------------------- 
0895K.O.-5415rev   (606) CGTCAGGGACATCTAGCGGGATAGCCACAATCTGGTCACCATTTAGATTGCTATTTAGAATACCACTGGCAACGGTGTAGCCATCTAAACCAATCATTAA 
0895K.O.-6008rev    (37) CGTCAGGGACATCTAGCGGGATAGCCACAATCTGGTCACCATTTAGATTGCTATTTAGAATACCACTGGCAACGGTGTAGCCATCTAAACCAATCATTAA 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (2072) CGTCAGGGACATCTAGCGGGATAGCCACAATCTGGTCACCATTTAGATTGCTATTTAGAATACCACTGGCAACGGTGTAGCCATCTAAACCAATCATTAA 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414   (208) CGTCAGGGACATCTAGCGGGATAGCCACAATCTGGTCACCATTTAGATTGCTATTTAGAATACCACTGGCAACGGTGTAGCCATCTAAACCAATCATTAA 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (526) CGTCAGGGACATCTAGCGGGATAGCCACAATCTGGTCACCATTTAGATTGCTATTTAGAATACCACTGGCAACGGTGTAGCCATCTAAACCAATCATTAA 
      WT-6008rev   (174) CGTCAGGGACATCTAGCGGGATAGCCACAATCTGGTCACCATTTAGATTGCTATTTAGAATACCACTGGCAACGGTGTAGCCATCTAAACCAATCATTAA 
       Consensus  (3673) CGTCAGGGACATCTAGCGGGATAGCCACAATCTGGTCACCATTTAGATTGCTATTTAGAATACCACTGGCAACGGTGTAGCCATCTAAACCAATCATTAA 
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                         3773                                                                                            3872 
    Spy0895 K.O.  (3168) GTTAAAGAGGGTGGCACGGTCACTGACCACAATTGATTTGTTGTGGGGCATCTGGGACATCATCTCTTCTGAAAAATAAAAGGAGTTGTGAATCCCTTGG 
   0895K.O.-5412   (882) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (706) GTTAAAGAGGGTGGCACGGTCACTGACCACAATTGATTTGTTGTGGGGCATCTGGGACATCATCTCTTCTGAAAAATAAAAGGAGTTGTGAATCCCTTGG 
0895K.O.-6008rev   (137) GTTAAAGAGGGTGGCACGGTCACTGACCACAATTGATTTGTTGTGGGGCATCTGGGACATCATCTCTTCTGAAAAATAAAAGGAGTTGTGAATCCCTTGG 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (2172) GTTAAAGAGGGTGGCACGGTCACTGACCACAATTGATTTGTTGTGGGGCATCTGGGACATCATCTCTTCTGAAAAATAAAAGGAGTTGTGAATCCCTTGG 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414   (308) GTTAAAGAGGGTGGCACGGTCACTGACCACAATTGATTTGTTGTGGGGCATCTGGGACATCATCTCTTCTGAAAAATAAAAGGAGTTGTGAATCCCTTGG 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (626) GTTAAAGAGGGTGGCACGGTCACTGACCACAATTGATTTGTTGTGGGGCATCTGGGACATCATCTCTTCTGAAAAATAAAAGGAGTTGTGAATCCCTTGG 
      WT-6008rev   (274) GTTAAAGAGGGTGGCACGGTCACTGACCACAATTGATTTGTTGTGGGGCATCTGGGACATCATCTCTTCTGAAAAATAAAAGGAGTTGTGAATCCCTTGG 
       Consensus  (3773) GTTAAAGAGGGTGGCACGGTCACTGACCACAATTGATTTGTTGTGGGGCATCTGGGACATCATCTCTTCTGAAAAATAAAAGGAGTTGTGAATCCCTTGG 
                         3873                                                                                            3972 
    Spy0895 K.O.  (3268) TCATAGCTCAGGTAAGGAAAATCTCTCAAGTCGTCCATGCTTAATAGGCTTTTAGTTGCTAGAGGATTTGATTTGCTGACAAAAATATGAGGCTGTGCCT 
   0895K.O.-5412   (882) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (806) TCATAGCTCAGGTAAGGAAAATCTCTCAAGTCGTCCATGCTTAATAGGCTTTTAGTTGCTAGAGGATTTGATTTGCTGACAAAAATATGAGGCTGTGCCT 
0895K.O.-6008rev   (237) TCATAGCTCAGGTAAGGAAAATCTCTCAAGTCGTCCATGCTTAATAGGCTTTTAGTTGCTAGAGGATTTGATTTGCTGACAAAAATATGAGGCTGTGCCT 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (2272) TCATAGCTCAGGTAAGGAAAATCTCTCAAGTCGTCCATGCTTAATAGGCTTTTAGTTGCTAGAGGATTTGATTTGCTGACAAAAATATGAGGCTGTGCCT 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414   (408) TCATAGCTCAGGTAAGGAAAATCTCTCAAGTCGTCCATGCTTAATAGGCTTTTAGTTGCTAGAGGATTTGATTTGCTGACAAAAATATGAGGCTGTGCCT 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (726) TCATAGCTCAGGTAAGGAAAATCTCTCAAGTCGTCCATGCTTAATAGGCTTTTAGTTGCTAGAGGATTTGATTTGCTGACAAAAATATGAGGCTGTGCCT 
      WT-6008rev   (374) TCATAGCTCAGGTAAGGAAAATCTCTCAAGTCGTCCATGCTTAATAGGCTTTTAGTTGCTAGAGGATTTGATTTGCTGACAAAAATATGAGGCTGTGCCT 
       Consensus  (3873) TCATAGCTCAGGTAAGGAAAATCTCTCAAGTCGTCCATGCTTAATAGGCTTTTAGTTGCTAGAGGATTTGATTTGCTGACAAAAATATGAGGCTGTGCCT 
                         3973                                                                                            4072 
    Spy0895 K.O.  (3368) TAAATAATGGAGAGGCGGTCAAATGATTGTCATCAAATAATTTGGTCAAGACATCTCGGTTATAGTCGTTGATAAAGAGAACACCAATTTCAGATCGAAA 
   0895K.O.-5412   (882) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (906) TAAATAATGGAGAGGCAGTCAAATGATTGTCATCAAATAATTTGGTCAAGA------------------------------------------------- 
0895K.O.-6008rev   (337) TAAATAATGGAGAGGCAGTCAAATGATTGTCATCAAATAATTTGGTCAAGACATCTCGGTTATAGTCGTTGATAAAGAGAACACCAATTTCAGATCGAAA 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (2372) TAAATAATGGAGAGGCGGTCAAATGATTGTCATCAAATAATTTGGTCAAGACATCTCGGTTATAGTCGTTGATAAAGAGAACACCAATTTCAGATCGAAA 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414   (508) TAAATAATGGAGAGGCGGTCAAATGATTGTCATCAAATAATTTGGTCAAGACATCTCGGTTATAGTCGTTGATAAAGAGAACACCAATTTCAGATCGAAA 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (826) TAAATAATGGAGAGGCGGTCAAATGATTGT---------------------------------------------------------------------- 
      WT-6008rev   (474) TAAATAATGGAGAGGCGGTCAAATGATTGTCATCAAATAATTTGGTCAAGACATCTCGGTTATAGTCGTTGATAAAGAGAACACCAATTTCAGATCGAAA 
       Consensus  (3973) TAAATAATGGAGAGGC GTCAAATGATTGTCATCAAATAATTTGGTCAAGA                                                  
                         4073                                                                                            4172 
    Spy0895 K.O.  (3468) GTTTTTGACATCATCAATGATTTCCCAAGTTCTTGTCTCGCGCAAAAAGAGTTCATACCGAGTCATGTCGGTCCGCTTGAGGAGTGAGACAAATGCATTG 
   0895K.O.-5412   (882) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (957) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev   (437) GTTTTTGACATCATCAATGATTTCCCAAGTTCTTGTCTCGCGCAAAAAGAGTTCGTACCGAGTCATGTCGGTCCGCTTGAGGAGTGAGACAAATGCATTG 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (2472) GTTTTTGACATCATCAATGATTTCCCAAGTTCTTGTCTCGCGCAAAAAGAGTTCATACCGAGTCATGTCGGTCCGCTTGAGGAGTGAGACAAATGCATTG 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414   (608) GTTTTTGACATCATCAATGATTTCCCAAGTTCTTGTCTCGCGCAAAAAGAGTTCATACCGAGTCATGTCGGTCCGCTTGAGGAGTGAGACAAATGCATTG 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (856) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev   (574) GTTTTTGACATCATCAATGATTTCCCAAGTTCTTGTCTCGCGCAAAAAGAGTTCATACCGAGTCATGTCGGTCCGCTTGAGGAGTGAGACAAATGCATTG 
       Consensus  (4073)                                                                                                      
                         4173                                                                                            4272 
    Spy0895 K.O.  (3568) ACTACGAAGGCATAATGTTGAGATGAAACGCTAAAGAGCTCTCGGCCAGTATTGTGGTTTTTATAGCGGTCTTCTAACAGTGATGTTTGCTCTATAATTT 
   0895K.O.-5412   (882) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (957) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev   (537) ACTACGAAGGCATAATGTTGAGATGAAACGCTAAAGAGCTCTCGGCCAGTATTGTGGTTTTTATAGCGGTCTTCTAACAGTGATGTTTGCTCTATAATTT 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (2572) ACTACGAAGGCATAATGTTGAGATGAAACGCTAAAGAGCTCTCGGCCAGTATTGTGGTTTTTATAGCGGTCTTCTAACAGTGATGTTTGCTCTATAATTT 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414   (708) ACTACGAAGGCATAATGTTGAGATGAAACGCTAAAGAGCTCTCGGCCAGTATTGTGGTTTTTATAGCGGTCTTCTAACAGTGATGTTTGCTCTATAATTT 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (856) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev   (674) ACTACGAAGGCATAATGTTGAGATGAAACGCTAAAGAGCTCTCGGCCAGTATTGTGGTTTTTATAGCGGTCTTCTAACAGTGATGTTTGCTCTATAATTT 
       Consensus  (4173)                                                                                                      
                         4273                                                                                            4372 
    Spy0895 K.O.  (3668) GGCGAGCATAAGATAAAAATTCCACCCCATCTTTTGTCAAGGTGATCCCTTTAGGATTTCGGTTGAAAATGGTAATGCCCATCTCCATTTCCAAATCCTT 
   0895K.O.-5412   (882) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (957) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev   (637) GGCGAGCATAAGATAAAAATTCCACCCCATCTTTTGTCAAGGTGATCCCTTTAGGATTTCGGTTGAAAATGGTAATGCCCATCTCCATTTCCAAATCCTT 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (2672) GGCGAGCATAAGATAAAAATTCCACCCCATCTTTTGTCAAGGTGATCCCTTTAGGATTTCGGTTGAAAATGGTAATGCCCATCTCCATTTCCAAATCCTT 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414   (808) GGCGAGCATAAGATAAAA-TTCCACCCCATCTTTTGTCAAGGTGATCCCTT------------------------------------------------- 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (856) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev   (774) GGCGAGCATAAGATAAAAATTCCACCCCATCTTTTGTCAAGGTGATCCCTTTAGGATTTCGGTTGAAAATGGTAATGCCCATCTCCATTTCCAAATCCTT 
       Consensus  (4273)                                                                                                      
                         4373                                                                                            4472 
    Spy0895 K.O.  (3768) GACCGCATTGGATAGACTTGGTTGTGTGATAAATAATTGCTTAGCAGCTTCATTCATAGAGCCGCACTCAACAATTTTGATAATATAATGCAGTTGTTGA 
   0895K.O.-5412   (882) ---------------------------------------------------------------------------------------------------- 
0895K.O.-5415rev   (957) ---------------------------------------------------------------------------------------------------- 
0895K.O.-6008rev   (737) GACCGCATTGGATAGACTTGGTTGTGTGATAAATAATT-------------------------------------------------------------- 
   0895K.O.-6005   (507) ---------------------------------------------------------------------------------------------------- 
         WT-0895  (2772) GACCGCATTGGATAGACTTGGTTGTGTGATAAATAATTGCTTAGCAGCTTCATTCATAGAGCCGCACTCAACAATTTTGATAATATAATGCAGTTGTTGA 
         WT-5412   (873) ---------------------------------------------------------------------------------------------------- 
         WT-5414   (858) ---------------------------------------------------------------------------------------------------- 
         WT-6005   (802) ---------------------------------------------------------------------------------------------------- 
      WT-5413rev   (865) ---------------------------------------------------------------------------------------------------- 
      WT-5415rev   (856) ---------------------------------------------------------------------------------------------------- 
      WT-6008rev   (874) GACCGCATTGGATAGACTTGGTTGTGTGATAAATA----------------------------------------------------------------- 
       Consensus  (4373)                                                                                                      
                         4473                                                         4537 
    Spy0895 K.O.  (3868) ATTCTCATAAGTACAGTCTAGCTCAAAAAAAATAAAGACGCAAGCACAAACGTCATCATGGGTTT 
   0895K.O.-5412   (882) ----------------------------------------------------------------- 
0895K.O.-5415rev   (957) ----------------------------------------------------------------- 
0895K.O.-6008rev   (775) ----------------------------------------------------------------- 
   0895K.O.-6005   (507) ----------------------------------------------------------------- 
         WT-0895  (2872) ATTCTCATAAGTACAGTCTAGCTCAAAAAAAATAAAGACGCAAGCACAAACGTCATCATGGGTTT 
         WT-5412   (873) ----------------------------------------------------------------- 
         WT-5414   (858) ----------------------------------------------------------------- 
         WT-6005   (802) ----------------------------------------------------------------- 
      WT-5413rev   (865) ----------------------------------------------------------------- 
      WT-5415rev   (856) ----------------------------------------------------------------- 
      WT-6008rev   (909) ----------------------------------------------------------------- 
       Consensus  (4473)                                                                  
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Figure: Region view of spy1536 operon in wildtype and spy1536 gene deletion mutant with a 
schematic representation of primer localization used for sequencing 
 
 
Sequence alignment spy1536 gene deletion mutant (deletion highlighted in yellow) 
 
                         269                                                                                              368 
   Spy1536 K.O.    (269) CTTGTTTAATGGTTACCATAGCCTTACCTCCTTGTAAAATAAGTTTATGGGGATTTTTCAATCTCAAGTTTTTAATTTAGTTGTTATAACGTTAACTTGT 
   1536K.O.-5416     (1) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-6009     (1) ----TTTAATGGTTACCATAGCCTTACCTCCTTGTAAAATAAGTTTATGGGGATTTTTCAATCTCAAGTTTTTAATTTAGTTGTTATAACGTTAACTTGT 
1536K.O.-5419rev     (1) ---------------------------------------------------------------------------------------------------- 
1536K.O.-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
         WT-1536   (169) CTTGTTTAATGGTTACCATAGCCTTACCTCCTTGTAAAATAAGTTTATGGGGATTTTTCAATCTCAAGTTTTTAATTTAGTTGTTATAACGTTAACTTGT 
         WT-5416     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5417rev     (1) --------------------------------TGTAAAATAAGTTTATGGGGATTTTTCAATCTCAAGTTTTTAATTTAGTTGTTATAACGTTAGCTTGT 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6009     (1) ---GTTTAATGGTTACCATAGCCTTACCTCCTTGTAAAATAAGTTTATGGGGATTTTTCAATCTCAAGTTTTTAATTTAGTTGTTATAACGTTAGCTTGT 
      WT-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus   (269)                                                                                                      
                         369                                                                                              468 
   Spy1536 K.O.    (369) CTATTGCAAGGCTTTCCAGAATAATAGAGTCATGGAATGGACTCATGATTATCTGCGCAAGTTCTTGGATGAGCTAGTGAAAAAAATCAATTTTCACTAG 
   1536K.O.-5416     (1) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-6009    (97) CTATTGCAAGGCTTTCCAGAATAATAGAGTCATGGAATGGACTCATGATTATCTGCGCAAGTTCTTGGATGAGCTAGTGAAAAAAATCAATTTTCACTAG 
1536K.O.-5419rev     (1) -------------------------------------------------------------TTCTTGGATGAGCTAGTGAAAAAAATCAATTTTCACTAG 
1536K.O.-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
         WT-1536   (269) CTATTGCAAGGCTTTCCAGAATAATAGAGTCATGGAATGGACTCATGATTATCTGCGCAAGTTCTTGGATGAGCTAGTGAAAAAAATCAATTTTCACTAG 
         WT-5416     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5417rev    (69) CTATTGCAAGGCTTTCCAGAATAATAGAGTCATGGAATGGACTCATGATTATCTGCGCAAGTTCTTGGATGAGCTAGTGAAAAAAATCAATTTTCACTAG 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6009    (98) CTATTGCAAGGCTTTCCAGAATAATAGAGTCATGGAATGGACTCATGATTATCTGCGCAAGTTCTTGGATGAGCTAGTGAAAAAAATCAATTTTCACTAG 
      WT-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus   (369)                                                              TTCTTGGATGAGCTAGTGAAAAAAATCAATTTTCACTAG 
                         469                                                                                              568 
   Spy1536 K.O.    (469) GTGTTTTTAGTATGCTCTATTTCCAGATAATCGACTAAAGTTTACTCAATTCTCTATTGCCTTTTTACC-ACTAGACTTTTATAACATCTTTTTTACGCT 
   1536K.O.-5416     (1) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-6009   (197) GTGTTTTTAGTATGCTCTATTTCCAGATAATCGACTAAAGTTTACTCAATTCTCTATTGCCTTTTTACC-ACTAGACTTTTATAACATCTTTTTTACGCT 
1536K.O.-5419rev    (40) GTGTTTTTAGTATGCTCTATTTCCAGATAATCGACTAAAGTTTACTCAATTCTCTATTGCCTTTTTACCCACTAGACTTTTATAACATCTTTTTTACGCT 
1536K.O.-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
         WT-1536   (369) GTGTTTTTAGTATGCTCTATTTCCAGATAATCGACTAAAGTTTACTCAATTCTCTATTGCCTTTTTACC-ACTAGACTTTTATAACATCTTTTTTACGCT 
         WT-5416     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5417rev   (169) GTGTTTTTAGTATGCTCTATTTCCAGATAATCGACTAAAGTTTACTCAATTCTCTATTGCCTTTTTACC-ACTAGACTTTTATAAAATCTTTTTTACGCT 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6009   (198) GTGTTTTTAGTATGCTCTATTTCCAGATAATCGACTAAAGTTTACTCAATTCTCTATTGCCTTTTTACC-ACTAGACTTTTATAAAATCTTTTTTACGCT 
      WT-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus   (469) GTGTTTTTAGTATGCTCTATTTCCAGATAATCGACTAAAGTTTACTCAATTCTCTATTGCCTTTTTACC ACTAGACTTTTATAA ATCTTTTTTACGCT 
                         569                                                                                              668 
   Spy1536 K.O.    (568) GTCAAGTTAGATATGTTTTATGTAAAAAATGATTGAACCCAAAAGACTGGTCAAGGATCTGTCTATCTGGTTCAACCGTTTTTTATGAGTTAATAGCGTG 
   1536K.O.-5416     (1) -------------------------------------------AGACTGGTCAAGGATCTGTCTATCTGGTTCAACCGTTTTTTATGAGTTAATAGCGTG 
   1536K.O.-6009   (296) GTCAAGTTAGATATGTTTTATGTAAAAAATGATTGAACCCAAAAGACTGGTCAAGGATCTGTCTATCTGGTTCAACCGTTTTTTATGAGTTAATAGCGTG 
1536K.O.-5419rev   (140) GTCAAGTTAGATATGTTTTATGTAAAAAATGATTGAACCCAAAAGACTGGTCAAGGATCTGTCTATCTGGTTCAACCGTTTTTTATGAGTTAATAGCGTG 
1536K.O.-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
         WT-1536   (468) GTCAAGTTAGATATGTTTTATGTAAAAAATGATTGAACCCAAAAGACTGGTCAAGGATCTGTCTATCTGGTTCAACCGTTTTTTATGAGTTAATAGCGTG 
         WT-5416     (1) --------------------------------------------GACTGGTCAAGGATCTGTCTATCTGGTTCAACCGTTTTTTATGAGTTAATAGCGTG 
      WT-5417rev   (268) GTCAAGTTAGATATGTTTTATGTAAAAAATGATTGAACCCAAAAGACTGGTCAAGGATCTGTCTATCTGGTTCAACCGTTTTTTATGAGTTAATAGCGTG 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6009   (297) GTCAAGTTAGATATGTTTTATGTAAAAAATGATTGAACCCAAAAGACTGGTCAAGGATCTGTCTATCTGGTTCAACCGTTTTTTATGAGTTAATAGCGTG 
      WT-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus   (569) GTCAAGTTAGATATGTTTTATGTAAAAAATGATTGAACCCAAAAGACTGGTCAAGGATCTGTCTATCTGGTTCAACCGTTTTTTATGAGTTAATAGCGTG 
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                         669                                                                                              768 
   Spy1536 K.O.    (668) AATATAATTGAATATAATACATTCATAGTTATTTTATTTGCGAAGATAAACCAGTGCCTCTTGAACAGTCGTAACAGGAACAATCTTCATTTTGGTCTTT 
   1536K.O.-5416    (58) AATATAATTGAATATAATACATTCATAGTTATTTTATTTGCGAAGATAAACCAGTGCCTCTTGAACAGTCGTAATAGGAACAATCTTCATTTTGGTCTTT 
   1536K.O.-6009   (396) AATATAATTGAATATAATACATTCATAGTTATTTTATTTGCGAAGATAAACCAGTGCCTCTTGAACAGTCGTAATAGGAACAATCTTCATTTTGGTCTTT 
1536K.O.-5419rev   (240) AATATAATTGAATATAATACATTCATAGTTATTTTATTTGCGAAGATAAACCAGTGCCTCTTGAACAGTCGTAATAGGAACAATCTTCATTTTGGTCTTT 
1536K.O.-6010rev     (1) -------------------------------------------------------------------------------------TTCATTTTGGTCTTT 
         WT-1536   (568) AATATAATTGAATATAATACATTCATAGTTATTTTATTTGCGAAGATAAACCAGTGCCTCTTGAACAGTCGTAACAGGAACAATCTTCATTTTGGTCTTT 
         WT-5416    (57) AATATAATTGAATATAATACATTCATAGTTATTTTATTTGCGAAGATAAACCAGTGCCTCTTGAACAGTCGTAACAGGAACAATCTTCATTTTGGTCTTT 
      WT-5417rev   (368) AATATAATTGAATATAATACATTCATAGTTATTTTATTTGCGAAGATAAACCAGTGCCTCTTGAACAGTCGTAACAGGAACAATCTTCATTTTGGTCTTT 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6009   (397) AATATAATTGAATATAATACATTCATAGTTATTTTATTTGCGAAGATAAACCAGTGCCTCTTGAACAGTCGTAACAGGAACAATCTTCATTTTGGTCTTT 
      WT-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus   (669) AATATAATTGAATATAATACATTCATAGTTATTTTATTTGCGAAGATAAACCAGTGCCTCTTGAACAGTCGTAA AGGAACAATCTTCATTTTGGTCTTT 
                         769                                                                                              868 
   Spy1536 K.O.    (768) AGTCGTTTGGCTGCCCGTTTGGCTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATA 
   1536K.O.-5416   (158) AGTCGTTTGGCTGCCCGTTTGGCTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATA 
   1536K.O.-6009   (496) AGTCGTTTGGCTGCCCGTTTGGCTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATA 
1536K.O.-5419rev   (340) AGTCGTTTGGCTGCCCGTTTGGCTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATA 
1536K.O.-6010rev    (16) AGTCGTTTGGCTGCCCGTTTGGCTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATA 
         WT-1536   (668) AGTCGTTTGGCTGCCCGTTTGGCTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATA 
         WT-5416   (157) AGTCGTTTGGCTGCCCGTTTGGCTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATA 
      WT-5417rev   (468) AGTCGTTTGGCTGCCCGTTTGGCTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATA 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev     (1) ---------------------------------------------------------------------------------------------------- 
         WT-6009   (497) AGTCGTTTGGCTGCCCGTTTGGCTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATA 
      WT-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus   (769) AGTCGTTTGGCTGCCCGTTTGGCTTCTTCGTAATTACTTATAGCATTTGGATTAACTTTTTTAATTTCCTTATCAACAGGATTATTCGGAACAAAAAATA 
                         869                                                                                              968 
   Spy1536 K.O.    (868) TATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATAGTTCCTGTACCTGCAATTGT 
   1536K.O.-5416   (258) TATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATAGTTCCTGTACCTGCAATTGT 
   1536K.O.-6009   (596) TATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATAGTTCCTGTACCTGCAATTGT 
1536K.O.-5419rev   (440) TATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATAGTTCCTGTACCTGCAATTGT 
1536K.O.-6010rev   (116) TATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATAGTTCCTGTACCTGCAATTGT 
         WT-1536   (768) TATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATAGTTCCTGTACCTGCAATTGT 
         WT-5416   (257) TATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATAGTTCCTGTACCTGCAATTGT 
      WT-5417rev   (568) TATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATAGTTCCTGTACCTGCAATTGT 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev     (1) --------------------------------------------------------------------------------------------------GT 
         WT-6009   (597) TATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATAGTTCCTGTACCTGCAATTGT 
      WT-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus   (869) TATCTGCACCAGCTTCAGCTGCTGCAACTACTTTAAGACCTGCACCACCAATATCTCCTACTTCGCCATCCTTGCCAATAGTTCCTGTACCTGCAATTGT 
                         969                                                                                             1068 
   Spy1536 K.O.    (968) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
   1536K.O.-5416   (358) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
   1536K.O.-6009   (696) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
1536K.O.-5419rev   (540) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
1536K.O.-6010rev   (216) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
         WT-1536   (868) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
         WT-5416   (357) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
      WT-5417rev   (668) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev     (3) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
         WT-6009   (697) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
      WT-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus   (969) ACGGCCCTTGCGTAAATCTTCTTTAGTTATTTGATCATATATATCAAGAGTAAACATTAGACCAGCACTAGGTCCTCCTACTCCTTTAGTACTAAAGATC 
                         1069                                                                                            1168 
   Spy1536 K.O.   (1068) ACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAAGGCAATGCCAATCCCA---------------------------------------------- 
   1536K.O.-5416   (458) ACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAAGGCAATGCCAATCCCA---------------------------------------------- 
   1536K.O.-6009   (796) ACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAAGGCAATGCCAATCCCA---------------------------------------------- 
1536K.O.-5419rev   (640) ACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAAGGCAATGCCAATCCCA---------------------------------------------- 
1536K.O.-6010rev   (316) ACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAAGGCAATGCCAATCCCA---------------------------------------------- 
         WT-1536   (968) ACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAAGGCAATGCCAATCCCATTTTTCCCATTTTTCAGTTTGATAATACGGCCAACTCCTTTTTTAG 
         WT-5416   (457) ACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAAGGCAATGCCAATCCCATTTTTCCCATTTTTCAGTTTGATAATACGGCCAACTCCTTTTTTAG 
      WT-5417rev   (768) ACTGTGTCTT------------------------------------------------------------------------------------------ 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev   (103) ACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAAGGCAATGCCAATCCCATTTTTCCCATTTTTCAGTTTGATAATACGGCCAACTCCTTTTTTAG 
         WT-6009   (797) ACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAAGGCAATGCCAATCCCATTTTTCCCATTTTTCAGTTTGATA-TACGGCCAACTCCTTTTTT-- 
      WT-6010rev     (1) ---------------------------------------------------------------------------------------------------- 
       Consensus  (1069) ACTGTGTCTTCTGAATTGACACTTGTATGATCAGTCAAGGCAATGCCAATCCCA                                               
                         1169                                                                                            1268 
   Spy1536 K.O.   (1122) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-5416   (512) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-6009   (850) ---------------------------------------------------------------------------------------------------- 
1536K.O.-5419rev   (694) ---------------------------------------------------------------------------------------------------- 
1536K.O.-6010rev   (370) ---------------------------------------------------------------------------------------------------- 
         WT-1536  (1068) GCTTATTATCACTCGTAAACTGAACCGTAACTTCATCCCCTAGTTTTAGGTGAGAAACATAGTCAATAAGTTCTGCTGAACTAGTAAACTGTTTACCATT 
         WT-5416   (557) GCTTATTATCACTCGTAAACTGAACCGTAACTTCATCCCCTAGTTTTAGGTGAGAAACATAGTCAATAAGTTCTGCTGAACTAGTAAACTGTTTACCATT 
      WT-5417rev   (778) ---------------------------------------------------------------------------------------------------- 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev   (203) GCTTATTATCACTCGTAAACTGAACCGTAACTTCATCCCCTAGTTTTAGGTGAGAAACATAGTCAATAAGTTCTGCTGAACTAGTAAACTGTTTACCATT 
         WT-6009   (894) ---------------------------------------------------------------------------------------------------- 
      WT-6010rev     (1) -----------------------------------------------------------------------------------------TGTTTACCATT 
       Consensus  (1169)                                                                                                      
                         1269                                                                                            1368 
   Spy1536 K.O.   (1122) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-5416   (512) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-6009   (850) ---------------------------------------------------------------------------------------------------- 
1536K.O.-5419rev   (694) ---------------------------------------------------------------------------------------------------- 
1536K.O.-6010rev   (370) ---------------------------------------------------------------------------------------------------- 
         WT-1536  (1168) TACACCTGTTACAGTATCTGCTAAGTGTAGCGTTCCTTTAAAAGTAGATTCGTTGTTTACGTCTAAAACATATACGCCTTTATAATCTAATGTAACTGGT 
         WT-5416   (657) TACACCTGTTACAGTATCTGCTAAGTGTAACGTTCCTTTAAAAGTAGATTCGTTGTTTACGTCTAAAACATATACGCCTTTATAATCTAATGTAACTGGT 
      WT-5417rev   (778) ---------------------------------------------------------------------------------------------------- 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev   (303) TACACCTGTTACAGTATCTGCTAAGTGTAACGTTCCTTTAAAAGTAGATTCGTTGTTTACGTCTAAAACATATACGCCTTTATAATCTAATGTAACTGGT 
         WT-6009   (894) ---------------------------------------------------------------------------------------------------- 
      WT-6010rev    (12) TACACCTGTTACAGTATCTGCTAAGTGTAACGTTCCTTTAAAAGTAGATTCGTTGTTTACGTCTAAAACATATACGCCTTTATAATCTAATGTAACTGGT 
       Consensus  (1269)                                                                                                      
                         1369                                                                                            1468 
   Spy1536 K.O.   (1122) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-5416   (512) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-6009   (850) ---------------------------------------------------------------------------------------------------- 
1536K.O.-5419rev   (694) ---------------------------------------------------------------------------------------------------- 
1536K.O.-6010rev   (370) ---------------------------------------------------------------------------------------------------- 
         WT-1536  (1268) TTTCCAGCTAAGGATAAAGCTTGATAAATAGCTGCATTTTGTGATGTTTCCATGTAAAATTGATTAATTCGAAGGAAATCAGCATCGCTGTATCCGCCTG 
         WT-5416   (757) TTTCCAGCTAAGGATAAAGCTTGATAAATAGCTGCATTTTGTGATGTTTCCATGTAAAATTGATTAATTC------------------------------ 
      WT-5417rev   (778) ---------------------------------------------------------------------------------------------------- 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev   (403) TTTCCAGCTAAGGATAAAGCTTGATAAATAGCTGCATTTTGTGATGTTTCCATGTAAAATTGATTAATTCGAAGGAAATCAGCATCGCTGTATCCGCCTG 
         WT-6009   (894) ---------------------------------------------------------------------------------------------------- 
      WT-6010rev   (112) TTTCCAGCTAAGGATAAAGCTTGATAAATAGCTGCATTTTGTGATGTTTCCATGTAAAATTGATTAATTCGAAGGAAATCAGCATCGCTGTATCCGCCTG 
       Consensus  (1369)                                                                                                      
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                         1469                                                                                            1568 
   Spy1536 K.O.   (1122) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-5416   (512) ---------------------------------------------------------------------------------------------------- 
   1536K.O.-6009   (850) ---------------------------------------------------------------------------------------------------- 
1536K.O.-5419rev   (694) ---------------------------------------------------------------------------------------------------- 
1536K.O.-6010rev   (370) ---------------------------------------------------------------------------------------------------- 
         WT-1536  (1368) TTGTATCTTCTGCTGTACTAATTTCAGTAAACGGTGTCAGCCAAGCATATAATAGCTGAGCGAGGCTGGCACGACTAATGCCCACTGCAACAAACTGGTA 
         WT-5416   (827) ---------------------------------------------------------------------------------------------------- 
      WT-5417rev   (778) ---------------------------------------------------------------------------------------------------- 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev   (503) TTGTATCTTCTGCTGTACTAATTTCAGTAAACGGTGTCAGCCAAGCATATAATAGCTGAGCGAGGCTGGCACGACTAATGCCCACTGCAACAAACTGGTA 
         WT-6009   (894) ---------------------------------------------------------------------------------------------------- 
      WT-6010rev   (212) TTGTATCTTCTGCTGTACTAATTTCAGTAAACGGTGTCAGCCAAGCATATAATAGCTGAGCGAGGCTGGCACGACTAATGCCCACTGCAACAAACTGGTA 
       Consensus  (1469)                                                                                                      
                         1569                                                                                            1668 
   Spy1536 K.O.   (1122) ------------------------------------------------------GTAAGCGCCTCCAGGCATTTCAATATAATAAGGTAGCGGAAAAAAT 
   1536K.O.-5416   (512) ------------------------------------------------------GTAAGCGCCTCCAGGCATTTCAATATAATAAGGTAGCGGAAAAAAT 
   1536K.O.-6009   (850) ------------------------------------------------------GTAAGCG--------------------------------------- 
1536K.O.-5419rev   (694) ------------------------------------------------------GTAAGCGCCTCCAGGCATTTCAATATAATAAGGTAGCGGAAAAAAT 
1536K.O.-6010rev   (370) ------------------------------------------------------GTAAGCGCCTCCAGGCATTTCAATATAATAAGGTAGCGGAAAAAAT 
         WT-1536  (1468) AGCTCCTTTTCGTTTGTCTTCTTTGCCATTGACTTGTAAGACAGTCCGAATATCGTAAGCGCCTCCAGGCATTTCAATATAATAAGGTAGCGGAAAAAAT 
         WT-5416   (827) ---------------------------------------------------------------------------------------------------- 
      WT-5417rev   (778) ---------------------------------------------------------------------------------------------------- 
         WT-5418     (1) ---------------------------------------------------------------------------------------------------- 
      WT-5419rev   (603) AGCTCCTTTTCGTTTGTCTTCTTTGCCATTGACTTGTAAGACAGTCCGAATATCGTAAGCGCCTCCAGGCATTTCAATATAATAAGGTAGCGGAAAAAAT 
         WT-6009   (894) ---------------------------------------------------------------------------------------------------- 
      WT-6010rev   (312) AGCTCCTTTTCGTTTGTCTTCTTTGCCATTGACTTGTAAGACAGTCCGAATATCGTAAGCGCCTCCAGGCATTTCAATATAATAAGGTAGCGGAAAAAAT 
       Consensus  (1569)                                                       GTAAGCGCCTCCAGGCATTTCAATATAATAAGGTAGCGGAAAAAAT 
                         1669                                                                                            1768 
   Spy1536 K.O.   (1168) AACGCTAGCAACAAAGAGATTAAAGCTAGCAGACCCACTAACCACCATTTGATTTTTTTAAGTCTTTTCATTCATTTTCTCCACTTGAGCAATAACCGAC 
   1536K.O.-5416   (558) AACGCTAGCAACAAAGAGATTAAAGCTAGCAGACCCACTAACCACCATTTGATTTTGTTAAGTCTTTTCATTCATTTTCTCCACTTGAGCAATAACCGAC 
   1536K.O.-6009   (857) ---------------------------------------------------------------------------------------------------- 
1536K.O.-5419rev   (740) AACGCTAGCAACAAAGAGATTAAAGCTAGCAGACCCACTAACCACCATTTGATTTTGTTAAGTCTTTTCATTCATTTTCTCCACTTGAGCAATAACCGAC 
1536K.O.-6010rev   (416) AACGCTAGCAACAAAGAGATTAAAGCTAGCAGACCCACTAACCACCATTTGATTTTGTTAAGTCTTTTCATTCATTTTCTCCACTTGAGCAATAACCGAC 
         WT-1536  (1568) AACGCTAGCAACAAAGAGATTAAAGCTAGCAGACCCACTAACCACCATTTGATTTTTTTAAGTCTTTTCATTCATTTTCTCCACTTGAGCAATAACCGAC 
         WT-5416   (827) ---------------------------------------------------------------------------------------------------- 
      WT-5417rev   (778) ---------------------------------------------------------------------------------------------------- 
         WT-5418     (1) AACGCTAGCAACAAAGAGATTAAAGCTAGCAGACCCACTAACCACCATTTGATTTTTTTAAGTCTTTTCATTCATTTTCTCCACTTGAGCAATAACTGAC 
      WT-5419rev   (703) AACGCTAGCAACAAAGAGATTAAAGCTAGCAGACCCACTAACCACCATTTGATTTTTTTAAGTCTTTTCATTCATTTTCTCCACTTGAGCAATAACTGAC 
         WT-6009   (894) ---------------------------------------------------------------------------------------------------- 
      WT-6010rev   (412) AACGCTAGCAACAAAGAGATTAAAGCTAGCAGACCCACTAACCACCATTTGATTTTTTTAAGTCTTTTCATTCATTTTCTCCACTTGAGCAATAACTGAC 
       Consensus  (1669) AACGCTAGCAACAAAGAGATTAAAGCTAGCAGACCCACTAACCACCATTTGATTTT TTAAGTCTTTTCATTCATTTTCTCCACTTGAGCAATAAC GAC 
                         1769                                                                                            1868 
   Spy1536 K.O.   (1268) TGAGGAACCAAACCTTCTAAGGAAGACTGAAAATGAATTAGCTCTCTCACACGACTAGAGCTAAGGGCCTGCCATTTATTTCTTGATATCAAATAGACGG 
   1536K.O.-5416   (658) TGAGGAACCAAACCTTCTAAGGAAGACTGAAAATGAATTAGCTCTCTCACACGACTAGAGCTAAGGGCCTGCCATTTATTTCTTGATATCAAATAGACGG 
   1536K.O.-6009   (857) ---------------------------------------------------------------------------------------------------- 
1536K.O.-5419rev   (840) TGAGGAACCAAACCTTCTAAGGAAGACTGAAAATGAATTAGCTCTCTCACACGACTAGAGCTAAGG---------------------------------- 
1536K.O.-6010rev   (516) TGAGGAACCAAACCTTCTAAGGAAGACTGAAAATGAATTAGCTCTCTCACACGACTAGAGCTAAGGGCCTGCCATTTATTTCTTGATATCAAATAGACGG 
         WT-1536  (1668) TGAGGAACCAAACCTTCTAAGGAAGACTGAAAATGAATTAGCTCTCTCACACGACTAGAGCTAAGGGCCTGCCATTTATTTCTTGATATCAAATAGACGG 
         WT-5416   (827) ---------------------------------------------------------------------------------------------------- 
      WT-5417rev   (778) ---------------------------------------------------------------------------------------------------- 
         WT-5418   (101) TGAGGAACCAAACCTTCTAAGGAAGACTGAAAATGAATTAGCTCTCTCACACGACTAGAGCTAAGGGCCTGCCATTTATTTCTTGATATCAAATAGACGG 
      WT-5419rev   (803) TGAGGAACCAAACCTTCTAAGGAAGACTGAAAATGAATTAGCTCTCTCACACGACTAGAGCTAAGG---------------------------------- 
         WT-6009   (894) ---------------------------------------------------------------------------------------------------- 
      WT-6010rev   (512) TGAGGAACCAAACCTTCTAAGGAAGACTGAAAATGAATTAGCTCTCTCACACGACTAGAGCTAAGGGCCTGCCATTTATTTCTTGATATCAAATAGACGG 
       Consensus  (1769) TGAGGAACCAAACCTTCTAAGGAAGACTGAAAATGAATTAGCTCTCTCACACGACTAGAGCTAAGGGCCTGCCATTTATTTCTTGATATCAAATAGACGG 
                         1869                                                                                            1968 
   Spy1536 K.O.   (1368) TTTCAATATTTGGAGCTAAAAGGTGATTAAAATATTCCAAATTTTCTTCATACTCAAAGTCAGTTGCATTTCGCAAGCCTCTAATCAAGTGAGTTACTCG 
   1536K.O.-5416   (758) TTTCAATATTTGGAGCTAAAAGGTGATTAAAATATTCCAAATTTTCTTCATACTCAAAGTCAGTTGCATTTCGCAAGCCTCTAATCAAGTGAGTTACTCG 
   1536K.O.-6009   (857) ---------------------------------------------------------------------------------------------------- 
1536K.O.-5419rev   (906) ---------------------------------------------------------------------------------------------------- 
1536K.O.-6010rev   (616) TTTCAATATTTGGAGCTAAAAGGTGATTAAAATATTCCAAATTTTCTTCATACTCAAAGTCAGTTGCATTTCGCAAGCCTCTAATCAAGTGAGTTACTCG 
         WT-1536  (1768) TTTCAATATTTGGAGCTAAAAGGTGATTAAAATATTCCAAATTTTCTTCATACTCAAAGTCAGTTGCATTTCGCAAGCCTCTAATCAAGTGAGTTACTCG 
         WT-5416   (827) ---------------------------------------------------------------------------------------------------- 
      WT-5417rev   (778) ---------------------------------------------------------------------------------------------------- 
         WT-5418   (201) TCTCAATATTTGGAGCTAAAAGGTGATTAAAATATTCCAAATTTTCTTCATACTCAAAGTCAGTTGCATTTCGCAAACCTCTAATCAAGTGAGTTACTCG 
      WT-5419rev   (869) ---------------------------------------------------------------------------------------------------- 
         WT-6009   (894) ---------------------------------------------------------------------------------------------------- 
      WT-6010rev   (612) TCTCAATATTTGGAGCTAAAAGGTGATTAAAATATTCCAAATTTTCTTCATACTCAAAGTCAGTTGCATTTCGCAAACCTCTAATCAAGTGAGTTACTCG 
       Consensus  (1869) TCTCAATATTTGGAGCTAAAAGGTGATTAAAATATTCCAAATTTTCTTCATACTCAAAGTCAGTTGCATTTCGCAA CCTCTAATCAAGTGAGTTACTCG 
                         1969                                                                                            2068 
   Spy1536 K.O.   (1468) TAATTCTTTAGCTACATCAATAGCTAAACGTTCGTGCGAAGTTACTACAATTACATTTGTAAAATCAGCCAGAGCTTGAGTAAGCATTGCTTTACGAACT 
   1536K.O.-5416   (858) TAATTCTTT------------------------------------------------------------------------------------------- 
   1536K.O.-6009   (857) ---------------------------------------------------------------------------------------------------- 
1536K.O.-5419rev   (906) ---------------------------------------------------------------------------------------------------- 
1536K.O.-6010rev   (716) TAATTCTTTAGCTACATCAATAGCTAAACGTTCGTGCGAAGTTACTACAATTACATTTGTAAAATCAGCCAGAGCTTGAGTAAGCATTGCTTTACGAACT 
         WT-1536  (1868) TAATTCTTTAGCTACATCAATAGCTAAACGTTCGTGCGAAGTTACTACAATTACATTTGTAAAATCAGCCAGAGCTTGAGTAAGCATTGCTTTACGAACT 
         WT-5416   (827) ---------------------------------------------------------------------------------------------------- 
      WT-5417rev   (778) ---------------------------------------------------------------------------------------------------- 
         WT-5418   (301) TAATTCTTTAGCTACATCAATAGCTAAACGTTCGTGCGAAGTTACTACAATTACATTTGTAAAATCAGCCAGAGCTTGAGTAAGCATTGCTTTACGAACT 
      WT-5419rev   (869) ---------------------------------------------------------------------------------------------------- 
         WT-6009   (894) ---------------------------------------------------------------------------------------------------- 
      WT-6010rev   (712) TAATTCTTTAGCTACATCAATAGCTAAACGTTCGTGCGAAGTTACTACAATTACATTTGTAAAATCAGCCAGAGCTTGAGTAAGCATTGCTTTACGAACT 
       Consensus  (1969) TAATTCTTT                                                                                            
                         2069                                                                                       2163 
   Spy1536 K.O.   (1568) TCTAGTTTAAAATAGCTTTTTTTGGTAGGATTATCAAAAATCCCAACATATATTTGATCAAATAGGCCACTTGCCCGTTTAACAATATCGAGATG 
   1536K.O.-5416   (867) ----------------------------------------------------------------------------------------------- 
   1536K.O.-6009   (857) ----------------------------------------------------------------------------------------------- 
1536K.O.-5419rev   (906) ----------------------------------------------------------------------------------------------- 
1536K.O.-6010rev   (816) TCTAGTTTAAAATAGCTTTTTTTGGTAGGATTATCAAAAATC----------------------------------------------------- 
         WT-1536  (1968) TCTAGTTTAAAATAGCTTTTTTTGGTAGGATTATCAAAAATCCCAACATATATTTGATCAAATAGGCCACTTGCCCGTTTAACAATATCGAGATG 
         WT-5416   (827) ----------------------------------------------------------------------------------------------- 
      WT-5417rev   (778) ----------------------------------------------------------------------------------------------- 
         WT-5418   (401) TCTAGTTTAAAATAGCTTTTTTTGGTAGGATTATCAAAAATCCCAACATATATTTGATCAAATAGGCCACTTGCCCGTTTAACAATATC------ 
      WT-5419rev   (869) ----------------------------------------------------------------------------------------------- 
         WT-6009   (894) ----------------------------------------------------------------------------------------------- 
      WT-6010rev   (812) TCTAGTTTAAAATAGCTTTTTTTGGTAGGATTATCAAAA-------------------------------------------------------- 
       Consensus  (2069)                                                                                                 
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